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Emerging infectious diseases represent imminent threats to human and animal health 
worldwide and can impose immense economic burdens, particularly on the world’s 
most impoverished regions. Cross-species transmission of pathogens represents a 
common path towards disease emergence, but the mechanisms that lead to successful 
host jumping are incompletely understood.  
 
Here I have addressed some of the pathogen-associated factors involved in successful 
host jumping and have analyzed the evolutionary dynamics of the novel pathogen in 
the new host after cross-species transfer. These studies were performed using two 
emerging diseases of dogs: Canine Parvovirus (CPV) and Canine Influenza virus 
(CIV). While CPV emerged in the mid-1970s from an endemic virus of cats and has 
since become endemic in the global dog population, CIV was first described as a 
pathogen of dogs in 2004 - thus representing a new, likely not completely host-
adapted virus. Contrasting the evolutionary dynamics of these two pathogens which 
share the same host species allowed a powerful analysis of the determinants and risk 
factors for disease emergence. In particular, I focused these studies on understanding 
the viral population dynamics in infected animals - contrasting where applicable the 
dynamics in the novel and the ancesteral host species, and dissecting host-associated 
effects and the impact of cross-immunity. For the case of CPV, I further analyzed the 
 evolutionary dynamics of the novel virus on a population level since its emergence - 
contrasting those to the dynamics observed in the ancesteral virus. Finally, I analyzed 
the effect of potentially host-specific codon usage and codon usage bias for the 
evolution of CPV.  Because CpG methylation might represent an important driver of 
codon bias in the CPV genome, some work was dedicated to obtain a more 
comprehensive understanding of this major driver in DNA virus evolution.  
 
The results presented here show similarities but also marked differences between the 
evolutionary dynamics of CPV and CIV, and between the novel and ancesteral 
viruses. Further research is needed but it appears that key drivers differ between 
pathogens and between time intervals after emergence. However, some common 
mechanisms appear to be shared between viruses and others appear conserved between 
hosts.
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CHAPTER 1 
HOST JUMPING AND DISEASE EMERGENCE – A UNIFYING VIEW 
 
 
 
 
 
 
 
 
 
 
 
1
1.1. The global importance of emerging infectious diseases 
Emerging infectious diseases (EIDs) represent important economic and public health 
burdens worldwide, which challenge particularly the world’s most impoverished 
regions (5, 33). Some evidence suggests that the frequency of EIDs has significantly 
increased over past decades, and anthropogenic ecosystem perturbations  - manifested 
for example as climate change or deforestation - might be partially responsible, even 
though this topic is still subject to debate (22, 23, 30, 32, 48). As our general 
understanding in the area of disease emergence is growing, several common risk 
factors begin to be indisputably recognized (see for example (1, 6-8, 11, 20)).   
Numerous socio-economic and ecological factors clearly influence emergence 
probabilities, but their nature and relative impact appear strongly correlated with the 
EID origin (22).   
 
1.2. The different paths to disease emergence 
The World Health Organization (WHO) defines EIDs as diseases which recently 
increased in incidence, or for which the incidence is likely to increase in the near 
future, thus encompassing three distinct origins of emerging diseases: (i) novel 
diseases recognized for the first time, (ii) diseases that were previously controlled 
through chemotherapeutic drugs or (iii) diseases with changed distribution pattern 
(Figure 1.1). With or without the acquisition of genetic mutations, diseases might 
suddenly appear in new geographic locations, might increase in incidence due to 
behavioral changes in the host population, or might become more frequent due to an 
increase in immune-suppressed hosts. The probably best-recognized examples thereof 
include the recent West Nile and Lyme disease epidemics in the Western Hemisphere 
and the global increase of opportunistic infections associated with the HIV epidemic 
(4, 13, 16, 33, 35). These diseases, frequently caused by parasites or vector-borne 
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viruses, appear strongly impacted by anthropogenic ecosystem perturbations or 
naturally occurring climate changes such as the El Nino/ Southern Oscillation 
phenomenon (22, 34).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. The different mechanisms of disease emergence and some of the 
important drivers associated with the route of emergence.  
 
Alternatively, disease incidence can increase as a consequence of resistance to 
antimicrobial drugs, for example multi-resistant tuberculosis, methicillin - resistant 
Staphylococcus aureus or chloroquine-resistant malaria (see for example (14, 21, 29, 
36, 40)). The emergence of resistance to antimicrobial drugs can in many cases be 
linked to their extensive - and often inadequate - use. High population density, 
agricultural practices which favor the use of chemotherapeutic drugs, and suboptimal 
antibiotic treatment regimes therefore represent important risk factors for this category 
of emerging diseases (22).  Many of the pathogens in this category are bacteria, even 
though some important exceptions do exist. 
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 1.3.  Disease emergence after cross-species transmission 
In some other cases, novel diseases emerge after cross-species transmission from an 
alternative host.  Intriguingly, nearly all EIDs that result from such host jumps are 
caused by viruses - a phenomenon frequently attributed to their comparably small 
genome sizes, relatively high mutation rates, large population sizes and, in most cases, 
their inability for error-correction during genome replication (38, 51). EIDs of viral 
origin have constituted between 25 and 44% of all documented emerging diseases in 
the last century, several of which originated from species jumps (8, 22, 44, 51). Cross-
species transmissions from animal reservoirs apparently gave rise to many devastating 
human viruses in the past, such as the SARS coronavirus, Niphavirus, Human 
immunodeficiency virus (HIV) 1 and 2 and Measles virus- and even the ‘Spanish flu’ 
is believed to have jumped from birds into humans (recently reviewed for example in 
(38, 45, 49)). The importance of animal and particularly wildlife reservoirs for human 
disease emergence is exemplified by the fact that approximately 75% of human EIDs 
are of a zoonotic origin and an estimated 43% of all EIDs during the past century 
arose from wildlife (22, 44).  
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Figure 1.2: Overview of some common risk factors associated with disease 
mergence through cross-species transmission.  
.4  Risk factors for successful host jumping 
relative abundance of domesticated animals and particularly the presence of non-
e
 
 
 
 
 
1
 
In general, EIDs in the tropics seem to arise more frequently from wildlife than 
domestic animals while that relationship appears reversed in temperate zones, but the 
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human primates in different geographic regions might confound this relationship (49). 
The probability of disease emergence from wildlife reservoirs seems to be determined 
by the frequency of human-wildlife contacts, the “zoonotic pool” of microorganisms 
present in a region and the degree of habitat perturbations as well as their effects on 
indigenous wildlife (48) (Figure 1.2). Similar factors probably impact the likelihood of 
emergence from domestic animals, and viruses with broad host range, particularly 
those that infect both domestic animals and wildlife, are more likely to give rise to 
human EIDs than those viruses with narrow host range, though the underlying factors 
are still incompletely understood (8). The route of disease transmission might also 
impact emergence probabilities and direct or indirect transmission might facilitate the 
emergence of pathogens, but this topic is still subject to discussion (50). 
Furthermore, the type and frequency of contact between host species probably 
impacts the likelihood with which host jumps occur, but again many questions remain 
unanswered. Some types of contact such as fighting, hunting or consumption might be 
more likely to lead to successful host jumps than other, more casual contacts, but the 
underlying molecular determinants are still unknown (20, 48). Historically the vast 
majority of human EIDs seem to have emerged from ungulate, carnivore or rodent 
species, which have been living in close proximity to humans since the beginning of 
human civilization (8, 50). Indeed, several human diseases such as measles, mumps, 
pertussis and smallpox have been linked to the beginning of agriculture, which marked 
the foundation of densely populated human settlements and for the first time gathered 
large human and animal populations in close proximity (49). However, a substantial 
number of human EIDs have been associated with other vertebrate sources such as 
primates, bats and birds (8, 50). Additional factors (for example,  the phylogenetic 
distance between the host species)  might also influence the likelihood of successful 
species jumps- a notion that mainly stems from anecdotal evidence that a 
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disproportionate number of recently emerged human viruses probably arose from non-
human primates (49). 
 
1.5. What we do and do not know about host-range barriers 
The molecular and physiological determinants of host-range barriers have rarely been 
defined in detail. However, it appears likely that a combination of different factors 
restrict the replication and spread of viruses in alternative hosts, which likely include 
physical barriers, immunological barriers and biochemical blockades (recently 
reviewed in (24, 38)).  The binding of species-specific cellular receptors or co-
receptors represents one of the best-studied host-range factors, which appears to be 
important for the emergence of numerous EIDs such as HIV, the SARS coronavirus, 
H5N1 avian influenza virus,  Venezuelan equine encephalitis virus, canine distemper 
virus and canine parvovirus (2, 18, 19, 25-28, 31, 37, 41, 42, 52). Indeed, multi-host 
pathogens, which seem to be more likely sources of EIDs than pathogens with narrow 
host ranges, appear to preferentially use highly conserved receptors such as the 
Coxsackie virus and adenovirus receptor  but further studies are needed to obtain 
conclusive results (50). Other host-range restrictions probably occur at the intracellular 
level, where viruses can for instance induce species-specific interferon responses, 
might be subjected to APOBEC 3-G related deamination or might be blocked through 
other species-specific host proteins (recently reviewed in (38)). Moreover, viral 
nucleotide composition and codon usage might further restrict host ranges. In several 
virus families (for instance influenza A, the asteroviridae and potentially the 
irioviridae) nucleotide composition and codon usage appear to correspond surprisingly 
well with those of the host species, and have been proposed as one mechanism of viral 
adaptation after cross-species transmission (15, 46, 47) 
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1.6. The evolutionary dynamics of cross-species transmission 
In most cases examined, a pathogen had to acquire several mutations to cross these 
host-range barriers (see for example (12, 24, 39)). It is still debated whether the 
phylogenetic relationship between the hosts is correlated with the required number of 
adaptive mutations, and whether  these mutations have to be pre-formed in the donor 
host or can arise after accidental spill-over into the recipient host (9, 10, 38). Pre-
adapted viruses might form in the donor host (a process potentially facilitated by 
relaxation of selective constraints) then be transmitted to the recipient host and 
subsequently colonize the new host.  Alternatively, adaptive mutations may arise in 
the recipient host after accidental spill-over. In this latter case, the original virus 
accidentally infects the recipient host during spill-over infections, after which the virus 
population is exposed to altered selection pressures. Selection will favor beneficial 
mutations in the new environment and the virus population will therefore rapidly 
accumulate adaptive mutations. Unfortunately, the currently available data are 
generally insufficient to determine conclusively which host-range mutations were 
generated de-novo in the recipient host and which had been pre-existing in the donor 
host. Moreover, the strong transmission bottleneck during cross-species transmission 
and the large number of deleterious or slightly deleterious mutations that arise 
simultaneously with a relatively small number of beneficial mutations complicate the 
analysis of these evolutionary dynamics, and complex epistatic interactions seem to 
frequently dominate the adaptation process ((43); reviewed in (24, 38)).  The success 
of the new pathogen appears to depend on the fitness cost associated with the 
‘intermediate’ viruses and the degree of genetic diversity present among viruses in the 
infected host, with more variable viral populations being particularly prone to generate 
successful emerging infections (3, 8, 50).  This intra-host diversity is a result of error-
prone viral replication and selection against mutation-bearing viruses. The structure of 
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viral populations in infected hosts and their major determinants, however, are rarely 
understood. It is further unclear how the emerging viruses acquire the necessary sets 
of host-range mutations. Given the potentially large size of viral sequence space, the 
specific sets of host-range mutations are very unlikely to arise simultaneously. Single 
mutations, on the contrary, are most likely deleterious as they will probably incur a 
fitness cost in the donor host and do not promote an expanded host spectrum, and are 
therefore likely selected against (10). Therefore, sequential accumulation of adaptive 
mutations appears also an unlikely event, raising the question of how viruses with 
altered host- range overcome this “fitness trade-off” (reviewed for example in (38)). 
Several evolutionary mechanisms such as recombination or somatic hypermutation 
might allow an expedited accumulation of mutations, but the key evolutionary 
conundrum of successful disease emergence remains unsolved.  
 
1.7. Onward transmission in the recipient host species 
The complete adaptation of pathogens to new host species is thought to be a sequential 
process involving several intermediate steps (3). After crossing the species barrier, 
successful onward transmission in the recipient host species appears to be the greatest 
hurdle for many EIDs. It is believed that most emerging viruses are initially unfit and 
frequently only cause stuttering, self-limiting transmission chains which are greatly 
affected by stochastic events. The population dynamics of the recipient host - and in 
particular its population density, contact rates and frequency of replenishment of naïve 
hosts - therefore strongly impact EID dynamics at this stage. Indeed, it has been 
shown through simulation approaches that novel pathogens with initial basic 
reproductive ratio (i.e. the number of secondary cases caused by the introduction of an 
index case into a naive, panmictic population) far lower than one can be successfully 
sustained in the recipient host population if the mutation rate is sufficiently large, 
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 exemplifying the potentially strong impact of stochastic events and the central role of 
the speed with which adaptive mutations can be harbored (3). Thus, only if further 
host adaptation occurs can the virus continue to circulate in the recipient host species 
and many novel viruses seem to fall short at this step.  The basic reproductive ratio 
most likely increases during this adaptation period and many  successful novel 
pathogens seems to have been circulating at low frequency in the recipient host 
species for years before causing widespread epidemics. For example, HIV strains 
dating back to the 1960s and 1970s have been described, often predating the HIV 
epidemic of the mid-1980s by more than a decade (reviewed for example in (17)).  
Wolfe et al. (2007) describe five distinct phases that human EIDs traverse as they 
emerge from zoonotic origins: (i) transmission restricted to animal hosts; (ii) spill-over 
into humans without onward transmission; (iii) spill-over with limited onward 
transmission; (iv) sustained transmission in human and animal species and (v) 
transmission restricted to humans. The authors hypothesize that diseases can stagnate 
at any of these stages and that this has happened for several well-recognized human 
diseases in the past. The authors further subdivide the fourth stage into three sub-
stages, depending on the relative importance of sylvatic cycles and direct human-to-
human transmission. Conversely, from the viewpoint of cross-species transmission, 
evolutionary stages two and three appear to be of greatest interest. During these 
periods with short, stuttering transmission chains, the detection and control of novel 
human EIDs appears most likely. Hendra and Nipha virus represent classical examples 
of stage 2 viruses while several hemorrhagic fevers (such as Ebola, Marburg and 
Lassa) represent viruses at stage 3 (Table 1.1). Avian influenza appears to be at the 
interface between steps two and three where only very limited human-to-human 
transmission appears possible.  
10
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1.8. Some unifying conclusions 
In conclusion, despite a significant increase in our understanding of EIDs over the past 
decades, several molecular, evolutionary, epidemiological and ecological drivers 
remain to be elucidated. A more complete understanding of host-range barriers, and of 
the evolutionary and population dynamics that allow EIDs to emerge and be sustained, 
might lead to better-targeted surveillance and control programs. Moreover, a better 
appreciation of the impact anthropogenic perturbations have on disease emergence 
will prove crucial as we face the global ecological challenges ahead.  
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CHAPTER 2 
 EVOLUTION AND VARIATION OF THE PARVOVIRUSES 
 
 
 
 
From:  Hoelzer, K. and Parrish, C.R. Evolution and variation 
of the parvoviruses. In: Origin and Evolution of Viruses, 2nd 
Ed. Domingo, E., Holland, J. and Parrish, C.R. (Eds).  
Elsevier, London 2008, with permission.  
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2.1. Summary 
The parvoviruses are small non-enveloped viruses that contain ~5,000 bases of linear 
ssDNA, and they are widespread in nature, infecting many different animals, from 
crustaceans to primates.  The viruses contain two large genes that encode proteins 
associated with the control of DNA replication and the capsid proteins, as well as 
variants of those proteins and some small accessory proteins.  These viruses replicate 
using the host cell polymerases, or for the AAVs with helper virus polymerase, but the 
amount of variation seen in nature or after tissue culture passage appears high, and the 
rates of sequence change of the viruses can be similar to that of some RNA viruses.  
Recombination clearly occurs among the parvoviruses, and may be an 
underappreciated evolutionary mechanism.  In specific examples the parvoviruses are 
shown to have different and often complex evolutionary processes.  The viruses 
appear to be remarkably adaptable in some cases; canine parvovirus for example was 
able to jump between hosts in a process that involved complex evolutionary 
mechanisms.   
 
2.2. Parvoviruses and their properties  
Parvoviruses are a family of small viruses with a non-enveloped capsid that contains a 
linear single stranded (ss) DNA genome of between 4,500 and 5,250 nts.  The viruses 
are very widely distributed in nature, and likely infect most vertebrate and invertebrate 
hosts (40, 115, 149).  The two subfamilies within the family Parvoviridae are the 
Parvovirinae which infect vertebrate hosts and the Densovirinae which infect 
invertebrates.   
 
19
Figure 2.1: The evolutionary relationship among the parvoviruses. A conserved 
region of the NS1 amino acid sequence of representative parvoviruses of vertebrates 
(i.e. residues 277 to 387 of MVM sequence NP_041242) was  aligned by eye and 
using the Clustal W algorithm available in MegAlign. Phylogenetic relationships were 
determined using PAUP version 4.0b10 for Unix to construct neighbor - joining trees.   
 
Within the Parvovirinae the phylogenetic relationships can be shown using a 
conserved region of the NS1 gene sequences. The parvovirinae fall into several 
distinct, well separated clades (Figure 2.1).  The five recognized genera are the 
parvoviruses , which include various rodent parvoviruses such as Minute Virus of 
Mice (MVM) and H1 as well as the parvoviruses of carnivores such as canine 
parvovirus (CPV), feline panleukopenia virus (FPV) and mink enteritis virus (MEV); 
the erythroviruses (human B19 virus and related viruses of primates); bocaviruses 
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(bovine parvovirus type 1, minute virus of canines (MVC) and human bocavirus); 
Amdoviruses (Aleutian mink disease virus (AMDV)) and the dependoviruses (adeno-
associated viruses (AAV)) of humans and other hosts, which primarily replicate in 
cells which are coinfected with an adenovirus or herpesvirus.  In the Densovirinae the 
four genera are the Densoviruses, Iteraviruses, Pefudensoviruses and 
Brevidensoviruses.  Densovirinae infect many different invertebrate hosts from the 
Classes Insecta and Crustacea. Viruses have been isolated from various insect hosts, 
including members of the Orders Lepidoptera, Diptera, and Orthoptera.  Several 
viruses infect members of the crustacean order Decapoda, but those viruses are still 
less well characterized.  The Densovirinae are considerably more diverged than the 
Parvovirinae. 
 
2.2.1. Gene Structure and Replication.   
The parvovirus virion contains a single ssDNA molecule, and most members of the 
parvovirus genus, such as MVM, H1 or CPV preferentially package the negative 
strand, while others such as the dependoviruses and erythroviruses and the parvovirus 
LuIII package ssDNA of both polarities with similar frequencies. The bovine 
parvovirus type 1 preferentially packages negative sense DNA, but approximately 
10% of viral capsids contain positive strand DNA (31). The detailed processes 
involved in ssDNA packaging and the molecular determinants responsible for the 
packaging bias involve the relative efficiency of the left- and right-hand origins of 
replication in initiating replication (42). Parvoviruses use parts of the host cell 
polymerase complex for viral DNA replication including the α and/or δ polymerases, 
perhaps among others, under various circumstances (12, 15, 36, 89) as well as a 
variety of cellular proteins including Cyclin A and chaperone-associated proteins. 
Viral DNA replication depends on the host cell passing through S-phase (41). Some 
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parvovirus proteins appear to affect the host cell cycle (113, 114, 126), generally by 
leading to cell cycle arrest in G1 or G2.  The ssDNA genome is filled in through 
reactions that may involve the cellular DNA repair responses.  In the case of the 
AAVs the viral genome is converted into circular and concatameric forms in the 
absence of active DNA replication.  However, parvoviruses do not directly induce 
mitosis, but must wait until the host cell enters S-phase (125). Dependoviruses require 
additional factors for productive infection, although genotoxic stimuli such as UV 
light, cyclohexamine treatment and heat exposure can lead to permissive replication 
(reviewed in (15)), but dependoviruses replicate mostly in the presence of early gene 
products of their helper viruses.  
 Replication initiates from the incoming genome which is converted into a 
double-stranded (ds) DNA intermediate within the nucleus, and then proceeds through 
a modified rolling-circle mechanism (rolling-hairpin), where the palindromes located 
in each end of the genome are used for replication of the virus templates (16, 38, 41, 
74). The dependoviruses and erythroviruses have identical palindromes at the 3’ and 
5’ end (inverted terminal repeats (ITRs)), while the parvoviruses, bocaviruses and 
ambdoviruses have different palindromes, leading to more complex replication 
mechanisms.  The 3’-end of the genome forms a base paired structure that primes 
second-strand synthesis, leading to the generation of the first replicative form (RF) 
DNA which extends and unfolds the 5’ palindrome.  Subsequent replication is NS1 
dependent and creates origins by nicking specific sites in the sequence to create a new 
5’ end, and the NS1 helicase activity unfolds the 5’-end of the DNA, and then that is 
replicated and refolds, a process termed hairpin transfer, giving inverted palindromes. 
Subsequently replication proceeds through the formation of dimeric or tetrameric RF 
DNA, where nicking by the viral NS1 protein and strand exchange is involved in the 
resolution of the DNA replication intermediates (43).  There are a number of aspects 
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of this replication scheme that would favor higher substitution rates compared to the 
normal cellular DNA replication.  The parvovirus replication may not require the 
complete polymerase complex used for the synthesis of the host DNA, the genome is 
likely not methylated so that the template strand is not identified during replication, 
the single stranded form of the genome would be vulnerable to base conversion and 
the initial fill-in is not error corrected.   
 
2.2.2. Viral gene functions.   
The parvoviruses are genetically simple, and their genomes contain two large open 
reading frames (ORFs), where the left-hand ORF encodes the non-structural genes and 
the right hand ORF encodes the capsid proteins (Figure 2.2). The genomes contain 
between 1 and 3 promoters, depending on the virus.  Alternative splicing, alternative 
transcription start sites, or alternative initiation of translation can give rise to 
additional gene products, and the two major ORFs give rise to messages for between 
one and 4 non-structural proteins, and between 2 and 4 capsid proteins.  The 
bocaviruses contain a third ORF, located between the other two ORFs which encodes 
a phosphorylated NP1 non-structural protein of unknown function (5, 32, 92, 141). 
 
2.2.3. Non-structural proteins.  
The NS1 and Rep proteins in the parvoviruses and dependoviruses, respectively, are 
multifunctional proteins required for DNA replication, for regulation of viral gene 
expression, and for integration of some AAV genomes into the host DNA, and they 
have site-specific nickase activity, ATPase, ligase and helicase activities. During 
replication they are covalently attached to the 5’ end of the viral DNAs. NS1 interacts 
with various cellular proteins including transcription regulators and members of the 
replication machinery, and it induces cytopathic effects. The phosphorylation status of 
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the protein is intricately involved in regulating the various NS1 functions (91, 121, 
122), and cytopathic potential (46).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: The genome structure of autonomous parvoviruses (MVM)  and 
Dependoviruses (AAV-2).  The members of the Parvoviridae vary in having from 1 to 
3 transcriptional promoters, one or more sites of poly-A addition, in the presence of 
smaller non-structural protein genes and in having identical or different terminal 
palindromes. R= transcriptional products; NS or Rep= non-structural proteins involved 
in replication; V= viral capsid protein; SAT= small open reading frame of largely 
unknown function.   
The smaller Rep proteins lack the DNA-binding and replication functions of 
the larger Rep proteins, but do retain the helicase and ATPase function, and they 
stimulate the production of ssDNA and are likely to be involved in packaging of the 
viral DNA (34, 51, 145).  The NS2 proteins of MVM or the rat virus LuIII appear 
dispensable for viral replication in host cells other than mouse or rat cells respectively, 
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but are required for efficient translation or assembly of the virus capsid in the natural 
host cells (35, 39, 45, 52, 94, 117).  The functions of NS2 are not completely defined, 
but the protein interacts with 14-3-3 family member proteins and with the Crm1 
proteins involved in nuclear export (22, 24, 107). NS2 is itself regulated by 
phosphorylation and may be involved in phosphorylation of the capsid proteins and 
nuclear export of capsids (45). In CPV NS2 does not appear required for virus 
replication in dog and cat cells in tissue culture or in dogs  (161).  
 
2.2.4. Capsid proteins and genes.   
VP1 and VP2 are produced by a variety of strategies, including alternative splicing of 
the viral mRNA producing ~10% VP1 and 90% VP2 (40).  The proteins overlap in 
sequence so that the entire 62-70 kDa VP2 is contained within the VP1 sequence, with 
VP1 having a unique N-terminal extension (~ 120 and 150 amino acids depending on 
the virus). Erythroviruses and Ambdoviruses have capsids containing only VP1 and 
VP2 while the capsids of Dependoviruses contain VP1, 2 and 3 which are obtained by 
alternative splicing of the mRNA. The full (DNA containing) capsids of members of 
the parvovirus genus contain a smaller VP3, which is generated from the VP2 protein 
by proteolytic cleavages of the N-terminus.  
 Located in the VP1 unique region of most parvoviruses is a phospholipase 2 
(PLA2) enzyme domain required for cell infection (56, 63, 169) most likely because it  
modifies the endosomal membrane and allows the viral particle to penetrate into the 
cytoplasm (56, 147). 
 
2.2.5. Structure of the viral capsid.   
The parvovirus capsids are small and appear to contain only a limited number of 
antigenic sites.  However, those have mostly been defined using analysis of naturally 
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or selected antibody escape mutants or by analysis of peptide binding, and it is not 
clear how accurately those represent the true binding sites of the normal host 
antibodies.  Most antigenic sites appear to be conformation dependent, but linear 
epitopes defined include the N-terminus of VP2 which is exposed to the exterior of 
CPV full (DNA containing) capsids, and the N-terminus of VP1 for the B19 
parvoviruses (95, 139, 146, 167) and AAV2 capsids (162, 163).  The role of antigenic 
variation and immune selection in the evolution of most parvoviruses is not well 
understood, and in some cases the analysis is complicated as many of the changes 
which result in antigenic variation also alter host range or other properties of the virus 
by altering binding to the cellular receptor (30, 128).  Genetically distinct viruses can 
be distinguished by serology with polyclonal sera, but within many virus groups little 
antigenic variation has been described even among viruses that have been separated by 
decades.  Variation of capsid epitopes of natural CPV or MEV isolates has been 
identified using monoclonal antibody analysis, and some variants have become widely 
distributed around the world (103, 118, 130, 146).  For MVM antigenic variants were 
selected in tissue culture after selection with neutralizing monoclonal antibodies, but it 
is not known whether such variation is common among the viruses in nature (95).  For 
many parvoviruses animals that have recovered from infection resist re-infection by 
antigenically related viruses, even those variant at one or more epitopes.  However, in 
natural transmission cycles low levels of waning maternal antibody may allow 
infection and provide an environment allowing selection of antigenic variation.   
 
2.3. Epidemiology and antiviral immunity 
The epidemiology and pathogenesis of the virus infections varies widely, and likely 
influences the variation and evolution of the viruses.  Many autonomous parvoviruses, 
including canine parvovirus (CPV), feline panleukopenia virus (FPV), porcine 
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parvovirus (PPV), and B19 human parvovirus, normally cause acute infections of their 
hosts lasting <10 days. Virus is usually cleared by the host immune response within 
this time span, after which infectious virus is not present, and the recovered hosts are 
no longer infectious for other animals (116, 129, 156).  However, prolonged 
replication and persistence may occur in some of those hosts, particularly during fetal 
infection or when immune suppressed.  Persistent infections may affect the 
development of intra-host variation, permit mixed infections, and could result in 
prolonged shedding with the re-introduction of older viruses back into circulation.  
Persistent infection and shedding occurs for some viruses, including rodent 
parvoviruses where persistence in the kidneys results in shedding in the urine. AMDV-
infected adult mink are persistently infected and the virus continues to replicate in a 
number of tissues for long periods (2, 81-83, 134, 137). In neonatal mink AMDV 
causes an acute disease without persistence developing. Viral replication in neonates 
occurs in type II pneumocytes, while in older animals replication is limited to 
macrophages in the lymph nodes with reduced transcription and replication. In many 
genotypes of mink a chronic immune complex mediated disease develops (1, 3, 84).  
A small proportion of chronic and persistent B19 infections occur in humans who are 
immune suppressed, or who do not develop effective immunity (27, 57, 168). Even in 
normal infections there may be low-level persistence of B19 DNA in the presence of 
antibodies, although that DNA may not be infectious (29, 93, 102).  Secondary 
infections by variant erythroviruses have been reported (67, 87).  
 The epidemiology of the newly discovered human bocavirus (101) is not well 
understood, but clinical disease appears to occur in the presence of other respiratory 
virus infections (58).  Whether human bocavirus is persistent is not yet known.  Some 
bovine parvoviruses can be recovered from fetal bovine sera, suggesting that those 
may also cause longer term or fetal infections (4).  The recently discovered human 
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parvoviruses PARV4 and PARV5 appear generally apathogenic, although an 
association with HIV infection is possible (102). 
 
2.4. Mechanisms of transmission 
Viruses similar to CPV use a fecal-oral transmission cycle, but replicate systemically 
in the host tissues before invading the intestine (99, 100, 129).  Some rodent 
parvoviruses also replicate in the intestine, but may be transmitted through urine after 
replication in the kidney (11, 81).  Although the human B19 virus replicates primarily 
in the bone marrow, it is thought to be transmitted by respiratory routes (26).  
Parenteral transmission is possible as B19 virus is inefficiently inactivated in blood 
and blood products (8, 20, 67, 133).  Veneral transmission might be important for 
porcine parvovirus (PPV) as PPV or viral DNA can be isolated from pig semen (66).  
Vertical transmission has been shown for several members of the parvovirus genus 
including several rodent parvoviruses, FPV and PPV (85, 106).  Transplacental 
transmission can occur for many parvoviruses, although the fetus might be protected 
by maternal antibodies, depending on the host species and type of placentation (25, 47, 
53, 68).  Since the non-enveloped parvovirus capsid is very resistant in the 
environment, viral spread through vectors or formites occurs and might explain the 
global spread observed for some parvoviruses such as CPV and B19.  
 
2.5. Immune response and protection 
There is clearly an important role for cell mediated immunity in recovery from 
infection and there may be limited numbers of T cell epitopes in the viral proteins 
(86).  However, for many vertebrate viruses humoral immunity, including maternal 
antibody, protects against infection by antigenically related viruses.  Antibody 
treatments can arrest CPV replication in dogs, and can terminate chronic human 
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infections by the B19 parvovirus (26, 27).  In the case of CPV, FPV, PPV and B19 the 
virus is functionally inactivated within a few days of the antibody response 
developing, while in contrast (as described previously) AMDV forms persistent 
infections despite the strong immune response (2, 137).  
 
2.6. Genetic relationships and variation among the members of the family 
parvovirus 
Comparing the sequences of conserved regions of the genome shows that all 
parvoviruses have sequences in common, and are related through a distant common 
ancestor (Figure 2.1).  The viruses are divide into distinct clades which may show 
some correlations to the hosts of origin (98).  As more viruses are collected and 
analyzed, a variety of more-or-less related viruses has been seen to infect many 
species.  For example, three distinct bovine parvoviruses (types 1, 2, and 3) infect 
cattle (4), and there are two distantly related parvoviruses infecting dogs (141).  The 
several erythroviruses from primates (B19 and related human and primate 
parvoviruses) are most closely related to each other and to the chipmunk parvovirus 
(98, 166).  Most viruses from rats, mice and hamsters were found to be within the 
same clade as CPV and the related viruses of carnivores and PPV, while AMDV was 
found to be quite distantly related to all the other vertebrate viruses (Figure 2.1).  The 
LuIII virus proved to be a recombinant between two different rodent viruses, most 
likely between MPV and Hamster PV (98), although whether that occurred in nature 
or during passage of the virus in tissue culture is not clear (Figure 2.3). True times of 
divergence of the various viruses are not known as no long term molecular clock can 
be estimated.  Whether particular vertebrate parvoviruses have co-evolved along with 
their hosts or have crossed between different hosts in more recent times is also not 
known, although both origins are likely for different viruses.    
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Figure 2.3: Analysis of the genome of the parvovirus LuIII, compared to the  
genome of mouse parvoviruses and the Hamster parvovirus, or to the genomes of 
MVM-related viruses, showing the position of recombination (arrows) around the 
middle of the genome. From ( Lukashov et al., 2001),  with permission. 
 
The LuIII virus proved to be a recombinant between two different rodent viruses, most 
likely between MPV and Hamster PV (98), although whether that occurred in nature 
or during passage of the virus in tissue culture is not clear (Figure 2.3). True times of 
divergence of the various viruses are not known as no long term molecular clock can 
be estimated.  Whether particular vertebrate parvoviruses have co-evolved along with 
their hosts or have crossed between different hosts in more recent times is also not 
known, although both origins are likely for different viruses.    
 
2.6.1. Human B19 and related erythroviruses.  There are several human 
erythrovirus strains that are related to B19. Strain variation of the B19 related viruses 
so far shows no association with specific clinical signs or tissue tropisms (50, 55, 60, 
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70, 140).  Three genotypes have been identified (142), with the prototype B19 viruses 
classified as genotype 1 (Figure 2.4). Genotype 2 was first identified as the LaLi strain 
(originally isolated from a Finnish skin sample), and also comprises the A6 strain, 
both of which are ~11% divergent from the B19 reference strains at the nucleotide 
level (73, 142, 164). Genotype 3 was originally isolated from a patient with aplastic 
crisis in Paris in 1995 (as the V9 virus) (120), and is ~12% divergent from B19 at the 
nucleotide level.  The different human erythroviruses are between 5 and 20% different 
at the DNA sequence level (29, 60, 73, 142), but most mutations are synonymous and 
the viruses are >96% homologous in amino acid sequence. Antibodies against 
genotypes 1 or 2 are cross-reactive (54, 69).  When examining the B19-related viruses, 
between 1 and 4% sequence variation was found between isolates within each clade.  
The simian erythroviruses were 40-50% divergent at the nucleotide level from human 
erythroviruses. 
 
2.6.2. CPV and related viruses.   
DNA sequences of viruses from dogs, cats, raccoons, mink, and arctic foxes have been 
examined in a number of studies (76, 80, 144, 155).  CPV was recognized in 1978 as 
the cause of new diseases of dogs, and all canine isolates derived from a common 
ancestor which arose during the late 1960s or early 1970s (144, 155) (Figure 2. 5). The 
sequences of viruses from cats, mink, raccoons or foxes all fell within a single clade, 
suggesting that interspecies transmission of those viruses occurs. 
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Figure 2.4: The diversity in the sequences of human erythroviruses related to the 
prototype B19 virus, showing the three distinct genotypes that have been 
characterized. From ( Servant et al., 2002), with permission. 
 
The specific origin of CPV has not been completely defined but the most closely 
related virus was an isolate from an Arctic fox in Finland (BFPV isolate, Figure 2.5).  
It was suggested early on that CPV might be derived from vaccine strains of FPV 
(152), but DNA sequence analysis showed the CPV isolates were unrelated to vaccine 
strains tested (154). Serology and analysis of viral DNA from paraffin-embedded 
tissues (158) show that CPV was circulating in Europe between 1974 and 1976.  Many 
of the substitutions in CPV were located in the capsid structure (Figure 2.6).  
Significant levels of antigenic variation have been demonstrated by monoclonal 
antibody (MAb) analysis, which showed that CPV isolates differed from viruses from 
cats, mink, or raccoons in two specific neutralizing epitopes- one present only on 
CPV, and the other present on FPV isolates (109, 130, 131, 146). 
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Figure 2.5:   Phylogenetic tree of 91 VP2 gene sequences from carnivore 
parvoviruses, rooted with the oldest sampled sequence. Bootstrap values are shown for 
relevant nodes, and nodes with > 70% support are marked with an asterisk. Horizontal 
branch length are drawn to scale. The name of each isolates is followed by the location 
and year of isolation.  Locations are coded as follows: UK, United Kingdom; US, 
United States; JA, Japan; FR, France; AU, Australia, FI, Finland; GE, Germany; TA, 
Taiwan, NZ, New Zealand; VI, Vietnam; EU, Europe (no further information 
available); PO; Poland; IT, Italy; SA, South Africa. The FPV clade is shown in blue, 
the CPV-2 subclade is shown in yellow, and the CPV-2a subclade is shown in red. 
BFPV, blue fox parvovirus. From (Shackelton et al., 2005); with permission.  
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During the later evolution of CPV a number of mutations altered the antigenic 
structure of the capsid.  However, many of the changes which altered the antigenic 
structure of the capsid also changed the TfR binding sites, making it difficult to 
determine which functions are under selection.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: A model of one asymmetric unit of the CPV capsid, showing the locations 
of substituted amino acids.  Sites that changed along the FPV-CPV branch are in blue, 
with the darker shade indicating surface-exposed residues and the lighter shade 
showing the relative position of the surface sites. Sites that underwent substitutions 
along the CPV-2 - CPV-2a branch are in green, and sites responsible for variants 
within the CPV-2a subclade are in yellow; all surface-exposed. From (Shackelton et 
al., 2005), with permission.  
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The various FPV and CPV isolates differ in their abilities to infect cells in 
culture and animals, and the subsequent evolution in dogs further changed their natural 
host ranges. The CPV type-2 isolates did not replicate in cats, but later viruses (CPV 
type-2a and its derivatives) replicated efficiently in cats (153).  This was a natural host 
range for the viruses as CPV type-2a and related viruses were isolated from 10 to 20% 
of cats which had natural parvovirus disease in Asia, Germany, Italy and the USA 
during the 1990s (13, 79, 108, 157).   
 
2.6.3. Aleutian Mink Disease Virus (AMDV).   
There is significant variation in the genomes of AMDV isolates, and the genetic 
variability of the viruses from a single farm or region was found to be up to 16% at the 
nucleotide sequence level (124).  AMDV isolates normally grow only in animals, but 
certain strains have been adapted to grow in feline cells in tissue culture.  A 2.5% 
sequence difference was seen between a wild type pathogenic strain of AMDV and a 
tissue culture adapted virus. Intriguingly, a hypervariable sequence was detected 
within the capsid protein gene, most likely located on the surface of the VP2 protein 
structure (21, 105, 123).  AMDV has also been recovered from ferrets, skunks, and 
raccoons.  The raccoon and skunk viruses appear similar to viruses isolated from 
farmed mink, although it is not known whether there is natural transmission between 
those hosts (123).  
 
 
2.6.4. Rodent parvoviruses.   
The known and suspected rodent parvoviruses are all >70% identical in DNA 
sequence, while viruses that are considered to be of the same type and given the same 
name are generally >95% identical (Figure 2.7). The rodent parvoviruses MVM, LuIII 
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and H1 have been intensively studied for their genetic and biochemical properties, but 
there is less information about the variation and evolution of their strains in nature.   
 
Figure 2.7: Relationship between the rodent parvoviruses, determined from the 
almost-complete genome sequences. The phylogeny was prepared by maximum 
likelihood using PAUP version 4.0 for Unix. Branch lengths are proportional to the 
distances between the different taxa, and the numbers on the branches indicate the 
number of substitutions. Viruses are: KRV, Kilham rat virus; H1, parvovirus H1; 
RPV, rat parvovirus; MPV, mouse parvovirus; MVM, minute virus of mice, which are 
divided into distinct clades. The porcine parvovirus (PPV) was used as an outgroup in 
the analysis.   
 
Many early strains were isolated from tissue cultures or transplantable tumors, 
and their true origin and degree of tissue culture or host adaptation are not fully 
understood.  Those viruses include the MVM prototype strain (MVMp) isolated from 
a murine adenovirus stock (44), H1 virus from the HEP-1 human tumor transplanted 
into rats and likely a rat virus (151) and LuIII from human cells.  Tissue culture 
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isolates of MVM isolated from lymphocytes in 1976 and immune suppressive in vitro 
were named MVMi (23) while MVM-Cutter (MVM-(c)) was a contaminant of 
BHK21 cells (17). A number of viruses have been detected directly in mice, including 
mouse parvovirus (MPV)) strains 1a, 1b, 1c, 2 and 3, a new MVM strain MVMm 
which is pathogenic in non-obese diabetic (NOD) mice, as well as viruses of hamsters 
(hamster parvovirus (HaPV)), and rats (rat parvovirus (RPV)) (11, 18, 19, 159, 160). 
These viruses appear common in wild rodents (14), and until these were identified and 
testing introduced they were also widespread in rodent colonies (10, 11, 18, 81, 160). 
Many of the rodent parvoviruses are difficult to grow in tissue culture and the 
adaptations allowing tissue culture growth are poorly understood.   
 Apart from the relationships between the viruses at the sequence level, little is 
known about the details of their evolutionary histories or any host range differences 
between these viruses, or about their temporal variation. Recombination has been 
demonstrated among the rodent parvoviruses (Figures 2.3 and 2.8) and porcine 
parvovirus and may be a common event. 
 
2.6.5. Adeno-associated viruses (AAV).   
AAVs have been isolated from primates and from many other mammalian and avian 
hosts. Most depend upon a helper virus for replication, while some related viruses 
replicate independent of helper viruses.  AAV was discovered in the 1960s as 
contaminant of Adenovirus preparations (7, 72).  
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Figure 2. 8: Phylogenetic analyses showing recombination among the rodent 
parvoviruses. Colors indicate different rodent virus types. Nodes with > 70% bootstrap 
support are shown and branch lengths are scaled according to nucleotide substitutions 
per site. From (Shackelton et al., 2007), with permission.  
 
The AAVs of humans and non-human primates are currently divided into 5 species 
(AAV 1-5) and two tentative species (AAV 7 and 8), with the AAV1 species 
containing 2 strains (AAV strain 1 and 6) and all other species containing one AAV 
strain (149) (Figure 2.9).  Screening of tissue samples from humans and other primates 
by PCR detected large numbers of DNA sequences, and in human and non-human 
primate tissue the AAV prevalence was ~19% (61, 62). AAV 1 and 6 were closely 
related, and sequence identity between the other strains ranged between 75% and 82%. 
The primate AAVs fell into a number of distinct clades (62). 
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Figure 2.9: Phylogenetic relationships between the VP1 protein sequences of primate 
AAVs. X = major nodes with bootstrap values of <75. Goose parvovirus and an avian 
AAV were used as the outgroup. Clades are indicated by name and by vertical lines. 
Viruses are identified by the serotype name or a reference to the species source (hu, 
human; rh, rhesus macaque; cy, cynomolgus macaque; bb, baboon; pi, pigtailed macaque; 
ch, chimpanzee), number = order of sequencing. Clade C originated through the 
recombination of known clades. The AAV2-AAV3 hybrid clade originated after one 
recombination event, and its phylogeny is shown. From (Gao et al., 2004), with 
permission.  
 
Clades B and C seemed most prevalent in humans, Clades A and F were only 
found in humans and clade D in macaques, while clade E was isolated from both 
humans and non-human primates. Evolution of AAVs might be at least partly driven 
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by their helper viruses, and some AAVs may also have co-evolved with their hosts but 
experimental or phylogenetic evidence is missing. Recombination between AAV 
genomes seems to occur frequently and can give rise to replication-competent vectors 
following homologous recombination (6, 61). 
 
2.7. Genetic variation and replication error rate 
The level of variation of the parvoviruses can be high when measured over defined 
time periods.  This has been seen in studies of variation for CPV and B19 parvovirus 
in nature (143, 144), in the growth of CPV through serial passage in tissue culture (9), 
and in the analysis of MVM during replication under selective conditions such as 
replication in alterative hosts (97) or monoclonal antibody selection (95).  However, it 
is not know how much variation occurs during the replication of the parvovirus 
genome.  Although the viral DNA is replicated using host cell DNA polymerases, the 
fidelity of replication is likely lower than that seen for the host chromosomal DNA 
replication.  If DNA repair mechanisms are activated during parvovirus replication 
those might also lead to higher mutation rates, perhaps due to the use of alternative 
DNA polymerases, or to the filling in of the replicated  ssDNA forms (90).   
 
2.8. Intra-host diversity during natural infections 
The degree of intra-host diversity has been assessed for B19, MVM and AMDV 
infections, and most recently also for one CPV infected cat.  While there are probably 
differences in selective pressures between the chronic infections of ADV and MVM 
and the acute infection of CPV, all of these studies showed intra-host variation or 
diversity. 
 Analyzing individual virus genomes isolated from one CPV infected cat 
revealed diversity in a 1745 bp fragment of the VP2 gene (13).  Sequences were 99.5 
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to 99.9% identical in nucleotide sequence and 99.3 to 99.8 % identical in amino acid 
sequence, but 10 distinct sequences were observed among 14 analyzed viral clones.  
Two antigenically distinct CPV variants (CPV type-2a and a variant with the VP2 
D426E substitution, named CPV type-2c) were isolated from this animal, indicating 
that this was likely a co-infection by co-circulating strains. The ratio of non-
synonymous to synonymous changes (dN/dS ratio), when compared to extant CPV 
strains circulating in Italy, ranged between 0.08 and 0.4 for individual clones, 
suggesting purifying selection on the capsid gene.   
 A spectrum of AMDV sequences was seen in experimentally infected Danish 
mink, with several different sequences in mink inoculated with a single inoculum.  
The sequences differed by up to 5% and also differed in the highly variable region 
(64).  Since AMDV can establish persistent infections, it is likely that mixed infections 
occur, and viral inocula used in these studies potentially contained multiple virus 
strains.  Comparing viral non-structural gene sequences (nts. 123-2208) from different 
AMDV isolates showed extensive variation in the different samples (65).   
Experimental MVM infections in immune deficient mice using molecularly 
cloned virus stocks showed emergence of variation over a period of days or weeks (95, 
96, 138).  The original viruses used had likely been tissue culture adapted, and MVMp 
variants contained non-synonymous changes in the VP1/2 gene at sites which gave 
lower affinity binding of sialic acid (96, 119) (Figure 2.10). When treating severe and 
combined immunodeficient (SCID) mice with a neutralizing monoclonal antibody, 
escape mutants rapidly arose and quickly dominated the viral population, leading to a 
delayed onset of clinical disease.  Substitutions were located close to a raised region at 
the 3fold axis of symmetry (95).  However, polyclonal anti-capsid antibodies did not 
allow escape mutations of the MVMi strain to be selected, and non-synonymous 
changes were restricted to the NS2 protein, along with two changes in both NS1 and 
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NS2.  NS2 changes clustered into two regions and altered the biochemical properties 
of the protein (97). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Sequence variation found in a part of the genome of the minute virus of 
mice prototype strain (MVMp) after growth in immunodeficient mice. (Top) Amino 
acid substitutions in the entire capsid protein (VP) gene of isolated MVMp clones 
from various organs (B=brain, K=kidney, L= liver). (Bottom) Distribution of amino 
acid changes in the collection of MVMp clones where a region of the genome (nt. 
3710 to 4200) from 48 viral clones from 7 mice (numbered 1-7) was amplified. The 
amino acid changes at residues 325, 362 and 368 of the VP2 sequence are outlined. 
N=number of clones with identical genotypes in this region. From (Lopez-Bueno et 
al., 2004), with permission.  
 
   
 Adeno-associated viruses show sequence diversity both within hosts and 
within the population.  Mutations are primarily located in variable regions of the 
capsid proteins which are exposed to the outside of the capsid and some represent 
antigenic sites or receptor binding sites (127, 165). Immune responses against AAVs 
in vivo suggest a potential role of immune escape (reviewed by (110)).   
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 2.9. Virus variation at a population level (spatial heterogeneity) 
Sequence variation of the B19 viruses in humans has been analyzed comparing viruses 
from different regions of the world or from chronic and acute infections.  There 
appears to be a global distribution of the viruses - there was close similarity between 
some isolates collected from various regions of the world, and also between viruses 
collected at various times over the past two decades.  However, viruses collected from 
one geographic area are generally more similar to each other.  For B19 viruses, viruses 
from patients with persistent infections appear to have a higher level of variation 
compared to viruses from patients with acute infections.  Comparing 7 isolates 
collected in Italy between 1989 and 1994 from one geographic area showed maximum 
variation of 0.61% in a 1000 nt. sequence within the amino terminal end of the VP 
genes (59).  Those viruses were 0.7% and 0.77% different on average from the 
prototype Wi and Au sequences of viruses collected in the UK and USA, respectively, 
and there were 9 non-synonymous changes, 7 between residues 4 and 114 in VP1 
sequence and 2 within the VP1/VP2 common region (59).  Viruses from Vietnam 
showed the presence of two genotypes of the type 1 B19 in that country (150) 
 The sequences of the complete VP1 and VP2 gene region (2343 nts) of 29 
isolates from 25 infected patients in various regions of the world were compared to 
each other, and to the 2 published Wi and Au sequences.  Those viruses included 10 
from an outbreak in Ohio, USA, one a mother-child pair, and other isolates from the 
USA, UK, Brazil, Ireland, Venezuela, Korea, Japan and China (55).  The sequences 
differed by between 2 and 99 nucleotides (4.2%), and by 0 and 13 (1.7%) in amino 
acid sequence.  Nucleotide variation was found throughout the VP1 and VP2 genes, 
but coding changes clustered in three regions,  the VP1-unique region, around the 
junction of the VP1 and VP2 coding regions, and within the VP1 and VP2 overlapping 
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region.  Isolates from the outbreak in Ohio were divided into two classes, represented 
by 7 and 2 samples each (55).  Within each group the sequences differed by only a few 
nucleotides, and where multiple isolates were collected from 4 individuals only a 
single difference was found in the sequences from each person.  There was some 
geographic clustering of the strains- viruses from China formed a distinct clade, while 
those from the USA were generally clustered, as were the isolates from Korea.   
 Viruses recovered from chronic and acute infections were examined in several 
studies, and in most cases no specific correlation was seen between any particular 
disease syndrome and any virus type (59, 88, 111, 112, 148).  Higher genomic 
variability has been seen in the B19 sequences recovered from cases of persistent 
infection compared to those from acute infections (78).   
 
2.9.1. Spatial heterogeneity of CPV and related viruses.   
CPV and the closely related viruses have also been examined closely. CPV-like 
viruses were first circulating in Europe in the mid to late 1970s, and early CPV-2 
isolates were essentially identical in nucleotide sequence, and were all replaced by the 
variant CPV-2a strain which spread worldwide in 1979 and 1980.  Other mutations 
have been seen worldwide in various countries since 1980, including a mutation 
changing VP2 residue 426 (referred to as CPV-2b) from Asn to Asp first seen around 
1984 which spread worldwide.  More recently viruses with residue 426 as a Glu 
(referred to as CPV type 2c) have been identified in Europe (48, 103), Vietnam (118), 
and in North and South America (136).  The reasons for the global spread of some 
mutations and the time of their emergence are hard to explain.  CPV types 2a and 2b 
co-circulated throughout the world (although in different proportions) over the 20 
years without either becoming fixed. CPV2a and 2b co-circulated in Brazil as early as 
1986 (135) while CPV-2b was the predominant variant circulating there between 1995 
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and 2001 (37).  The dominant CPV type circulating in Italy at that time was CPV-2a 
(104), while both CPV2a and 2b circulated at similar frequencies in 1999/2000.  There 
appear to be Taiwanese-Japanese and Indian CPV populations which are 
phylogenetically distinct from US American and Vietnamese populations (33, 49, 71). 
Additional mutations that have been observed include Ser297Ala and Glu300Asp, 
which may affect receptor binding or host range properties of the viruses.  However, 
an analysis of CPV isolates from Brazil and other regions failed to detect clear 
geographic pattern in extant parvovirus isolates (135).   
 
2.10. Temporal variation 
Good temporal data analyzing the evolution of parvoviruses are still relatively rare.  
The best defined are those that examine the evolution of CPV after the host jump into 
dogs, where all viruses have evolved from a single common ancestor with an 
accumulation of mutations. Early time points after the colonization of a new host are 
thought to coincide with accelerated mutation rates due to host adaptation, while other 
times in the CPV pandemic appear to be characterized by selective constraints.  
During the emergence of the CPV lineage the viruses showed a steady rate of change 
of around 10-5 /site/year (144).  Many of the capsid protein gene differences between 
CPV and the FPV-like viruses are associated with changes in host range, antigenicity, 
and sialic acid binding properties of the viruses, suggesting they are under strong 
selection (30, 75, 77).  The CPV lineage split into two major variants during the mid-
1970s, with the CPV type-2 strains emerging worldwide in 1978, and the CPV type-2a 
variant replacing the CPV type-2 viruses during 1979 and 1980 (Figure 2. 5).  The rate 
of variation of FPV was lower than that seen for CPV (76, 144). Analysis of Brazilian 
CPV2 sequences indicated neutral evolution in the early phase of the pandemic 
(analyzing isolates collected around 1980), while later time points (isolates collected 
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around and after 1990) were associated with strong purifying selection, with the 
exception of a change of VP2 residue 297, which was under strong positive selection. 
A Bayesian Skyline plot analysis showed an initial very rapid spread with a 
subsequent decreasing spread (135) (Figure 2.11).  
CPV isolates collected during 1978 and early 1979 were all antigenically identical 
worldwide, but the CPV type-2a strain differed in the VP1/VP2 protein by 4-5 amino 
acids compared to CPV type-2 isolates. CPV type-2a also differed from CPV type-2 in 
having lost two antigenic epitopes and gained two epitopes on the capsid (146).  Other 
antigenic variants emerging around 1984, and during the later 1990s and early 2000s 
each contained a single amino acid sequence difference within neutralizing epitopes in 
the capsid (28, 79, 80, 118).  Despite the small numbers of differences those viruses 
each became globally distributed within a year or two of being detected.  Natural 
antigenic variation of FPV and MEV isolates has also been described (109, 131, 132). 
It is unclear what the consequences are of the antigenic variation that is seen in some 
of the viruses, but in general there appears to be good cross-protection between 
antigenically variant strains.   
 
 
2.11. Conclusions 
Our understanding of the evolution of the parvoviruses is still being developed, but 
there are some interesting conclusions that can be drawn.  All of the parvoviruses 
appear to derive from a common ancestral virus, but the different genera are mostly 
well separated genetically, suggesting long divergence times.  Surveys for non-host 
DNA sequences often show sequences of previously unknown parvoviruses, 
suggesting that there are many different viruses still to be discovered.   
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Figure 2.11: Evolutionary dynamics of canine parvovirus in Brazil. (A) Bayesian 
skyline plot obtained for the VP2 gene sequences of CPV strains from Brazil. The X 
axis is in years before 2000, the black line represents the mean and the grey line the 
95% highest probability density limits. (B) Major genetic events occurring during the 
period of CPV epidemics. The vertical dashed line delineates the distinct patters of 
CPV evolution characterized by two intervals (1) the period between 1980 and 1990 
with stochastic allele fixation and the occurrence of antigenic types CPV-2a and -2b, 
and (2) the period after 1990 distinguished by deterministic allele fixation, presence of 
only the antigenic type CPV-2a strain with positive mutation such as VP1 intron 
deletion, and a synonymous mutation in codon 220 of theVP2 gene region. From 
(Pereira, et al., 2007), with permission.  
 
  
Levels of sequence variation within a virus genus appears to differ significantly 
between different parvoviruses, and this may be due both to different life styles (such 
as whether they cause acute or persistent infections), and to differences in the levels of 
variation that are tolerated, particularly in the capsid protein gene.  Selection is likely 
to be on both the gene products and on the DNA sequences themselves.  Mixed 
infections by closely related strains of the same virus or by genetically or serologically 
different viruses may be common for some viruses, but these are overlooked unless 
subpopulations in DNA mixtures are specifically tested for.  High rates of variation 
may be seen among many parvoviruses when they are placed under selection. The 
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 replication fidelity and rates of mutation are not known. Although replicated by host 
or helper virus DNA polymerases, fidelity is likely considerably lower than those seen 
during replication of the host genomes.  Global spread of genomic variants of some 
viruses occurs, and has been seen for the distribution of CPV during the early stages of 
the pandemic, or B19 virus in the human population. Transmission between related 
host species might be frequent for some parvoviruses (rodent parvoviruses, 
parvoviruses of the feline parvovirus group, or AAVs of the E clade), while host 
restrictions appear to be strict for others.  
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 3.1. Summary 
Canine parvovirus (CPV), first recognized as an emerging virus of dogs in 1978, 
resulted from a successful cross-species transmission.  CPV emerged from the 
endemic feline panleukopenia virus (FPV), or from a closely related parvovirus of 
another host.  Here we refine our current understanding of the evolution and 
population dynamics of FPV and CPV.  By analyzing nearly full-length viral 
sequences we show that the majority of substitutions distinguishing CPV from FPV 
are located in the capsid protein gene, and that this gene is under positive selection in 
CPV, resulting in a significantly elevated rate of molecular evolution.  This provides 
strong phylogenetic evidence for a prominent role of the viral capsid in host 
adaptation.  In addition, an analysis of the population dynamics of more recent CPV 
reveals, on a global scale, a strongly spatially subdivided CPV population with little 
viral movement among countries and a relatively constant population size.  Such 
limited viral migration contrasts with the global spread of the virus observed during 
the early phase of the CPV pandemic, but corresponds to the more endemic nature of 
current CPV infections. 
 
3.2. Introduction 
Efficient transmission in a new host species is a major obstacle to the successful cross-
species transmission and emergence of viruses.  Many emergent viruses are likely to 
be mal-adapted to the new host species and therefore cause only short transmission 
chains (18).  Hence, the process of viral emergence will often require multi-stage 
adaptations to a new host, an idea supported by the observation that RNA viruses, 
which often exhibit evolutionary plasticity, are the most common agents of emerging 
disease (41).  Indeed, there is growing evidence that although replication fidelity is 
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low in RNA viruses (and some ssDNA viruses), it has been fine-tuned in some cases 
(33, 34, 39) and might be environment-specific (30). 
Canine parvovirus (CPV) represents one of the few examples where the 
process of cross-species viral transmission has been observed in ‘real time’.  CPV 
emerged during the 1970s as a host-range variant of an endemic parvovirus of cats, 
mink, or related hosts within the order Carnivora.  This group of closely related 
viruses includes feline panleukopenia virus (FPV) and mink enteritis virus (MEV), 
both of which have long been endemic in their natural hosts.  These viruses are 
globally distributed and infect a variety of domestic and feral hosts including cats, 
raccoons, foxes and mink (1, 25).  Host range barriers restrict transmission of these 
viruses among dogs and related canids, in which viral replication is limited to the 
thymus and probably bone marrow (37). 
CPV was first recognized in 1978 when it spread world-wide, but while this 
virus had probably circulated locally before that time, the exact time of emergence is 
uncertain.  The first CPV identified is referred to as CPV-2 to distinguish it from the 
previously identified but distantly related parvovirus of dogs, minute virus of canines 
(canine minute virus).  CPV-2 caused a severe pandemic with high mortality in dogs, 
but was unable to infect cats, raccoon or mink.  A variant virus (referred to as CPV-
2a) emerged in 1979 and replaced CPV-2 worldwide in approximately one year (27).  
CPV-2a differed antigenically from CPV-2 and infected both dogs and cats.  Another 
antigenic variant (referred to as CPV-2b) with an equivalent host-range was defined 
by a single substitution (N426D) in the capsid protein gene and spread globally after 
1984.  Further mutations arose and spread widely, such as a mutation at residue 297 of 
the capsid protein.  Currently, another mutation at the exposed capsid residue 426 
(D426E), with a thus far uncharacterized impact on fitness, is spreading globally.  This 
mutation was first described in Italy in 2000 (2), but has since been observed in other 
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European countries (7, 8, 20), South America (29), Asia (22) and most recently in the 
United States (11, 16).   
Parvoviruses are small DNA viruses with a single-stranded linear genome of 
about 5kb. Their replication is dependent upon the host cell replication machinery, but 
estimates of rates of nucleotide substitution for both CPV and FPV are more 
comparable to those observed in RNA viruses than in other DNA viruses (35).  The 
CPV genome contains two open reading frames (ORFs), one encoding the two non-
structural proteins NS1 and NS2, and the other encoding the two structural proteins 
VP1 and VP2.  The amino terminal (N-terminal) ends of NS1 and NS2 are identical in 
sequence, but the carboxy-terminal (C-terminal) end of the NS2 protein is derived by 
differential splicing of the mRNA, being translated in a different reading frame which 
overlaps that of NS1.  VP1 and VP2 are splice variants and are identical in sequence 
except for a 143 amino acid (aa) long N-terminal stretch unique to VP1.  VP2 is the 
major capsid protein, and accounts for approximately 90% of the viral capsid.  The 
capsid is the major determinant of host range (14) and subject to antibody mediated 
selection (24).  To date, most studies have focused on the evolution of the VP2 gene, 
with limited work on the non-structural genes.   
Despite widespread vaccination of domestic carnivores, FPV and CPV have 
remained important pathogens of domestic and wild carnivores.  In addition, both the 
patterns of CPV dispersal and the selection pressures acting across the viral genome 
are poorly understood.  This non-enveloped virus causes only short infections with no 
persistent virus remaining after infection, but is highly resistant in the environment.  
The global spread of the virus could therefore occur through the movement of infected 
animals or mechanical vectors, although the spatial dynamics of CPV have not been 
examined in detail.  Here we explore these ideas by performing the largest 
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evolutionary analysis of CPV undertaken to date, incorporating 143 sequences from 
13 countries sampled over 29 years. 
 
3.3. Materials and Methods 
3.3.1. Isolate collection and sequencing.  
Viral DNA was amplified by polymerase chain reaction (PCR) from clinical 
specimens collected at various points before or after the emergence of CPV.  The 
DNA was either amplified directly from the clinical specimen, or after purification 
using the QIAamp viral DNA purification kit (Qiagen), according to the 
manufacturer’s recommendations.  PCR amplification was performed using Phusion 
hot start polymerase (New England Biolabs) and primers that flanked either the NS1 
or VP1 genes, respectively, or that spanned the whole coding region.  PCR products 
were either sequenced directly after purification with the QIAquick PCR purification 
kit, or after subcloning of the viral DNA into the bacterial vectors pJET 1.2 blunt 
(Fermentas) or pSMART GC HK (Lucigen Corporation) and each nucleotide was 
sequenced multiple times.  Consensus sequences were constructed using the ‘Seqman’ 
program in the LaserGene 7.0 software package (DNASTAR). A total of 5 FPV and 6 
CPV sequences that cover the complete viral coding region have been generated and 
were deposited in GenBank (accession numbers EU659111 to EU659121). 
 
 
3.3.2. Sequence data.  
The sequences of 27 near full-length genomes, 54 NS1 and 199 VP2 genes from CPV, 
FPV and closely related parvoviruses were either determined here or obtained from 
GenBank (Table 3.1).  Several CPV-2c sequences (GenBank accession numbers 
AY3880577, AY742942, EF375479, EF375481) covered only smaller parts of the 
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coding region and where therefore excluded from the analysis.  Similarly, not all 
published isolations of CPV-2c strains were apparently accompanied by GenBank 
submission of the viral sequences (see for example Kapil et al., 2007, Hong et al., 
2007 or Decaro et al., 2007).  Of the sequences compiled, 23 near full-length 
sequences, 50 NS1 and 126 VP2 gene sequences contained information on the time of 
isolation, while the place of isolation was available for 52 NS1 and 178 VP2 gene 
sequences.  The first 4 codons of the VP2 sequences were deleted from the VP2 gene 
alignment, as some of the sequences were incomplete, resulting in an alignment of 
1721 nucleotides (nt).  For the analysis of selection pressures acting on the VP1 
unique region, a second alignment of 26 VP1 gene sequences was constructed with the 
intron within the VP1 unique N-terminus removed, resulting in an alignment of 2181 
nt.  The complete 2001 nt coding region of the NS1 gene was also analyzed, and for 
the analysis of selection pressures on the NS2 gene, the N-terminal 89 codons were 
combined with the 76 codon-long C-terminal region in the correct reading frame, 
resulting in an alignment of 495 nt.  The near full-length sequences were trimmed to 
the complete NS1 and VP1 coding regions, with the introns included, resulting in a 
4269 nt alignment.  Sequences were aligned by hand in the Se-Al program 
(http://tree.bio.ed.ac.uk/software/seal/). 
 
 
 
3.3.3. Inference of phylogenetic trees.  
Maximum likelihood (ML) phylogenetic trees were estimated using PAUP* version 
4.0 (36) with the best-fit model of nucleotide substitution determined using Modeltest 
(31).  The HKY85 substitution model was the best-fit for the full-length data set and 
the key parameters (i.e. transition and transversion rates) were estimated from the data.  
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For the VP2 data sets, the GTR+I+Γ4 substitution model was optimal.  To assess 
support for individual nodes, bootstrap resampling values were estimated with 1000 
neighbor-joining trees, again employing PAUP* (36).  
 
3.3.4. Estimation of substitution rate and population dynamics.   
Rates of nucleotide substitution per site, per year (subs/site/year) were estimated using 
the Bayesian Markov chain Monte Carlo (MCMC) method available in the BEAST 
package (http://beast.bio.ed.ac.uk/).  Phylogenetic trees were estimated using the 
HKY85 substitution model, and either strict (constant) or relaxed (uncorrelated 
lognormal) molecular clocks were assumed.  Four different demographic models were 
compared, assuming constant population size, exponential or logistic population 
growth or a Bayesian skyline model, which provides a piecewise depiction of changes 
in relative genetic diversity through time.  Models were compared using Bayes 
Factors, with uncertainty in each parameter estimate depicted in values of the 95% 
highest probability density (HPD) interval.  All analyses were run for sufficient time 
to ensure convergence as assessed using the TRACER program 
(http://tree.bio.ed.ac.uk/software/tracer/), with 10% of runs removed as burn-in.  For 
those models supporting population growth, estimates of the population doubling time 
(λ) were obtained from the BEAST estimates of population growth (r) by using the 
formula λ = ln (2)/r.  
 
3.3.5. Estimates of site-specific selection pressures.  
We used the Single Likelihood Ancestor Counting (SLAC), Fixed Effects Likelihood 
(FEL) and Random Effects Likelihood (REL) algorithms available in the Datamonkey 
web interface of the HyPhy software package (17) to estimate the relative rates of 
synonymous (dS) and nonsynonymous (dN) substitutions per site (ratio dN/dS) in our 
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 sample of CPV and FPV isolates.  The HKY85 substitution model was employed in 
each case.  
 
3.3.6. Analysis of migration patterns.  
To determine the strength of phylogenetic clustering by country of virus isolation we 
employed a parsimony character mapping approach (3).  Each CPV sequence was first 
assigned a character state reflecting its country of origin.  Given the ML phylogeny for 
these sequences (as determined above), the minimum number of state changes needed 
to produce the observed distribution of country character states was estimated using 
parsimony (excluding ambiguous changes).  To determine the expected number of 
changes under the null hypothesis of complete mixing among countries, the states of 
all isolates were randomized 1000 times.  The difference between the mean number of 
observed and expected state changes indicates the level of geographic isolation, with 
statistical significance assessed by comparing the total number of observed state 
changes to the number expected under random mixing.  All analyses were performed 
using PAUP* (Swofford, 2003). 
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Table 3.1: List of  sequences analyzed here.  The viral clade, sequence name 
and GenBank number are shown.  Where applicable, information on the year 
and place of isolation are provided. *= sequence determined during study. 
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name GenBank number isolation date 
isolation 
location 
full-length viral sequences 
FPV    
FPLV-XJ-1.ch EF988660 - China 
FPV-193.au_70 X55115 1970 Australia 
MEV-Aba.ja_78 D00765 1978 Japan 
FPV-b.us_67 M38246 1967 US 
FPV-3.us_67 EU659111* 1967 US 
FPV-4.us_64 EU659112* 1964 US 
FPV-8a.us_89 EU659113* 1989 US 
FPV-8b.us_89 EU659114* 1989 US 
FPV_kai.us_06 EU659115* 2006 US 
CPV-2    
CPV-pD8 NC_001539 - - 
CPV-bM38245 M38245 - - 
CPV-N.us_78 M19296 1978 US 
CPV-5.us_79 EU659116* 1979 US 
CPV-6.us_80 EU659117* 1980 US 
CPV-2abc    
CPVB-2004.ch_104' EF011664 2004 China 
CPV-395.us_98 AY742936 1998 US 
CPV-U6.ge_95 AY742935 1995 Germany 
CPV-447.ge_95 AY742934 1995 Germany 
CPV-339.nz_94 AY742933 1994 New Zealand 
CPV-193.us_91 AY742932 1991 US 
CPV-AJ564427.in AJ564427 - Northern India 
CPV-Y1.ja_82 D26079 1982 Japan 
CPV-cpv/nj01/06.ch.06 EU310373 2006 China 
CPV-13.us_81 EU659118* 1981 US 
CPV-410.us_100 EU659119* 2000 US 
CPV-411a.us_98 EU659120* 1998 US 
FPV    
FPLV-XJ-1.ch EF988660 - China 
FPV-193.au_70 X55115 1970 Australia 
MEV-Aba.ja_78 D00765 1978 Japan 
FPV-b.us_67 M38246 1967 US 
FPV-3.us_67 EU659111* 1967 US 
FPV-4.us_64 EU659112* 1964 US 
FPV-8a.us_89 EU659113* 1989 US 
FPV-8b.us_89 EU659114* 1989 US 
FPV_kai.us_06 EU659115* 2006 US 
 
74
Table 3.1 (continued) 
name GenBank number isolation date 
isolation 
location 
FPLV-PLI-IV.fr_68 AB000057 1968 France 
FPLV-Obihiro_ja_74 AB000055 1974 Japan (Hokkaido) 
FPLV-TU2_ja_75 AB000065 1975 Japan (Tokyo) 
FPLV-TU4_ja_75 AB000067 1975 Japan (Tokyo) 
FPLV-TU8_ja_76 AB000069 1976.5 Japan (Tokyo) 
MEV-Abashiri_ja_78 D00765 1978 Japan 
FPLV-TU10_ja_79 AB000062 1979 Japan (Tokyo) 
FPLV-TU12_ja_79 AB000063 1979 Japan (Tokyo) 
FPLV-483_ja_90 AB000048 1990 Japan (Hokkaido) 
FPLV-Fukagawa_ja_93 AB000053 1993 Japan (Fukushima) 
FPLV-941_ja_94 AB000049 1994 Japan (Tottori) 
FPLV-AO1_ja_94 AB000051 1994 Japan (Hokkaido) 
FPLV-Som1_ja_94 AB000058 1994 Japan (Nara) 
FPLV-Som4_ja_94 AB000060 1995 Japan (Saitama) 
CPV-2    
CPV-pD8 NC_001539 - - 
CPV-bM38245 M38245 - - 
CPV-N.us_78 M19296 1978 US 
CPV-5.us_79 EU659116* 1979 US 
CPV-6.us_80 EU659117* 1980 US 
CPV-d.us_79 M38245 1979 US 
CPV-2abc    
CPVB-2004.ch_104' EF011664 2004 China 
CPV-395.us_98 AY742936 1998 US 
CPV-U6.ge_95 AY742935 1995 Germany 
CPV-447.ge_95 AY742934 1995 Germany 
CPV-339.nz_94 AY742933 1994 New Zealand 
CPV-193.us_91 AY742932 1991 US 
CPV-AJ564427.in AJ564427 - Northern India 
CPV-Y1.ja_82 D26079 1982 Japan 
CPV-cpv/nj01/06.ch.06 EU310373 2006 China 
CPV-13.us_81 EU659118* 1981 US 
CPV-410.us_100 EU659119* 2000 US 
CPV-411a.us_98 EU659120* 1998 US 
CPv-411b.us_98 EU659121* 1998 US 
CPV-31.us_83 AY787929 1983 US 
CPV-15.us_84 AY787926 1984 US 
CPV-39.us_84 AY787930 1984 US 
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Table 3.1 (continued) 
 
name GenBank number isolation date 
isolation 
location 
CPV-24.us_90 AY787928 1990 US 
CPV-133.us_90 M74852 1990 US 
CPV-402.us_98 AY742946 1998 US 
CPV-407.us_98 AY742950 1999 US 
CPV-412.us_98 AY742948 1998 US 
CPV-431.us_103 AY742952 2003 US 
CPV-435.us_103 AY742954 2003 US 
CPV-436.us_104 AY742956 2004 US 
NS1 sequences 
FPV    
FPLV-XJ-1.ch EF988660 - China 
FPV-193.au_70 X55115 1970 Australia 
MEV-Aba.ja_78 D00765 1978 Japan 
FPV-b.us_67 M38246 1967 US 
FPV-3.us_67 EU659111* 1967 US 
FPV-4.us_64 EU659112* 1964 US 
FPV-8a.us_89 EU659113* 1989 US 
FPV-8b.us_89 EU659114* 1989 US 
FPV_kai.us_06 EU659115* 2006 US 
FPLV-PLI-IV.fr_68 AB000057 1968 France 
FPLV-Obihiro_ja_74 AB000055 1974 Japan (Hokkaido) 
FPLV-TU2_ja_75 AB000065 1975 Japan (Tokyo) 
FPLV-TU4_ja_75 AB000067 1975 Japan (Tokyo) 
FPLV-TU8_ja_76 AB000069 1976.5 Japan (Tokyo) 
MEV-Abashiri_ja_78 D00765 1978 Japan 
FPLV-TU10_ja_79 AB000062 1979 Japan (Tokyo) 
FPLV-TU12_ja_79 AB000063 1979 Japan (Tokyo) 
FPLV-483_ja_90 AB000048 1990 Japan (Hokkaido) 
FPLV-Fukagawa_ja_93 AB000053 1993 Japan (Fukushima) 
FPLV-941_ja_94 AB000049 1994 Japan (Tottori) 
FPLV-AO1_ja_94 AB000051 1994 Japan (Hokkaido) 
FPLV-Som1_ja_94 AB000058 1994 Japan (Nara) 
FPLV-Som4_ja_94 AB000060 1995 Japan (Saitama) 
CPV-2    
CPV-pD8 NC_001539 - - 
CPV-bM38245 M38245 - - 
CPV-N.us_78 M19296 1978 US 
CPV-5.us_79 EU659116* 1979 US 
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Table 3.1 (continued) 
 
name GenBank number isolation date 
isolation 
location 
CPV-6.us_80 EU659117* 1980 US 
CPV-d.us_79 M38245 1979 US 
CPV-2abc    
CPVB-2004.ch_104' EF011664 2004 China 
CPV-395.us_98 AY742936 1998 US 
CPV-U6.ge_95 AY742935 1995 Germany 
CPV-447.ge_95 AY742934 1995 Germany 
CPV-339.nz_94 AY742933 1994 New Zealand 
CPV-193.us_91 AY742932 1991 US 
CPV-AJ564427.in AJ564427 - Northern India 
CPV-Y1.ja_82 D26079 1982 Japan 
CPV-cpv/nj01/06.ch.06 EU310373 2006 China 
CPV-13.us_81 EU659118* 1981 US 
CPV-410.us_100 EU659119* 2000 US 
CPV-411a.us_98 EU659120* 1998 US 
CPv-411b.us_98 EU659121* 1998 US 
CPV-31.us_83 AY787929 1983 US 
CPV-15.us_84 AY787926 1984 US 
CPV-39.us_84 AY787930 1984 US 
CPV-24.us_90 AY787928 1990 US 
CPV-133.us_90 M74852 1990 US 
CPV-402.us_98 AY742946 1998 US 
CPV-407.us_98 AY742950 1999 US 
CPV-412.us_98 AY742948 1998 US 
CPV-431.us_103 AY742952 2003 US 
CPV-435.us_103 AY742954 2003 US 
FPV    
FPLV-XJ-1.ch EF988660 - China 
FPV-193.au_70 X55115 1970 Australia 
MEV-Aba.ja_78 D00765 1978 Japan 
FPV-b.us_67 M38246 1967 US 
FPV-3.us_67 EU659111* 1967 US 
FPV-4.us_64 EU659112* 1964 US 
FPV-8a.us_89 EU659113* 1989 US 
FPV-8b.us_89 EU659114* 1989 US 
FPV_kai.us_06 EU659115* 2006 US 
FPLV-PLI-IV.fr_68 AB000057 1968 France 
FPLV-Obihiro_ja_74 AB000055 1974 Japan (Hokkaido) 
FPLV-TU2_ja_75 AB000065 1975 Japan (Tokyo) 
FPLV-TU4_ja_75 AB000067 1975 Japan (Tokyo) 
FPLV-TU8_ja_76 AB000069 1976.5 Japan (Tokyo) 
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Table 3.1 (continued) 
 
name GenBank number isolation date 
isolation 
location 
MEV-Abashiri_ja_78 D00765 1978 Japan 
FPLV-TU10_ja_79 AB000062 1979 Japan (Tokyo) 
FPLV-TU12_ja_79 AB000063 1979 Japan (Tokyo) 
FPLV-483_ja_90 AB000048 1990 Japan (Hokkaido) 
FPLV-Fukagawa_ja_93 AB000053 1993 Japan (Fukushima) 
FPLV-941_ja_94 AB000049 1994 Japan (Tottori) 
FPLV-AO1_ja_94 AB000051 1994 Japan (Hokkaido) 
FPLV-Som1_ja_94 AB000058 1994 Japan (Nara) 
FPLV-Som4_ja_94 AB000060 1995 Japan (Saitama) 
CPV-2    
CPV-pD8 NC_001539 - - 
CPV-bM38245 M38245 - - 
CPV-N.us_78 M19296 1978 US 
CPV-5.us_79 EU659116* 1979 US 
CPV-6.us_80 EU659117* 1980 US 
CPV-d.us_79 M38245 1979 US 
CPV-2abc    
CPVB-2004.ch_104' EF011664 2004 China 
CPV-395.us_98 AY742936 1998 US 
CPV-U6.ge_95 AY742935 1995 Germany 
CPV-447.ge_95 AY742934 1995 Germany 
CPV-339.nz_94 AY742933 1994 New Zealand 
CPV-193.us_91 AY742932 1991 US 
CPV-AJ564427.in AJ564427 - Northern India 
CPV-Y1.ja_82 D26079 1982 Japan 
CPV-cpv/nj01/06.ch.06 EU310373 2006 China 
CPV-13.us_81 EU659118* 1981 US 
CPV-410.us_100 EU659119* 2000 US 
CPV-411a.us_98 EU659120* 1998 US 
CPv-411b.us_98 EU659121* 1998 US 
CPV-31.us_83 AY787929 1983 US 
CPV-15.us_84 AY787926 1984 US 
CPV-39.us_84 AY787930 1984 US 
CPV-24.us_90 AY787928 1990 US 
CPV-133.us_90 M74852 1990 US 
CPV-402.us_98 AY742946 1998 US 
CPV-407.us_98 AY742950 1999 US 
CPV-412.us_98 AY742948 1998 US 
CPV-431.us_103 AY742952 2003 US 
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Table 3.1 (continued) 
 
name GenBank number isolation date 
isolation 
location 
CPV-435.us_103 AY742954 2003 US 
CPV-436.us_104 AY742956 2004 US 
VP2 sequences    
FPV    
CPV-435.us_103 AY742954 2003 US 
BFPV.fi_83 U22185 1983 Finland 
FPLV/Lion/PT06.pt_106 EF418569 2006 Portugal 
FPLV/Tiger/PT06.pt_106 EF418568 2006 Portugal 
FPLV-483.ja_90 D88286 1990 Japan 
FPLV-941.ja_94 AB000050 1994 Japan 
FPLV-A04.ja_94 AB000052 1994 Japan 
FPLV-ARG01.ar EU018145 - Argentina 
FPLV-ARG02.ar EU018144 - Argentina 
FPLV-ARG03.ar EU018143 - Argentina 
FPLV-ARG04.ar EU018142 - Argentina 
FPLVb-CU4 M24004 - - 
FPLV-fk.ja_93 AB000054 1993 Japan 
FPLV-Gercules-Biocentr AY665655 - - 
FPLV-JF-3 DQ099431 - - 
FPLV-obi.ja_74 AB000056 1974 Japan 
FPLV-pliIV.fr_68 D88287 1968 France 
FPLV-Som1.ja_94 AB000059 1994 Japan 
FPLV-Som4.ja_95 AB000061 1995 Japan 
FPLV-tu10.ja_79 D78584 1979 Japan 
FPLV-tu12.ja_79 AB000064 1979 Japan 
FPLV-tu2.ja_75 AB000066 1975 Japan 
FPLV-tu4.ja_75 AB000068 1975 Japan 
FPLV-tu8.ja_76.5 AB000070 1976.5 Japan 
FPLV-V142 AB054225 - - 
FPLV-V208 AB054226 - - 
FPLV-V211 AB054227 - - 
FPLV-XJ-1.ch EF988660 - China  
FPLV-ZF-5 DQ099430 - - 
FPV-193.au_70 X55115 1970 Australia 
FPV-23.us_90 U22187 1990 USA  
FPV-377.ge_93 U22188 1993 Germany 
FPV-a.uk_62 M24002 1962 United Kingdom 
FPV-T1 AF015223 - - 
MEV-a.us_73 M23999 1973 USA 
MEV-Aba.ja_78 D00765 1978 Japan 
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Table 3.1 (continued) 
name GenBank number isolation date 
isolation 
location 
MEV-b.us_75 M24001 1975 USA 
MEV-Beregovoj-
Biocentr AY665656 - - 
MEV-Cherepanovo98 AF201477 - - 
MEV-d.uk_65 U22190 1965 United Kingdom 
MEV-EF428258 EF428258 - - 
MEV-EU137663 EU137663 - - 
MEV-Rodniki-Biocentr AY665657 - - 
RPV.us_79 M24005 1979 USA 
FPV-3.us_67 EU659111* 1967 USA 
FPV-4.us_64 EU659112* 1964 USA 
FPV-8a.us_89 EU659113* 1989 USA 
FPV-8b.us_89 EU659114* 1989 USA 
FPV_kai.us_106 EU659115* 2006 USA 
CPV-2    
CPV-RD87.fi_87 U22193 1987 Finland 
CPV-dCornell320 M23255 - - 
CPV-128.us_78 U22186 1978 USA 
CPV-RD80.fi_80 U22192 1980 Finland 
CPV-pD8 NC_001539 - - 
CPV-N.us_78 M19296 1978 USA 
CPV-AJ698134.in AJ698134 - India 
CPV-M10989 M10989 - - 
CPV-5.us_79 EU659116* 1979 USA 
CPV-6.us_80 EU659117* 1980 USA 
CPV-2abc    
BR133.br_94 DQ340427 1994 Brazil 
BR135.br_80 DQ340405 1980 Brazil 
BR136.br_93 DQ340423 1993 Brazil 
BR137.br_80 DQ340406 1980 Brazil 
BR137.br_93 DQ340424 1993 Brazil 
BR145.br_80 DQ340407 1980 Brazil 
BR154.br_80 DQ340408 1980 Brazil 
BR17.br_90 DQ340412 1990 Brazil 
BR18.br_90 DQ340413 1990 Brazil 
BR183.br_85 DQ340409 1985 Brazil 
BR209.br_94 DQ340428 1994 Brazil 
BR22.br_93 DQ340422 1993 Brazil 
BR227.br_93 DQ340425 1993 Brazil 
BR237.br_94 DQ340429 1994 Brazil 
BR31.br_90 DQ340414 1990 Brazil 
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Table 3.1 (continued) 
 
name GenBank number isolation date 
isolation 
location 
BR315.br_86 DQ340410 1986 Brazil 
BR43.br_91 DQ340415 1990 Brazil 
BR46.br_95 DQ340430 1994 Brazil 
BR47.br_91 DQ340416 1991 Brazil 
BR491.br_92 DQ340418 1992 Brazil 
BR52.br_91 DQ340417 1991 Brazil 
BR56.br_95 DQ340431 1995 Brazil 
BR570.br_92 DQ340419 1992 Brazil 
BR315.br_86 DQ340410 1986 Brazil 
BR593.br_92 DQ340420 1992 Brazil 
BR597.br_92 DQ340421 1992 Brazil 
BR6.br_80 DQ340404 1980 Brazil 
BR62.br_95 DQ340432 1995 Brazil 
BR7168.br_100 DQ340433 2000 Brazil 
BR8.br_90 DQ340411 1990 Brazil 
BR8155.br_100 DQ340434 2000 Brazil 
BR84.br_94 DQ340426 1994 Brazil 
CPV-133.us_90 M74852 1990 USA 
CPV-15.us_84 M24003 1984 USA 
CPV-193.us_91 AY742932 1991 USA 
CPV-209.vi_97 AB054219 1997 Vietnam 
CPV-24.us_90 U22896 1990 USA 
CPV2a-AJ564427.in AJ564427 - India 
CPV2a-APD1.ch EU213074 - China 
CPV2a-BD2.ch EU213079 - China 
CPV2a-BD3.ch EU213080 - China 
CPV2a-BD4.ch EU213081 - China 
CPV2a-BJ004/O7.ch EF666059 - China, Beijing 
CPV2a-BJ005/O7.ch EF666060 - China, Beijing 
CPV2a-BJ008/O7.ch EF666061 - China, Beijing 
CPV2a-BJ010/O7.ch EF666062 - China, Beijing 
CPV2a-BJ015/O7.ch EF666063 - China, Beijing 
CPV2a-BJ017/O6.ch EF666065 - China, Beijing 
CPV2a-BJ017/O7.ch EF666064 - China, Beijing 
CPV2a-BJ018/O7.ch EF666066 - China, Beijing 
CPV2a-BJ020/O7.ch EF666067 - China, Beijing 
CPV2a-BJ027/O7.ch EF666068 - China, Beijing 
CPV2a-BJ034/O7.ch EU145953 - China 
CPV2a-BJ042/O7.ch EF666069 - China, Beijing 
CPV2a-BJ050/O7.ch EU145955 - China 
CPV2a-BJ064/O7.ch EU145956 - China 
CPV2a-BJ068/O7.ch EU145957 - China 
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Table 3.1 (continued) 
 
name GenBank number isolation date 
isolation 
location 
CPV2a-BJ069/O7.ch EU145958 - China 
CPV2a-BJ077/O7.ch EU145959 - China 
CPV2a-BJ082/O7.ch EU145960 - China 
CPV2a-BJ085/O7.ch EU145961 - China 
CPV2a-HT.ch EU213077 - China 
CPV2a-HZ0761.ch EU213073 - China 
CPV2a-JB1.ch EU213076 - China 
CPV2a-K001.sk EU009200 - South Korea 
CPV2a-K014.sk EU009201 - South Korea 
CPV2a-K015.sk EU009202 - South Korea 
CPV2a-K022.sk EU009203 - South Korea 
CPV2a-K026.sk EU009204 - South Korea 
CPV2a-KT1.ch EU213082 - China 
CPV2a-KT2.ch EU213083 - China 
CPV2a-NJ-04.ch EU095252 - China, Beijing 
CPV2a-Sho-nan AB128923 - - 
CPV2a-ZD2.ch EU213084 - China 
CPV2a-ZD3 EU213085 - - 
CPV2b-BD1.ch EU213075 - China 
CPV2b-BJ044/O7.ch EU145954 - China 
CPV2b-HN-3.ch Q177497 - China 
CPV2b-K029.sk EU009205 - South Korea 
CPV2b-K031.sk EU009206 - South Korea 
CPV2b-ZD1.ch EU213078 - China 
CPV2c-Pome.sk EF599098 - South Korea 
CPV2-DQ903936.ch DQ903936 - China 
CPV-31.us_83 M24000 1983 USA 
CPV-314.ja_93 D78585 1993 Japan 
CPV-339.nz_94 AY742933 1994 New Zealand 
CPV-39.us_84 M74849 1984 USA 
CPV-395.us_98 AY742936 1998 USA 
CPV-431.us_103 AY742951 2003 USA 
CPV-435.us_103 AY742953 2003 USA 
CPV-436.us_104 AY742955 2004 USA 
CPV-447.ge_95 AY742934 1995 Germany 
CPV-46.po_94 Z46651 1994 Poland 
CPV-584.it_94 AF306446 1994 Italy 
CPV-616.it_95 AF306449 1995 Italy 
CPV-618.it_95 AF306447 1995 Italy 
CPV-632.it_96 AF306445 1996 Italy  
CPV-637.it_95 AF306450 1995 Italy 
CPV-677.it_98 AF306448 1998 Italy 
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Table 3.1 (continued) 
 
name GenBank number isolation date 
isolation 
location 
CPV-695.eu_99 AF401519 1999 Europe 
CPV-699.eu_100 AF393506 2000 Europe 
CPVB-2004.ch_104 EF011664 2004 China 
CPV-CPVKK0501 EF189717 - - 
CPV-DH326.sk EF599097 - South Korea 
CPV-DH426.sk EF599096 - South Korea 
CPV-Ik.ja_97 AB115504 1997 Japan 
CPV-RPPV.ch_104 DQ354068 2004 China 
CPV-SHZ EU170352 - China 
CPV-T10.ta_95 U72696 1995 Taiwan 
CPV-T25.ta_95 U72697 1995 Taiwan 
CPV-695.eu_99 AF401519 1999 Europe 
CPV-699.eu_100 AF393506 2000 Europe 
CPV-T37.ta_95 U72698 1995 Taiwan 
CPV-T4.ta_94 U72695 1994 Taiwan 
CPV-Ta9.ta_98 AB054213 1998 Taiwan 
CPV-TWN1.ta_106 EF592511 2006 Taiwan 
CPV-U6.ge_95 AY742935 1995 Germany 
CPV-V120.vi_97 AB054215 1997 Vietnam 
CPV-v123.vi_97 AB054218 1997 Vietnam 
CPV-v129.vi_97 AB054216 1997 Vietnam 
CPV-V139.vi_97 AB054222 1997 Vietnam 
CPV-V154.vi_97 AB054217 1997 Vietnam 
CPV-V203.vi_97 AB054224 1997 Vietnam 
CPV-V204 AB054221 - - 
CPV-v217.vi_97 AB054220 1997 Vietnam 
CPV-w42.it_95 AF306444 1995 Italy 
CPV-Y1.ja_82 D26079 1982 Japan 
HCM-18.ho.vi_102 AB120722 2002 Vietnam 
HCM-23.ho.vi_102 AB120723 2002 Vietnam 
HCM-6.ho.vi_102 AB120720 2002 Vietnam 
HCM-8.ho.vi_102 AB120721 2002 Vietnam 
HNI-1-18.ha.vi_102 AB120728 2002 Vietnam 
HNI-2-13.ha.vi_102 AB120724 2002 Vietnam 
HNI-3-11.ha.vi_102 AB120726 2002 Vietnam 
HNI-3-4.ha.vi_102 AB120725 2002 Vietnam 
HNI-4-1.ha.vi_102 AB120727 2002 Vietnam 
LCPV-t1.ta_95 AB054214 1995 Taiwan 
LCPV-V140.vi_97 AB054223 1997 Vietnam 
Taichung.ta_103 AY869724 2003 Taiwan 
CPV-13.us_81 EU659118* 1981 USA 
CPV-410.us_100 EU659119* 2000 USA 
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 Table 3.1 (continued)    
CPV-411a.us_98 EU659120* 1998 USA 
CPV-411b.us_98 EU659121* 1998 USA 
CPV-cpv/nj01/06.ch_106 EU310373 2006 China 
 
3.4. Results 
3.4.1. Phylogenetic analysis of the full-length genome.  
We analyzed 27 near full-length genomes of carnivore parvoviruses, several of which 
were determined during the course of this study.  The FPV sequences cover a time 
period of 42 years (1964 to 2006) and were collected in various geographical regions.  
The oldest CPV isolate was collected in 1978, the year in which CPV was first 
described, and the CPV sequences cover a total of 29 years.  The topology of the ML 
tree of these data (Figure 3.1) was similar to that of trees inferred from the VP2 
region, with the longest internal branch separating the FPV and CPV clades.  16 
nucleotide substitutions separated the FPV and CPV clades, while 7 substitutions 
separated the CPV-2 from the CPV-2a clade.  The majority of these substitutions (11 
between FPV and CPV and 5 between CPV-2 and CPV-2a) were located in the capsid 
protein region (data not shown).  
 
 
3.4.2. Substitution rates and population dynamics.  
Bayesian MCMC estimates of rates of nucleotide substitution were inferred for the 
full-length genome, and separately for the NS1 and VP2 genes, either analyzing all 
carnivore parvoviruses simultaneously or subdividing the sequences into FPV and 
CPV (i.e. all CPV-2, CPV-2a and derived viruses).  For the VP2 sequence, two 
additional data sets were analyzed, one consisting of the CPV-2a sequences, and the 
other comprising all FPV and most CPV sequences but excluding the original CPV-2 
sequences.
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Figure 3.1: Phylogenetic tree of 27 full-length carnivore parvovirus sequences, 
rooted with the oldest FPV sequence (FPV-4.us.64).  Horizontal branch lengths are 
drawn to scale (nucleotide substitutions per site), and bootstrap support (>85%) is 
indicated above the respective branches.  The three recognized clades, FPV and 
related viruses, CPV-2 and CPV-2a and derived viruses, are indicated.   
 
Very similar substitution rates were obtained for individual data sets under all 
molecular clock and demographic models, reflecting the robustness of this analysis 
(all results available from the authors on request).  However, estimates of the 
substitution rate from the capsid protein gene were strikingly different between FPV 
and CPV (Table 3.2). The mean substitution rate for FPV was 8.2 × 10-5 subs/site/year 
(95% HPD = 3.6 × 10-5 – 1.3 × 10-4 subs/site/year), while that of CPV was 
significantly higher at 2.2 × 10-4 subs/site/year (95% HPD = 1.7 × 10-4 - 2.7 × 10-4 
subs/site/year).  Estimates of substitution rate for both FPV and CPV based on the 
NS1 gene were similar (6.6 × 10-5 subs/site/year and 1.0 × 10-4 subs/site/year, 
respectively), with overlapping HPD values.   
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Table 3.2: Nucleotide substitution rates, population dynamics and times to 
common ancestry for CPV and FPV. - = not applicable; const. = constant population 
size; log. = logistic population growth; BSP = Bayesian skyline model; Mean 
substitution rate = subs/site/year; HPD = 95% highest probability density interval; 
Time to Most Recent Common Ancestor (TMRCA) = age since most recent sequence 
included in analysis (i.e. 2006).  
 
 
VP2 NS1 full-
length FPV CPV CPV-2a 
no 
CPV-2 all FPV CPV all 
demographic 
model 
 
const. log. log. const. BSP const. const. const const. 
sequence 
length (bp) 
 
1721 1721 1721 1721 1721 2007 2007 2007 4269 
number of 
sequences 
 
30 96 90 120 126 22 27 49 23 
date range of 
sequences 
1962-
2006 
1978- 
2004 
1980-
2004 
1962-
2006 
1962-
2006 
1963-
2006 
1978-
2004 
1963
-
2006 
1964-
2006 
Mean 
substitution 
rate  
 
 
8.2 x 
10-5 
2.2 x 
10-4 
2.1 x  
10-4 
1.6 x  
10-4 
1.4 x 
10-4 
6.4 x 
10-5 
1.0 x 
10-4 
6.2 x 
10-5 
1.2 x 
10-4 
HPD 
substitution 
rate | 
3.6x 
10-5- 
1.7 x 
10-4- 
1.6 x  
10-4- 
1.1 x  
10-4- 
1.1 x 
10-4- 
1.7 x 
10-5- 
2.2 x 
10-5- 
3.4 x 
10-5- 
7.1 x 
10-5- 
1.3x 
10-4 
2.7 x 
10-4 
2.7 x 
10-4 
2.0 x  
10-4 
1.7 x 
10-4 
1.2 x 
10-4 
2.0 x 
10-4 
9.3 x 
10-5 
1.7 x 
10-5 
Time to Most 
Recent 
Common 
Ancestor 
(years) 
 
 
98 32 28 71 105 128 85 127 71 
HPD age 
53- 29- 26- 50- 100- 50- 30- 65- 47- 
169 37 32 100 117 260 192 215 103 
mean growth 
rate (1/years) 
 
- 0.2 0.4 - - - - - - 
HPD growth 
rate 
(years) 
- 0.1 0.1 - - - - - - 
- 0.3 0.4 - - - - - - 
Mean 
epidemic 
doubling time 
(λ) 
- 3.7 1.8 - - - - - - 
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Using the same approach we were able to estimate the Time to the Most 
Recent Common Ancestor (TMRCA) of both FPV and CPV.  The estimated TMRCA 
for FPV was 98 years from the most recent analyzed isolate collected in 2006 (95% 
HPD = 53 – 168 years) while that for CPV was 32 years (95% HPD = 29 – 37 years) 
which closely corresponds with the first CPV case recognized in 1978. 
 The mean TMRCA estimate for CPV-2a (28 years) is lower than that 
for all CPVs, again matching the first observed CPV-2a collected in 1979.  The 
TMRCA estimates based on the NS1 gene place the emergence of FPV, and 
particularly CPV, considerably earlier than those based on the capsid protein gene 
(128 years for FPV and 85 years for CPV).  However, the HPD values are very wide 
(and overlap with those inferred from VP2), revealing the inherent statistical 
uncertainty in this estimate (although more recent dates are observed under other 
demographic models tested – results not shown).  
The population dynamics of all CPVs and the CPV-2a subset were best 
described by logistic population growth in which a rapid growth phase is followed by 
a phase of increasingly slower growth, while a constant population size provided a 
better description of both the FPV data set and the data set containing all sequences 
except the CPV-2 strain.  The complete data set, comprising all VP2 sequences, was 
best described by the more complex Bayesian skyline model, reflecting the inclusion 
of viruses with differing epidemiological dynamics.  Notably, the mean epidemic 
doubling time for CPV-2a and derived viruses (1.8 years) is approximately half that 
for all CPVs combined (3.7 years), revealing the initially rapid spread of the CPV-2a 
variant (although, again, the 95% HPD values overlap).  However, these estimates of 
growth rate should be treated with caution due to the potentially confounding effect of 
population subdivision.  Both FPV and CPV NS1 sequences were best described by 
models of constant population size.   
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 3.4. 3. Selection pressures in CPV and FPV.  
An analysis of selection pressures, manifest as dN/dS ratios, across both viruses and 
genes revealed the sporadic action of positive selection, with mean dN/dS values of 
0.15 for NS1, 0.53 for NS2, 0.15 for the VP1 unique region and 0.12 for VP2 (Table 
2.3).  Notably, the short NS2 protein contained four positively selected sites, all within 
the 76 aa long C-terminal region where the encoded sequence overlaps that of NS1 in 
a different reading frame. 
Hence, the ‘positively selected’ sites in this region are difficult to interpret.  
While the possibility of positive selection cannot be ruled out, the results might 
represent false-positives caused by synonymous mutations in the alternate reading 
frame.  In contrast, only a single NS1 site, at codon 597, appeared to be under positive 
selection.  This amino acid is located in the C-terminal region of NS1, in the region 
where NS2 is encoded in the different reading frame, and overlaps with residues 106 
and 107 of NS2, again suggesting that this result might be false-positive.  No 
positively selected sites were detected in the VP1 unique region.   
As expected given the capsid’s known role in host range control, four surface exposed 
capsid residues, at VP2 positions 101 (dN/dS= infinity; dN= 2.24), 300 (dN/dS = infinity; 
dN= 3.0), 324 (dN/dS = infinity; dN= 4.43) and 426 (dN/dS = infinity; dN= 4.56), were 
under positive selection across all sequences (Figure 3.2).  Among the FPV sequences, 
only VP2 codon 562 in the VP2 gene appears to be under positive selection (dN/dS = 
infinity; dN = 13.05).  Among the CPV sequences, VP2 residues 87 (dN/dS = infinity; 
dN= 5.03) and 426 (dN/dS = infinity; dN= 4.55) were under positive selection.  
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Figure 3.2: The positively selected capsid protein residues are mapped onto the 
crystal structure of the CPV half capsid.  Red= residues positively selected among 
FPV and CPV; blue= residue positively selected only among FPV sequences; yellow= 
residues positively selected only among CPV sequences; green= residue 426.  
 
3.4.4. Migration patterns of CPV.  
The differences between the observed and expected numbers of migration events 
involving CPV isolates sampled from different countries are shown in Table 3.4, with 
negative values indicative of population subdivision and positive values characterizing 
directional migration between the specified geographic regions.  Overall, we detected 
a strong signal of population subdivision, with only a few instances of migration 
between specific localities.  Indeed, only 12 of the 182 possible directional migration 
pathways showed signs of CPV migration, and none had strong signals, suggesting 
only sporadic geographical movement of these viruses.   
 
89
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3:  Analysis of selection pressures in each genomic region.  P-
values or, in the case of REL, Bayes factors, are reported.  P-values < 0.1 
and Bayes factors > 100 are shown in bold. - =none detected;∞ = 
“infinity”; *=residues were mapped to the NS2 gene of minute virus of 
mice using a previously published alignment (40) and the functions listed 
correspond to those known in that virus. ; †= only detected in the full-
length data set; ‡= location and function of the NS1 and NS2 mutations 
were inferred from the known functions of homologous regions in minute 
virus of mice;  TfR = Transferrin receptor; #= sequence contained too 
many sequences for analysis.
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Conversely, 95 of the 182 possible pathways were negative, indicative of 
population subdivision, sometimes strongly so. Interestingly, China represents a far 
weaker source of viruses for other regions than expected given the number of available 
sequences from this country.  Similarly, Brazil is also a weaker source population than 
expected by chance (especially for movements to China and Taiwan), but appears to 
be a source for movement to Europe (Italy and Poland) and potentially the United 
States.  Overall, the strongest evidence of viral movement was from the United States 
to Vietnam (observed-expected = 1.54) and from Vietnam to China (observed-
expected = 1.36), but the signal was weak.  
When we mapped the positively selected sites onto the phylogenetic tree 
depicted in Figure 3.3 (data not shown), the VP2 N426D mutation appeared to be co-
circulating in several countries, such as South Korea, the United States and Taiwan, 
but was absent in all but four sequences collected in China (CPV2b-BD1.ch, CPV2b-
BK044/07.ch,CPV2b-HN-3.ch and CPV2b-ZD1.ch), of which the first three clustered 
with sequences from Vietnam.  Interestingly, the N426D mutation was not 
monophyletic, indicating that it has arisen independently in these countries.  Only a 
single Brazilian sequence (BR185.br_85) had the N426D mutation, and this sequence 
had signatures of migration, since it clustered with the European and U.S. isolates. 
instead of the other Brazilian isolates.  Geographic structure was even more striking in 
the case of the Y324I mutation.  This was only present in sequences from China and 
South Korea and again was not monophyletic.  Conversely, the VP2 mutations at 
codons 87, 101 and 300 were present in all but five CPV-2a sequences.
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Figure 3.3: Phylogenetic tree of 152 CPV VP2 sequences used for the analysis of 
migration patterns.  Horizontal branch lengths are drawn to scale (nucleotide 
substitutions per site), and bootstrap support (>85%) is indicated above their 
respective branches.  The country of isolation is indicated by color-coding, as 
indicated in the key.  
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 Three of the Vietnamese sequences collected in 1997 from feral cats (CPV-
V139.vi_97, CPV-V203.vi_97 and LCPV_V140.vi_97) and one sequence from South 
Korea (CPV-2c-Pome) harbored a G300D mutation (15) and one Chinese sequence 
isolated from a red panda in 2004 (CPV-RPPV.ch_104) possessed a G300V mutation 
(32).  Finally, only one sequence in the data set (HNI-4-1.ha.vi_102) contained the 
VP2 D426E mutation.  As such, no inference can be made from this dataset regarding 
the global movement of this mutation. 
 
 3.5. Discussion 
This study provides novel insights into the population dynamics of the emerging CPV 
virus, contrasting the evolutionary pressures acting on CPV and FPV, and among the 
genes of CPV.  The emergence of CPV was characterized by strong selection for 
specific mutations within VP2 but not NS1.  Optimal receptor binding and antigenic 
escape were the likely driving forces, as indicated by the location and function of the 
positively selected sites in the capsid protein (located at VP2 codons 101, 300, 324, 
426).  
This study is the first to systematically explore CPV dynamics on a global 
scale.  Notably, we found the CPV population to be spatially structured, with very 
limited gene flow between clusters.  This is in contrast with a previous study which 
reported strong temporal, but mild or absent spatial clustering, among CPV isolates 
from Brazil, the U.S. and Europe (Pereira et al., 2000), but is consistent with other 
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reports of geographic clustering of isolates from Vietnam, Japan/Taiwan and the 
United States (9).  Three of the mutations at positively selected sites (at VP2 residues 
87,101 and 300) arose soon after CPV emerged.  The mutations at residues 87 and 101 
have arisen once and all but five of the CPV-2a viruses harbor the A300G mutation.  
The remaining CPV-2a viruses were isolated from feral feline hosts and show 
alternative substitutions of residue 300, suggesting a role of this residue in the feline 
adaptation of CPV.  We have previously shown that an Asp at residue 300 is selected 
during passage of CPV-2 in feline cells in culture, and also that this prevents the 
infection of dog cells (Parrish and Carmichael, 1986; Parker and Parrish, 1997).  The 
two positively selected mutations at VP2 residues 324 and 426 arose later, and 
apparently independently, in different geographic locations.  Thus the early period of 
CPV emergence was characterized by global viral spread and global strain 
replacement, while later mutations likely arose through parallel emergence of the same 
mutations in separate geographic regions.  Indeed, by far the strongest 
phylogeographic signal in these data is that of population subdivision, with relatively 
little movement of viruses between geographic areas.  In addition, the majority of 
migrations that do occur are between countries in close geographic proximity, such as 
Taiwan or Vietnam and China, or between countries with close economic connections 
such as the United States and Germany or Italy, indicating that CPV is likely spread 
among countries through the movement of mechanical vectors or, in some cases, 
infected animals.  The movement of viruses from the United States to Vietnam 
appears surprising, but all of these sequences were isolated in 1997, only 3 years after 
the embargo against Vietnam was lifted, indicating a potential role of the developing 
trade relations between the countries.   
 While recombination can potentially impact phylogenetic relationships, we 
found no clear signal of recombination among the FPV or CPV isolates studied here 
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(unpublished data; available from the authors on request).  Indeed, the presence and 
role of recombination among FPV or CPV sequences is uncertain.  While phylogenetic 
evidence of recombination has been detected for related parvoviruses of mink 
(Aleutian mink disease virus), swine (porcine parvovirus) and rodents (several rodent 
parvoviruses including LuIII) (Shackelton et al, 2007), there is no clear evidence for 
the process among the FPV- and CPV-related parvoviruses studied to date.  It is 
therefore unlikely that the analyses reported here were strongly impacted by 
recombination. 
Our molecular clock estimates of emergence times for CPV-2 and CPV-2a are 
notable in that they are very close to the dates when the viruses were first detected in 
nature.  In particular, we estimate that CPV-2 emerged around 1974 (i.e. 32 years 
before the most recent analyzed sequence collected in 2006), only four years before it 
spread globally in 1978.  This is compatible with serological evidence that the virus 
circulated in Europe a few years before the CPV pandemic (38).  Similarly, our 
estimate for the emergence date of CPV-2a is approximately four years later than 
CPV-2, which corresponds closely with the first detection of CPV-2a in nature in 
1979.  Notably, the pattern of logistic population growth for CPV-2 and CPV-2a 
indicates the initially rapid spread of the virus among animals.  This corresponds to the 
expected population dynamics of a newly emerging pathogen, and has also been 
reported by previous studies (28, 35).  In marked contrast, FPV evolution is 
characterized by constant population sizes, as expected for an endemic pathogen.  
The change in evolutionary dynamics associated with the process of 
emergence is also apparent in the significantly higher rate of substitution in the capsid 
protein gene of CPV compared to the FPV sequences, with mean rates of 1.2 and 0.4 
substitutions per genome per year, respectively.  Although these rates are comparable 
to those inferred previously (12, 28, 35), this is the first time a statistically significant 
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difference between FPV and CPV has been revealed.  In theory, the elevated rate of 
evolutionary change in CPV might be due to either lower replication fidelity in dogs 
or increased positive selection after the transmission to the new host.  Since these 
viruses are all replicated by host cell DNA polymerases, significantly different 
fidelities appear unlikely.  Moreover, substitution rates inferred from the NS1 gene 
were comparable between FPV and CPV sequences, and similar to that inferred for 
FPV based on the capsid gene, indicating that the elevated substitution rate observed 
among the CPV sequences was most likely due to strong positive selection, probably 
driven by host adaptation and immune escape.  
 There is clear evidence for strong positive selection on the capsid protein gene, 
and differences among the host species again appear to be of importance in this regard.  
Four VP2 residues - 101, 300, 324 and 426 - are subject to positive selection among 
all carnivore parvoviruses.  Residues 101 and 300 are located on a surface-exposed 
region of the viral capsid (Figure 3.2), interact with the transferrin receptor (which is 
the receptor mediating viral entry), and partially determine the re-acquired feline host 
range of CPV-2a.  The substitution at residue 324 has not been previously 
characterized, but is adjacent to residue 323, a known host-range mutation, which 
together with residue 93 controls canine TfR binding and the canine host range (13).  
The 324 mutation appears to be circulating only in China and South Korea (data not 
shown), and has appeared a number of times independently.  Although clear 
information on time of sampling is available for only a few of the sequences 
containing this mutation, most appear to have been collected in 2006 or 2007, 
indicating that this mutation probably arose recently.  Mutations at aa 426 change the 
antigenic profile of the virus (23, 26).  This codon has undergone two mutations since 
CPV emerged, first from asparagine to aspartate, and more recently to glutamate, 
indicating complicated selection dynamics acting on this residue.  The exact 
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phenotypic consequences of the mutations are not clear, and the N426D mutation has 
been present in some CPV populations for decades without replacing the wild-type 
(Parrish et al., 1991). 
Mapping the codon 426 variants onto the phylogenetic tree in Figure 3.2 
revealed both the Asn and Asp amino acids were co-circulating in the United States, 
Taiwan, Vietnam and Europe, while the Asp mutation was at very low frequency in 
China and Brazil (data not shown; available from the authors on request).  
Interestingly, the Asp codon-containing sequences from those countries showed 
signatures of migration and clustered with sequences from other countries that carried 
the respective mutation.  The D426E mutation has recently been isolated from several 
countries around the world, but only a single VP2 sequence of known origin that 
harbored this mutation was available, preventing more detailed analysis.  One 
additional sequence containing the D426E mutation (GenBank accession number 
AF401519) was excluded from the analysis since the place of isolation could not be 
clearly determined.  Among the CPV sequences, residues 87 and 426 are under strong 
positive selection.  Residue 87 is also surface exposed and, although its specific 
functions are unknown, appears to be associated with the re-gained feline host range 
of CPV-2a, together with residue 300. 
Less positive selection was observed in FPV, and only VP2 codon 562 
appeared to be under positive selection, although relatively strongly.  Adaptive 
evolution at this site has not been described previously.  However, two residues in 
close spatial proximity, 564 and 568, partially determine the in vivo host range of FPV 
(Truyen et. al, 1994a).   
Finally, our study is notable in that we detected putatively positively selected 
sites in the NS1 (codon 597, overlapping codon 107 in NS2) and NS2 (codons 94, 
107,151 and 160) genes, although these are potentially false positives due to the 
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overlapping reading frames.  The role of NS2 in the CPV life-cycle is unclear and 
knock-out mutants appear to behave similarly  to wild-type both in tissue culture and 
in dog infections (40).  However, in the related rodent parvoviruses, NS2 is required 
for efficient translation and capsid assembly in cells from natural host species but not 
in cells from other hosts (4-6, 10, 19, 21).  A possible role for NS2 in host adaptation 
therefore merits further study.  
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CHAPTER 4 
WITHIN-HOST DYNAMICS OF EMERGING AND ENDEMIC 
PARVOVIRUSES OF DOGS AND CATS 
 
 
From:  Hoelzer, K., Shackelton, L.A., Holmes, E.C. and 
Parrish, C.R. Within-host genetic diversity of endemic and 
emerging parvoviruses of dogs and cats. J. Virol. 2008. 82: 
11096-11105, with permission.  
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4.1. Summary 
Viral emergence can result from the adaptation of endemic pathogens to new or 
altered host environments, a process that is strongly influenced by the underlying 
sequence diversity. To determine the extent and structure of intra-host genetic 
diversity in a recently emerged single-stranded DNA virus, we analyzed viral 
population structures during natural infections of animals with canine parvovirus 
(CPV) or its ancestor feline panleukopenia virus (FPV). We compared infections that 
occurred shortly after CPV emerged with more recent infections, and examined the 
population structure of CPV after experimental cross-species transmission to cats. 
Infections with CPV and FPV showed limited genetic diversity regardless of the 
analyzed host tissue or year of isolation. Co-infections with genetically distinct viral 
strains were detected in some cases, and rearranged genomes were seen in both FPV 
and CPV. The sporadic presence of some sequences with multiple mutations 
suggested the occurrence of either particularly error-prone viral replication or co-
infection by distantly related strains. Finally, some potentially organ-specific host 
effects were seen during experimental cross-species transmission, with many of the 
mutations located in the non-structural protein NS2.  These included residues with 
evidence of positive selection at the population level, which is compatible with a role 
of this protein in host adaptation.  
 
4.2. Introduction 
Emerging viruses that gain new host ranges are major threats to human and animal 
health. However, the evolutionary mechanisms that allow viruses to infect new hosts 
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and establish self-sustaining transmission chains are complex and far from understood.  
In most cases studied to date, several mutations together determine the new host range, 
but where, when, and how these mutations arise has largely remained enigmatic. Many 
cases of viral emergence probably represent multi-stage adaptations to an altered host 
environment, where the initial emerging virus is poorly adapted to the recipient host 
and causes only inefficient transmission. Further mutations are then required for 
complete adaptation to the new host. The success of the new pathogen is therefore 
likely to be highly influenced by the genetic diversity of the viral population, with 
more variable viral populations being particularly prone to generate successful 
emerging infections. 
The extent of genetic diversity present within viral populations is largely 
determined by a balance between erroneous replication (measured as mutation rate) 
and purifying selection (which is commonly expressed in the substitution rate, which 
is the number of fixed mutations/ base pair/year), with particularly high error rates in 
RNA viruses that replicate using RNA-dependent RNA polymerases (15), or, in the 
case of retroviruses,  reverse trancriptases. Although large double-stranded DNA 
viruses possess mutation rates far lower than those seen in RNA viruses, some small 
single-stranded (ss) DNA viruses appear to both mutate (14, 39) and have substitution 
rates closer to RNA viruses than to dsDNA viruses (reviewed in (16)).  The 
parvoviruses represent a particularly well-studied case, with the mean substitution rate 
for the canine parvovirus (CPV) capsid protein gene at ~1 × 10-4 
substitutions/nucleotide/year (38, 42).  However, the extent and structure of within-
host variability in ssDNA viruses, including co-infection as a potential source of 
genetic diversity, has rarely been analyzed. 
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Various phenomena such as recombination, non-random codon usage and host 
effects such as hypermutation mediated by “Apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3B” (APOBEC3G) might also affect standing genetic 
diversity, although their role in the evolution of ssDNA viruses is largely unclear. In 
addition, some rapidly evolving viruses such as HIV undergo tissue-specific variation 
(24, 47). Tissue-specific effects may also occur during infections with parvoviruses, 
but this has not been analyzed previously. 
CPV emerged in the 1970s as a new virus of dogs, being derived from either 
feline panleukopenia virus (FPV) or a very closely related virus of another host 
(Figure 4.1). After circulating undetected in dogs in Europe or Eurasia for a few years, 
the virus spread globally in 1978 (35). This virus is referred to as CPV type-2 (CPV-2) 
to distinguish it from the distantly related minute virus of canines.  In 1979 a variant 
strain of CPV-2 (named CPV-type2a (CPV-2a)) emerged and replaced CPV-2 
globally by the end of 1980 (37).  The emerging strain differed antigenically and 
readily infected cats, while CPV-2 did not replicate in felines (44).  In 1984 an 
antigenic variant of CPV-2a with apparently identical host range, which is referred to 
as CPV-2b, arose. CPV-2a and CPV-2b are currently co-circulating in the global dog 
population, but their relative frequencies appear to vary between geographic regions 
and are potentially also subject to temporal fluctuation (reviewed in (20)). Natural 
infections of cats and wild felines with CPV have been reported (4, 18, 31), but FPV 
has remained the more prevalent parvovirus causing disease in cats.  
Both FPV and CPV cause acute infections of young animals, resulting in the 
development of long lived protective immunity (7).  Infection occurs through the oro-
nasal route and initial replication takes place in the lymphatic tissues of the oro-
pharynx (Figure 4.4A). After a primary viremia, the virus begins to replicate in the 
thymus, spleen and bone marrow 2 to 3 days after infection.  The virus then becomes 
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disseminated throughout the animal, and replication is seen in the gut- associated 
lymphoid tissues, particularly the Peyer’s patches.  The virus subsequently replicates 
in the rapidly dividing epithelial cells within the crypts of the small intestinal villi, and 
is shed at high levels in the feces 4 to 7 days post infection (6, 7, 29, 33).  The viruses 
appear to be cleared less than 2 weeks post infection with no residual replicating virus 
remaining (reviewed in (33).  
The CPV genome (depicted in Figures 4.2 (below the consensus sequences) 
and 4.3 (top panel)), contains two open reading frames (ORFs), one of which encodes 
the two nonstructural proteins NS1 and NS2, with the other encoding the two 
structural proteins VP1 and VP2 (40).  The amino terminal ends of NS1 and NS2 
overlap and are identical in sequence, but the carboxy terminal domain of NS2 is 
derived by differential splicing, fusing it to a different reading frame which overlaps 
that of NS1.  The sequence of VP2 is completely contained within that of VP1, which 
has an additional 143 amino acid (aa) long N-terminal sequence.  VP2 makes up 90% 
of the viral capsid, which is the major determinant of canine and feline host ranges (8, 
22, 32).   Since the feline host range of CPV-2a was not due to back-mutations to the 
FPV sequences, some of the newly arisen mutations that characterized CPV-2a were 
likely of compensatory nature(43, 45).  
Here we analyze the DNA sequence diversity and population structures of 
CPV and FPV within samples collected during natural and experimental infections.  
We define both the sequence variation generated de novo and that which likely results 
from co-infection. FPV samples from various tissues or feces were collected over a 43 
year period, with the oldest sample originating from 1963. The earliest CPV sample 
was collected in 1979, the second year of the pandemic in dogs. We inoculated cats 
with CPV collected from naturally infected dogs, and analyzed the developing 
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 population structures of the virus in different feline organs, comparing the sequence 
diversity in these populations to that present in the inoculum. 
 
4.3. Materials and Methods 
4.3.1. Virus samples.  
The viruses examined are listed in Table 4.1.  All samples were collected as original 
clinical specimens (feces or tissues) from infected animals, and were stored at -80°C.  
Diluted samples were either added directly to polymerase chain reaction (PCR) 
reactions without any prior preparation, or were purified using the QIAamp DNA Mini 
kit (Qiagen, Valencia, CA) according to the manufacturer’s recommendation before 
amplification.  
 
4.3.2. PCR, cloning and sequencing.   
PCR analysis was performed using the high fidelity Phusion Hot Start DNA 
polymerase (New England Biolabs, Beverly, MA) and primer pairs that either flanked 
the region between nts. 118 and 4837 in the viral genome (compared to CPV-2 
reference sequence, GenBank accession number: M38245.1), or that amplified that 
region as two overlapping fragments (nts. 118 to 2419 and nts. 2033 to 4837 (reverse 
primer 1) or nts. 2033 and 4680 (reverse primer 2), all primer sequences available 
from the authors upon request).
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PCR products were purified by agrose gel purification using the Qiaquick gel 
extraction kit (Qiagen) and were either prepared for cloning into the pSMART GC HK 
vector  according to the manufacturers recommendation (Lucigen Corporation, 
Middelton,WI), or were used without further preparation for cloning into the pJET1.2 
vector (Fermentas, Glen Burnie, MD) using the manufactuerer’s blunt-end cloning 
protocol. Inserts were sequenced using primer sets that covered the entire insert in 
both directions (primer sequences available from the authors upon request).  
 
4.3.3. Quantitative PCR analysis.   
A TaqMan real-time PCR assay for quantification of parvovirus genomes was 
established, targeting a conserved 60 nt region located between nts. 1039 and 1114 of 
the CPV genome (qPCR forward primer: AAATGAAACCAGAAACCGTTGAA; 
qPCR reverse primer: TCCCGCGCTTTGTTTCC). A TaqMan minor groove binding 
probe (MGB, ABI) was designed to bind to the amplified region (TaqMan MGB 
probe: ACAGTGACGACAGCAC). The linearized sequence of a CPV-2b genome, 
cloned into a plasmid, was used as an external standard for quantification of copy 
numbers. 
 
4.3.4. Sequence analysis. 
 Isolate consensus sequences have been published previously (19), and are available as 
GenBank accession numbers EU659111 to EU659121.  Mutations detected in the 
course of this study were compared to all publically available FPV and CPV 
sequences covering the respective genome region (alignments were identical to those 
published previously (19)).   
Some nucleotide sequences contained deletions or insertions, which were 
further analyzed using BLAST (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). These 
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sequences were aligned separately to the consensus sequence. Gene rearrangements 
were only confirmed if the exact boundaries of the deletion or duplication event could 
be inferred from the sequence information.  To confirm that those re-arranged 
sequences were present in the original samples before PCR amplification, we chose 
one of the gene rearrangements, detected in the FPV-kai.us.106 sample, and designed 
PCR primer pairs for which one primer each binds within the duplicated gene region 
(sequence available from the authors upon request). 
 
4.3.5. Experimental cat infections.  
All animal infections were approved by the Cornell University Animal Care and Use 
Committee.  The original virus-containing specimens (not tissue culture passaged) 
were resuspended in phosphate-buffered saline (pH 7.2) and sterile-filtered through a 
0.22 micron filter prior to inoculation.  The viral titers in the CPV isolates CPV-
13.us.81 and CPV-410.us.100 were determined as TCID50 in Nordon Laboratories 
feline kidney (NLFK) cells as described previously (44) and the viral genome copy 
numbers were determined by quantitative PCR. Groups of two ~5 week old parvovirus 
seronegative kittens (Liberty Research, Waverly, NY) were inoculated through the 
oro-nasal route with 5 × 105 TCID50 of CPV-13.us.81 or with 3×105 TCID50 of CPV-
410.us.100. Those contained 5.5 × 1014 or 3.4 x 1014 viral copy numbers respectively 
as determined by qPCR.  The kittens were monitored daily for clinical symptoms and 
viral shedding was assessed by PCR analysis of rectal swabs. On days 0 and 6 post 
inoculation, serum samples were collected to confirm the absence of anti-viral 
antibodies in hemagglutination inhibition (HI) tests as described elsewhere (34). On 
day 6 (for the CPV13 virus challenged kittens) or 8 (for the CPV410 virus challenged 
kittens) after inoculation the kittens were euthanized, then thymus, bone marrow and 
 
113
fecal samples were collected and examined for viral DNA by PCR.  PCR products 
(where these were generated) were cloned and sequenced as described above. 
 
 
4.4. Results 
Overall we obtained approximately 900,000 nucleotides of sequence, including 190 
clones covering the NS1/2 gene region and 172 covering the VP1/2 gene region (Table 
4. 1).  
 
4.4.1. Analysis of natural FPV infections.  
We analyzed viral genetic diversity in clinical FPV samples collected over a 43 year 
period (Figure 4.1), representing a broad variety of host tissues (Table 4.1). Most 
mutations that distinguished isolate consensus sequences were synonymous (Figure 
4.2A). No mutations were detected in the NS1 carboxy-terminus where NS2 is 
encoded in a different reading frame and only 1 nonsynonymous mutation was 
observed among the 12 mutations in the VP2 protein gene (8.3%). 
 
The population structures within individual FPV samples were very 
homogenous and comparable across samples (Figure 4.3A). Eleven of 90 sequences 
(12.2%) that covered the capsid protein gene harbored a mutation, with 3 of those 
being nonsynonymous. The VP2 Ile 101 to Thr change was present in 3 of 7 
sequences from the same sample. Six of 93 (6.5%) NS1-covering sequences harbored 
one or more mutations each, of which 64% were nonsynonymous. One mutation at 
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nucleotide position 2166 resulted in nonsynonymous mutations in both the NS1 and 
C-terminal NS2 reading frames (Figure 4.3A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Overview of natural virus samples analyzed. The host from which the 
sample was collected, the virus type, and year of collection are indicated. The likely 
natural host range and year of global spread are indicated. Viruses used for inoculation 
of kittens are marked. 
 
In most FPV samples, one mutation was detected every 4-6 × 10-5 nucleotides 
and the majority of mutations were generally located in the NS1 coding region (Table 
4.3). About half of the mutations detected in viral genomes from infected feline hosts 
can also be found in FPV GenBank sequences, such as 10 of 20 mutations in regions 
with sufficient sequence data available in GenBank.   
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Figure 4.2.  Mutations in the consensus sequences. The isolate consensus sequences 
from clinical samples of FPV (A) or CPV (B) infections were compared, using the 
oldest FPV or CPV samples as reference sequence in each case. The nucleotide 
position is indicated on the top, and the character state of individual nucleotides is 
indicated below each sequence. Changes in amino acid sequence are characterized 
above the sequence where appropriate. Synonymous changes are indicated by black 
boxes, nonsynonymous changes by red boxes, while the location in the viral genome 
can be inferred by referring to the genome map shown below the sequences. 
 
Of the 12 nonsynonymous mutations, 4 (33%) were also present in GenBank 
FPV sequences (Table 4.2) indicating a likely relatively high associated fitness of 
these mutations.    
Moreover, in the cases of FPV-8.us.89 and CPV-411.us.98 the possibility of co-
infections is underlined by the presence of these respective mutations in the global 
FPV population. 
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Figure 4.3.  Intra-host diversity in FPV and CPV samples. (A)  The gene regions 
covered by PCR amplification and a corresponding translation map of the parvovirus 
genome are indicated. B and C). Divergent viral sequences detected in naturally FPV 
(B) or CPV (C) infected animals are shown. The location of mutations in the 
parvovirus genome and the type of nucleotide substitution are indicated for each 
divergent sequence, the number of individual clones analyzed for each sample and the 
gene product affected by nonsynonymous mutations are indicated and the year of 
isolation is identified.  
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Table 4.2. Characterization of within-host mutations detected in individual 
FPV or CPV sequences. The location of single mutations detected in (A) FPV or 
(B) CPV samples. Nonsynonymous mutations are further characterized, and 
mutations present in other GenBank sequences are indicated by shading. (C) Since 
the sample CPV-411.us.98 most likely contained two co-infecting virus strains we 
analyzed the two virus populations (1998a and 1998b) separately and then 
compared the two consensus sequences present in sample CPV-411. 
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Virus Virus type 
Year of 
isolation 
nt 
location 
Protein 
region 
Amino 
acid 
change 
in 
nature 
Potential
function 
FPV-4 FPV 1964 798 NS1 R176G no DNA bindinga 
   809 NS1 - no - 
   1279 NS1 A336E no helicase a 
   3333 VP2 M183V no unclear 
FPV-3  1967 256 NS1 - * - 
   339 NS1 D23N yes DNA bindinga 
   581 NS1 - yes - 
   764 NS1 - yes - 
   893 NS1 - yes - 
   1013 NS1 H247Q yes DNA binding a 
   1015 NS1 T248I yes DNA binding a 
   2166 NS1/NS2 
V632I 
(NS1) 
R141H 
(NS2) 
no 
VP2 
phosphor
ylationa 
   3876 VP2 A363P no helicasea 
   4077 VP2 - yes - 
   4600 VP2 - * - 
FPV-8 FPV 1989 396 NS1 V42L no DNA bindinga 
   3088 VP2 I101T yes TfR binding 
FPV-
Kai FPV 2006 808 NS1 A179V no 
DNA 
bindinga 
   1815 NS1 K515E no 
VP2 
phosphor
ylationa 
   2534 VP1 - yes - 
   2954 VP2 - no - 
   2957 VP2 - yes - 
   4578 VP2 - * - 
   4760 VP2 - * - 
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Table 4.2 (continued) 
 
Virus Virus type 
Year of 
isolation 
nt 
location 
Protein 
region 
Amino 
acid 
change 
in 
nature 
Potential
function 
CPV-5 CPV-2 1979 4302 VP2 - no unclear 
CPV-6 CPV-2 1980 - - - - - 
CPV-
13 
CPV-
2a  581 NS1 - yes - 
  1981 1943 NS1 - no - 
   2090 NS1/NS2 
D606E 
(NS1)/ 
P116T 
(NS2) 
no 
Intra-
cellular 
traffickin
g a 
CPV-
411a 
CPV-
2b 1998a 719 NS1 - no - 
CPV-
411b 
CPV-
2b 1998b 3157 VP2 G124E no - 
CPV-
410 
CPV-
2b 2000 963 NS1 S231G no unclear 
CPV-
411 
CPV-
2b 1998a/ 413 NS1 - yes - 
  1998b 941 NS1 - yes - 
   1319 NS1 - yes - 
   1481 NS1 - yes - 
   1562 NS1 - yes - 
   2195 NS1/  NS2 
D151N 
(NS2) yes 
VP2 
phosphor
ylationa 
   2247 VP1 - yes - 
   2358 VP2 - yes - 
   2846 VP2 - yes  
   2951 VP2 - yes - 
   3157 VP2 G124E no unclear 
   3323 VP2 - yes - 
   3749 VP2 N321K yes 
possibly 
TfR 
binding 
   3947 VP2 - yes - 
   4023 VP2 - yes - 
   4494 VP2 K570E yes unclear 
   4510 VP2 - yes - 
   4526 VP2 - * - 
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Finally, genomic rearrangements were detected within the capsid protein gene 
regions of FPV-3.us.67 and FPV-kai.us.106 (Table 4.1) (with the FPV-kai.us.106 
clones spanning the complete viral coding region between nts. 140 and 4815) and 
were verified as described above (data not shown). 
 
4.4.2. Analysis of natural CPV infections.  
Clinical CPV samples were isolated over a 22 year period, starting the year after CPV 
spread worldwide (Figure 4.1). Most samples were in feces, except for CPV-5.us.79 
which was a sample from the spleen (Table 4.1). The sequences were assigned to the 
previously defined CPV-2 (CPV-5.us.79 and CPV-6.us.80), CPV-2a (CPV-13.us.81) 
and CPV-2b (CPV-410.us. 00 and CPV-411.is.98) antigenic types (Figure 4. 1) 
(35,37). Most mutations that distinguished the isolate consensus sequences clustered 
in the capsid protein gene (Figure 4.2B). Eleven of 20 (55%) mutations in this gene 
were nonsynonymous while genome-wide 14 nonsynonymous mutations were found 
among the 30 mutations (46.7%). Three mutations were located in the carboxy 
terminal region of NS1 where NS2 is encoded in a different reading frame, changing 
residues 641 of NS1 or 94 and 152 of NS2.  
The CPV-411.us.98 sample, collected from a puppy infected during a shelter 
outbreak, harbored two clearly distinct viral populations (Figure 4.3B). Both strains 
were the CPV-2b type and all but one of the distinguishing mutations were also 
detected in GenBank sequences (Table 4.2), indicating that this likely represented a 
co-infection by two different viruses. The sample also contained a single capsid 
protein gene clone that was of CPV-2 type, possibly a remnant of vaccine virus.  
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Table 4.3. Analysis of heterogeneity in the viral population. The total number of 
mutations detected in each sample is indicated. In cases where co-infection was 
suspected (i.e. samples FPV-8.us.89 and CPV-411.us.98), the data was analyzed 
both by looking at the two viral populations separately and disregarding mutations 
distinguishing the potential subpopulations (A) and by disregarding the potential of 
co-infection and counting all mutations detected within an infected animal (B). 
Comparable estimates were then calculated from a previously published study of 
heterogeneity in a CPV infected cat.  The number of mutations within an animal 
equals the total number of mutations detected, thus counting mutations that were 
present in more than one sequence multiple times. The average number of 
mutations/ nucleotide equals the total number of mutations detected in the 
respective sample, divided by the number of nucleotides analyzed. 
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However, since the possibility of cross-contamination in this case could not be ruled 
out, the sequence was excluded from further analyses. 
In most CPV samples, one mutation was detected every 2-4 × 10-5  nucleotides, 
and mutations appeared to be somewhat more frequent in the NS1 than VP2 ORF 
(Table 4.3).  Four of the 97 NS1 clones (4.1%) and two of the 83 VP2 clones (2.4%) 
harbored mutations from the consensus sequences, with individual clones harboring 1 
or 2 mutations. Only one of the 7 mutations detected within CPV-infected dogs 
(14.3%) was also detected in sequences from GenBank (Table 4.2). We found 
evidence of one gene duplication and deletion in the VP2 gene fragment of CPV-
13.us.81 (Table 4.1), and 3 of 21 CPV-13.us.81 sequences differed in the frequencies 
of a repeated 62 nt sequence located in the 3’ end of the viral genome (Figure 4.3B), a 
phenomenon described previously for CPVs and FPVs (36).  
 
4.4.3. Analysis of experimental cat infections.  
Only low levels of viral replication and little evidence of clinical disease were seen in 
the two kittens inoculated with CPV-13.us.81.  Kitten 1 developed mild clinical signs 
on day 4 after inoculation and shed low amounts of parvovirus in the feces the 
following day, while Kitten 2 showed mild clinical signs and viral shedding on day 6 
post inoculation. Neither of the kittens inoculated with CPV-410.us.100 showed 
clinical signs, and no clear evidence of viral fecal shedding was detected by 
conventional or qPCR (data not shown). We analyzed a total of 29 NS1 and 22 VP2 
spanning clones isolated from different tissues of the two CPV-13.us.81 inoculated 
animals (Figure 4.4B). In general, all viral populations were highly homogeneous. 
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Table 4.4. Mutations and re-arrangements detected in individual CPV sequences 
after experimental passage through cats.  (A) Single mutations and (B) gene re-
arrangements in samples collected after experimental infection with CPV-13.us.81. 
The functional impact of non-synonymous mutations is indicated where known or 
suspected. No virus could be recovered after experimental inoculation of cats with 
CPV-410.us.00.  Mutations also observed in GenBank sequences are indicated by 
shading.  
 
 
Cat # Organ of isolation 
Gene 
region nt location 
Amino acid 
change 
Observed in 
nature 
Functional 
implication 
1 feces NS1 941 - yes - 
1 feces NS1 1319 - yes - 
1 feces NS1/2 2024 T94A (NS2) yes 
Intra-
cellular 
trafficking a 
1 feces NS1/2 2198 
M152V 
(NS2) yes 
Interaction 
with  
members of 
the 14-3-3 
protein 
family a 
1 feces VP2 2798 start codon no VP2 start codon 
1 bone marrow 
NS1/
2 1855 D528V yes 
VP2 
phosphoryl
ationa 
Cat 
# 
Organ of 
isolation Gene region 
Deleted 
region (nt) 
Detected in 
inoculum 
  
 2134-2875 no 
1 thymus VP2 2274-3342 no 
  
 2676-3770 no 
Mutations were detected in the bone marrow (VP2 Asp528 to Val)) and feces of 
Kitten 1, with the later affecting the start codon of VP2. Two distinct sequences were 
recovered from the feces of Kitten 1, with 4 of the 8 clones identical to the challenge 
virus (Figure 4.3B). The other 4 clones harbored the same set of 4 mutations in the 
NS1 region, two synonymous changes in the NS1 carboxy terminal sequence and 
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nonsynonymous in the NS2 ORF (Thr94 to Ala and Met152 to Val) and two 
synonymous and located in the NS1 amino terminus. All mutations except the one in 
the VP2 gene of Kitten 1 were also present in GenBank sequences (Table 4.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  Analysis of the sequence recovered from experimental CPV-13.us.81 
infection of cats. (A) Summary of the expected pathogenesis of FPV in cats, including 
the viral location at various days post infection (p.i.) and organs infected. (B) 
Characterization of viral sequences recovered from different organs, including the type 
of nucleotide substitution and the attained protein (for nonsynonymous changes) of 
each infected cats. 
 
Gene re-arrangements were detected in sequences from the thymus of Kitten 1 and 
both forms of 62 nt repeat arrangements (Table 4.4), which were present in the 
challenge virus, were detected after experimental passage in cats.  
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 4.5. Discussion 
 
The emergence of CPV provides a valuable opportunity to examine the mechanisms of 
cross-species transmission, allowing a comparison of the viruses under endemic and 
emerging conditions. Here we define the levels of variation among the viral sequences 
in different hosts, comparing the long-adapted FPV in cats, CPV in dogs at various 
times after its global spread in 1978, as well CPV sequences during single 
experimental passages in cats. We compared the degree of sequence diversity in 
naturally infected dogs and cats, distinguishing between newly arising variation and 
heterogeneity due to co-infection, and analyzed the effect of host switching on the 
degree of sequence heterogeneity detected.  
 
4.5.1. Intra-host sequence diversity.  
In general, we observed low levels of sequence variation during natural infections by 
either FPV or CPV, and also during the experimental cross-species transfer of CPV to 
cats.  Only 6.3% of viral sequences cloned from natural infections harbored any 
mutations. This contrasts with most previous studies of intra-host population structure 
during parvovirus infections, but has also been suggested by one other recent study of 
CPV in dogs (3).  Battalani et al. (2006) analyzed individual virus genomes isolated 
from a single CPV-infected cat and detected high levels of sequence diversity within a 
1745 nt fragment of the VP2 gene (4), with 10 distinct sequences observed among 14 
analyzed viral clones (71%).  Two antigenically distinct CPV variants (CPV type-2a 
and a variant with the VP2 D426E substitution, referred to as CPV type-2c) were 
isolated from this single animal, indicating that at least part of the observed variation 
was likely due to co- or superinfection rather than newly arising mutations. 
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 4.5.2. Evidence for co-infections.  
Notably, our study provided strong evidence for multiple infections. In particular, 3 of 
7 clones analyzed for FPV-8.us.89 contained the same change (VP2 residue Ile101 to 
Thr) in the capsid protein gene, while being otherwise identical to the consensus 
sequence.  This particular mutation is circulating in the FPV (Table 4.2) and CPV (19) 
population, thereby making a co-infection event a plausible explanation. The CPV-
411.us.98 isolate presented particularly strong evidence of co-infection. This sample 
contained two genetically distinct CPV-2b viruses (CPV-411a.us.98 and CPV-
411b.us.98), which are distinguished by 6 and 12 mutations in the NS1 or VP1 gene, 
respectively. All but one of the mutations differentiating those two viral strains are 
present in GenBank sequences, again supporting the idea of co-infection since the 
mutations are clearly circulating in the global CPV population. If we assumed co-
infection as the source of some heterogeneity, the average number of mutations per 
nucleotide was in the range of 2 × 10-5 - 6 × 10-6 in all but one of the analyzed samples 
(the estimate for kitten 1 was excluded here as the artificial host switching might 
impact the developing population structure and the estimates might therefore not be 
comparable).  Conversely, the estimates were considerably higher for the questionable 
samples if it was assumed that all variation arose by de-novo mutation.  These higher 
estimates were in the range estimated based on the report of Batallani et al. (3), so that 
similar reasoning might explain the high diversity reported by these authors. Co-
infections have been described for vaccine and field strains of CPV (13) and for 
several related parvovirus families, including the human parvovirus B19 (5).  Co-
infections with multiple parvovirus strains may thus occur frequently, potentially 
facilitating recombination (41). 
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4.5.3. Gene rearrangements.  
We detected several gene duplication and deletion events among the FPV and CPV 
genomes examined. Such rearranged sequences have long been recognized among the 
parvoviruses (1, 10, 21), and likely result from template switching of the polymerase 
during replication. This process, which is also thought to be responsible for non-
homologous and homologous recombination among RNA viruses (23, 28), may be 
facilitated by the complex secondary structures of the viral ssDNA genome. 
Recombination among CPV genomes was suggested as the source of genomes 
containing various combinations of mutations after extended tissue culture passage 
(2).   
 
4.5.4. Effect of host species, organ or sampling time after CPV emergence.  
The viral population structures in all isolates were generally characterized by low 
levels of sequence diversity, regardless of their host species, organ or time of isolation, 
or of the specific viral strain. On average, one mutation was detected every 104 -105 
nucleotides, which is comparable to the annual substitution rate estimates of these 
viruses obtained on a population level (43, 19). Since variant CPV sequences arise 
very readily during tissue culture passage (2), strong purifying selection appears to 
quickly purge most arising mutants during natural infections, resulting in the low 
degree of sequence diversity within infected hosts. We detected no observable 
differences in intra-host population structure between CPV isolates collected during 
the first wave of spread (from 1979 and 1980) compared to those collected after the 
virus had been circulating in dogs for longer times, suggesting that dynamics of intra-
host mutation and selection did not change markedly during this time period.   
 To better determine the effects of a single cross-species transmission event on 
the virus, we examined experimental CPV infections of cats, which revealed only 
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limited viral replication in the susceptible cats.  The CPV sequences recovered from 
the cats showed low levels of heterogeneity, but parts of the viral capsid protein gene 
were deleted in some cases, indicative of defective genomes. In addition, one virus 
isolated from the feces of Cat 1 harbored a likely lethal mutation that altered the start 
codon of VP2. Mutations were detected in the NS1/2 regions of viruses isolated from 
bone marrow and feces, with approximately 50% of viruses in the feces of cat 1 
harboring the same set of 4 mutations. Two of the changes (at residues 94 and 152 of 
NS2) mapped to the gene region where NS2 is derived from a different reading frame 
overlapping the NS1 reading frame and have been identified as potentially positively 
selected on a population level (19). Since these represent 2 of 4 apparently linked 
mutations observed after artificial host switching, a role of some or all of these 
residues in host adaptation is likely.  Little is known about the function of NS2 in 
CPV, and NS2 knock-out mutants showed no obvious differences in replication in cell 
culture or dogs (46). In the rodent parvoviruses MVM and LuIII, NS2 appears to be 
required for efficient translation, capsid assembly, and nuclear transport. In these 
viruses host-specific effects modulate the functions of NS2 (9, 11, 12, 17, 25, 30). 
Interestingly, upon infection of severe combined immunodeficient (SCID) mice with 
MVM in the presence of polyclonal anti-capsid antibodies, the viral population 
harbored nonsynonymous changes in the NS2 C-terminus which likely affected CRM1 
binding (27). In this case nonsynonymous mutations were absent from the capsid 
protein genes (27), although such mutations arose readily during infections in the 
absence of polyclonal antibodies (26). The role of NS2 in host adaptation of CPV 
therefore merits further study. 
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 4.5.5. Distribution of mutations in the genomes.  
The majority of mutations involved in the emergence of CPV -2 clustered in the 
capsid protein ORF, and on a population level this genome region has continued to 
evolve more rapidly than the non-structural ORF, at least among the CPV sequences 
(19).  Among the FPV sequences, on the contrary, these differences between the 
genome regions were not observable (19). Interestingly, the mutations observed within 
individual infected animals here generally showed no clear clustering in any specific 
genome region, though mutations were somewhat more likely to occur in the non-
structural ORF. Particularly the scarcity of mutations detected in the capsid protein 
region after experimental cross-species transmission to cats appears surprising and 
highlights the limited effect of positive selection within a single infected animal.  
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CHAPTER 5 
INTRAHOST DYNAMICS OF CANINE INFLUENZA VIRUS IN NATURALLY 
AND EXPERIMENTALLY INFECTED DOGS 
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5.1.   Summary 
Canine Influenza virus (CIV) is a novel pathogen of dogs. The virus emerged around 
2004 following a host jump from an H3N8 equine influenza virus. CIV is still 
spreading in certain US dog populations, even though some evidence suggests 
relatively low virus transmissibility. Little is known about the factors facilitating this 
successful cross-species transmission or the subsequent evolution, spread and 
potentially continuing host adaptation of CIV. Here we address these questions by 
analyzing the intra-host dynamics of CIV in dogs over the course of infection.  
Virus populations in experimentally infected dogs were characterized by low levels of 
genetic diversity, which decreased over time. Intriguingly, where a sample for day 4 
post inoculation was available, genetic diversity appeared to increase slightly on this 
day, after reaching a nadir on day 3 post inoculation. Most detected mutations had low 
prevalence (largely singletons), and most mutations present at higher prevalence were 
pre-existing in the challenge virus. Mutations were often not detected on more than 
one subsequent day and variable sites were not strongly correlated between animals or 
between days. However, several mutations that were not detected in the challenge 
virus seemed to be maintained in the infected animals over several days, and many 
mutations that reached higher frequency were located in known antigenic sites.  
 
5.2.  Introduction 
Host-jumping viruses can represent important threats to human and animal health. 
Numerous devastating emerging human pathogens such as the human 
immunodeficiency virus, Influenza A virus, or SARS coronavirus and several 
common human diseases such as mumps, measles and pertussis have been shown or 
are believed to have emerged after cross-species transmission from an animal host (4, 
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7, 14, 19, 21). However, despite the profound evolutionary importance of cross-
species transmission, the evolutionary mechanisms underpinning this process remain 
opaque.  In general, the adaptation of a pathogen to a new host is believed to be a 
sequential process, where the initial virus may be maladapted to the new host and only 
inefficiently transmitted.  Consequently, further adaptation is required before the novel 
pathogen can cause wide-spread epidemics (1, 11). During this adaptation phase, the 
virus may only circulate locally and causes predominantly short, self-limiting 
transmission chains.  Many outbreaks of novel diseases end at this stage - but the 
factors determining the success or failure of these host-transferred viruses are unclear 
(21).  
 
 The propensity for a virus to generate genetic variation, as well as the fitness 
distribution of mutations within individual hosts, is therefore essential to 
understanding the process of cross-species transmission and emergence.  In general, 
the shape of a viral population within an infected host represents a balance between 
diversity generated through error-prone replication and how rapidly it is removed by 
purifying selection. The shapes of these viral populations are likely host-specific and 
might be strongly impacted by host-associated factors such as immune status or age. 
However, the within-host population structure of most newly emerged viruses, and the 
relative importance of intra-host dynamics on disease emergence and subsequent 
adaptation, are unknown.  
 
Canine influenza virus (CIV) was first recognized as a new pathogen of dogs 
in January 2004, when it caused an outbreak of respiratory disease in racing 
greyhounds in Florida (3). Serological testing of archival samples later revealed that 
the virus had been circulating in Florida racetracks since at least 2000, and CIV 
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seroprevalence was high in racing greyhounds and shelter dogs by mid-2004 (3). By 
August 2004, the disease had also been detected in dogs at greyhound race tracks in 
Texas, Alabama, Arkansas, West Virginia and Kansas (3). CIV continued to spread 
across the US, increasingly affecting non-racing dogs (12, 22). By October 2008, a 
national syndromic serosurvey had analyzed CIVantibody-positive samples from 26 
different states and the District of Columbia (Cornell University College of Veterinary 
Medicine, http://diaglab.vet.cornell.edu/issues/civ-stat2.asp). This survey included 
dogs presenting with clinical signs that were compatible with CIV infection, but that 
were unassociated with greyhound racetracks. Between 2005 and 2008, > 6000 
serological samples had been analyzed though this program. On average, 17% of 
samples tested positive for CIV, with the ratio ranging from 1.4% to 63% depending 
on the state. High percentages of positives were detected in samples from Colorado 
(62.6%), Delaware (56.9%) and Wyoming (43.4%), while samples from Arizona 
(27.3%), Illinois (19.6%), Massachusetts (23.4%), New York (23.3%), Pennsylvania 
(16.7%) and Washington DC (21.8%) showed lower levels of positives. Intriguingly, 
few or no positives were detected in samples from Georgia (n=62), Maryland (n=64), 
Minnesota (n=68), North Carolina (n=69), Ohio (n=183), Texas (n=119), Virginia 
(n=106), Washington State (n=130) and Wisconsin (n=73), indicating a very 
heterogeneous, patchy distribution of the virus, and likely very local viral spread.   
 
Phylogenetic analysis suggests that CIV emerged through direct transfer of an 
intact equine H3N8 influenza strain, suggesting a probably negligible role of 
reassortment in this emergence event (3). Moreover, all CIV sequences analyzed to 
date are monophyletic, indicating that a single cross-species transmission event has 
occurred (3, 22). In the hemagglutinin (HA) gene (H3) a set of five amino acid 
changes appears to distinguish the currently sequenced CIV isolates from their equine 
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ancestors, while another three amino acid changes in this gene distinguish the more 
recent from the older CIV isolates, thus potentially representing the result of further 
host adaptation or antigenic escape (12).   Intriguingly, the CIV isolates are 
antigenically similar to contemporary EIV isolates, while qualitative differences 
between older and more recent CIV isolates my exist (12). However, to date there is 
limited data available for CIV and many questions regarding the emergence of CIV 
and its subsequent spread in the North American dog population have remained 
unanswered.  
 
Here we analyzed, for the first time, the viral intra-host sequence variation and 
temporal dynamics of CIV during infections of dogs. To address the potential impact 
of our experimental inoculation, we compared the dynamics observed during our 
experimental infections with those observed in the field by analyzing a selected 
sample collected from a naturally infected dog.   
 
 
5.3. Materials and Methods 
 
5.3. 1.  Experimental dog infections.  
The dog infections and analysis of antibody titers, clinical symptoms and viral 
shedding have been described previously (15) and are summarized below for the dogs 
analyzed in this study (Tables 5.1). In short, 12 purpose-bred intact beagle bitches 
(Marshall Farms), approximately 8 weeks of age, were placed in group housing prior 
to challenge inoculation and were not separated based on group affiliation. Individual 
dogs were identified by ear tattoos and none of the dogs had detectable antibodies to 
CIV, as determined by HA Inhibition assay, prior to vaccination.  
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  The dogs were randomly divided into three groups of four.  The allocation of 
individual dogs remained obscured for the duration of the experiment and the 
evaluation of serological data.  Dogs were vaccinated subcutaneously (SC) and group 
1 received 2.4 X 106 PFU of a recombinant equine herpesvirus expressing the viral 
HA (rH_EIV) (15), while group 2 received a commercial equine H3N8 subunit 
vaccine. Group 3 received only virus resuspension buffer (negative control).  The dogs 
received a booster vaccination of 4.1 X 106 PFU of rH_EIV, the commercial subunit 
vaccine or resuspension buffer 4 weeks later.  All dogs were challenged three weeks 
after booster vaccination with 1x106 PFU A/canine/PA/10915-07 which had been 
amplified by growth in embryonated eggs. For the inoculation, 2 ml of virus-
containing allantoic fluid were placed in a custom-engineered nebulizer and 
administered with flow-through oxygen to each individual dog for ~10 minutes. 
 
  Blood was drawn from the cephalic vein on days -56 (initial vaccination), -35, 
-21 (booster vaccination), -14, and -7 before challenge.  In addition, blood was drawn 
on days 0, 8, and 15 post challenge.  Two nasal swabs were taken from each dog on 
days 0 to 10 post inoculation (p.i.) using one 3” non-sterile foam-tipped swab (Fisher) 
and one TX754B Mini Alpha swab (ITW Texwipe).  The swabs were placed 
immediately in 1 ml of transport media (PBS supplemented with 10% glycerol, 4% 
penicillin/streptomycin/amphotericin B, 10% FBS, and 0.05% enrofloxacin (Baytril®)) 
on ice. 
 
  Physical examinations were performed 2 days prior to challenge, on the day 
of challenge (day 0) and from days 1 to 8, 10 and 15 post challenge and have been 
described previously (15).  Briefly, observations of the activity level, demeanor, heart 
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rate, respiratory rate, rectal temperature, and overall general appearance were 
performed and subsequently combined.  A fever was defined as a rectal temperature 
above 39.5°C (i.e. 103.1 degrees Fahrenheit).  Clinical signs were scored using 5 
categories, with 1 = absence of symptoms; 2 = mild clinical signs or mildly depressed 
animals; 3 = moderate clinical signs or moderately depressed animals; 4 = severe 
clinical signs or depressed animals with clear clinical signs and 5 = severe clinical 
signs and clearly depressed animals.  
 
All sera were tested by use of standard microtiter haemagglutination inhibition 
(HI) and an inhibition enzyme-linked immunosorbent (ELISA) assay and results have 
been reported previously (15).  
 
Two naïve dogs were selected based on the clinical manifestation (Table 5.1), 
rectal temperature (Table 5.1) and antibody titers (Table 5.2), and CIV sequences 
isolated from these animals were prepared for sequencing as described below.  
 
Table 5.1: Summary of clinical data for experimentally infected dogs, previously 
published by (15). Days analyzed during this study are indicated by bolding. Pyrexia 
was defined as a temperature above 103.1 degrees Fahrenheit.  Code for clinical signs: 
1= no symptoms; 2= mild clinical signs or mildly depressed; 3= moderate clinical 
signs or moderately depressed; 4= severe clinical signs or depressed with clear clinical 
signs; 5= severe clinical signs and clearly depressed.  
 
measure dog # Immune 
status 
days post inoculation 
day 1 day 2 day 3 day 4 day 
5 
temperature 1 naïve  101.3 104.0 103.2 103.5 102.6
2 101.8 103.8 102.4 103.3 102.6
clinical signs 1 naïve 2 2 3 3 4 
2 2 3 2 2 1 
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Table 5.2: Changes in anti-influenza antibody (HA inhibition) titers of naïve and 
vaccinated dogs after mock vaccination (day-53) and after inoculation (day 0), 
previously published by (15).   
 
dog # Immune  
status days  post vaccination
 day (-)14 day 0 day 8 day 15
1 naïve 8 8 128 1024
2  8 8 128 256
 
5.3.2. Naturally infected dog sample.  
A nasal swab from a naturally infected, clinically sick and client-owned animal was 
submitted to the Cornell Diagnostic lab for routine CIV testing. Aliquots of nasal 
swabs from CIV-positive dogs were stored at -80C° until viral RNA isolation. 
 
5.3.3.  RNA isolation, RT-PCR analysis, cloning and sequencing.  
Viral RNA from experimentally or naturally infected dogs was isolated using the 
QIAamp viral RNA mini kit (QIAGEN, Valencia, CA) according to the 
manufacturer’s recommendation, starting with 140 μl nasal swab material, and eluting 
in a total volume of 70 μl of buffer AVL (QIAGEN, Valencia, CA). Viral RNA was 
stored at -80°C until reverse transcription (RT). Viral RNA was reversed transcribed 
using two-step reverse transcription. The circular DNA (cDNA) was generated using 
Superscript III reverse transcriptase (INVITROGEN, Carlsbad, CA) according to the 
manufacture’s recommendation, starting from 5 μl viral RNA . Primer Bm-HA1 (5’ 
TATTCGTCTCAGGGAGCAAAAGCAGGGG3’) (previously published by (8)) was 
used to generate the cDNA and RT was performed at 55°C  for 90 min, followed by 
incubation at 70°C  for 10 min. The second strand was generated using Platinum Pfx 
DNA polymerase (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
protocol, starting from 5 μl cDNA. Primers  Bm-HA1 and EHA1007rw 
(5’TTGGGGCATTTTCCATATGT3’) were used for the PCR amplification, which 
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was performed during 40 cycles (94°C for 30 sec, 55°C for 1 min and 68°C for 1 min), 
followed by a final extension at 68°C for 10 min.  Primers spanned the region between 
nt -43 (upstream of the HA1 start codon) and nt 965, generating a fragment of 1008 
nts.  
 
PCR products were purified by agrose gel purification using the Qiaquick gel 
extraction kit (QIAGENE) and were cloned into pCR4Blunt-TOPO (Invitrogen) 
according to the manufacturer’s protocol. Cloned constructs were transformed into 
electrocompetent E. coli hosts (One Shot TOP10 cells, Invitrogen) and plated with 
ampicillin or kanamycin selection. Amplicons were sequenced using commercial 
primers M13 forward and M13 (20) reverse. To test whether sequences generated by 
Sanger and Cornell University were comparable, three samples were partially 
sequenced at both places, and the phylogenetic relationship between the sequences 
generated at either place was compared (data not shown).  
 
5.3.4. Evolutionary analysis. 
 Between 22 and 88 HA1 sequences from each sample, and on each day (Table 5.5), 
were determined as described above and aligned by hand in the Se-Al program 
(http://tree.bio.ed.ac.uk/software/seal/). Sequence alignments were trimmed to cover 
amino acids 1 to 316 of the nascent HA1, thus including the signal peptide. To map 
the amino-acids onto the inferred sequence of the mature HA, alignments were further 
trimmed to correspond to the mature HA1 (all alignments available from the authors 
on request). To compare the evolutionary dynamics within infected animals to those 
observed on a population level, we constructed alignments of 165 equine sequences 
and 6 CIV sequences, both covering the corresponding region (Tables 5.3 and 5.4), 
from the Influenza Virus Resource 
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(http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html). These alignments were 
trimmed using Se-Al, and analyzed as described below. Due to the very limited 
number of CIV sequences available in GenBank, no population-level analysis of CIV 
was performed.  
 
 Unrooted maximum likelihood (ML) phylogenetic trees were estimated for the 
challenge virus, the alignment of EIV sequences and for sequences collected from 
each analyzed animal using PAUP* version 4.0 (18) with the best-fitting model of 
nucleotide substitution determined using Modeltest (13) (all parameter values 
available from the authors on request). The mean pairwise genetic diversity for each 
sample was subsequently calculated from the uncorrected pairwise distance matrix 
between taxa (available from the authors upon request).    
We used the Single Likelihood Ancestor Counting (SLAC) algorithm available 
in the Datamonkey web interface of the HyPhy software package (10) to estimate the 
relative rates of synonymous (dS) and nonsynonymous (dN) substitutions per site (ratio 
dN/dS) in our challenge virus, the sequences collected from individual infected 
animals, the EIV consensus sequences, and the EIV alignment (again employing the 
best-fitting substitution model from Modeltest).  
 
Mutations detected within individual infected animals were characterized 
further as to their frequency and presence in other samples, and were mapped to 
inferred amino acid sequences of the mature HA1. Mutations present at a frequency > 
1 were subsequently compared to the alignments of 165 equine H3N8 and 6 CIV 
sequences (Tables 5.3 and 5.4) to assess their presence in the canine or equine H3N8 
population.  
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  Table 5.3: Overview of H3N8 equine influenza virus sequences used to assess the 
population-level evolution of equine influenza virus.  
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 Genbank 
accession 
Country of 
isolation
Year of 
isolation virus name
AB360549 Japan 2007 A/equine/Ibaraki/1/07(H3N8) 
AB369862 Japan 2007 A/equine/Kanazawa/1/2007(H3N8)
AB435160 Japan 2008 A/equine/Tokyo/3/2008(H3N8) 
AB435161 Japan 2008 A/equine/Hyogo/1/2008(H3N8) 
AB436910 Mongolia 2008 A/equine/Mongolia/1/2008(H3N8)
AF197241 USA 1998 A/equine/Kentucky/1/1998(H3N8)
AF197242 USA 1994 A/equine/Florida/1/94(H3N8) 
AF197243 Canada 1990 A/equine/Saskatoon/1/1990(H3N8)
AF197244 Argentina 1995 A/equine/Argentina/1/95(H3N8)
AF197245 Argentina 1994 A/equine/Argentina/2/94(H3N8)
AF197246 Argentina 1996 A/equine/Argentina/1/96(H3N8)
AF197247 USA 1995 A/equine/Kentucky/9/1995(H3N8)
AF197248 USA 1996 A/equine/Kentucky/1/1996(H3N8)
AF197249 USA 1997 A/equine/Kentucky/1/1997(H3N8)
AJ223192 
United 
Kingdom 1989 A/equine/Lichfield/89(H3N8) 
AJ223193 
United 
Kingdom 1989
A/equine/Newmarket-Bob 
Champion/89(H3N8) 
AJ223194 Germany 1989 A/equine/Berlin/3/89(H3N8) 
AJ223195 Germany 1989 A/equine/Berlin/4/89(H3N8) 
AJ223196 Germany 1991 A/equine/Berlin/1/91(H3N8) 
AJ223197 Germany 1991 A/equine/Berlin/2/91(H3N8) 
AX018718 n/a n/a Equine influenza virus H3N8 
AY048077 Argentina 1997 A/equine/Argentina/97(H3N8) 
AY048078 Argentina 1999 A/equine/Argentina/99-2(H3N8) 
AY048079 Argentina 1999 A/equine/Argentina/99-3(H3N8) 
AY048080 Argentina 1999 A/equine/Argentina/99-4(H3N8) 
AY048081 Argentina 1999 A/equine/Argentina/99(H3N8) 
AY273167 USA 1999 A/equine/New York/99(H3N8) 
AY273168 USA 2000 A/equine/Oklahoma/2000(H3N8) 
AY383755 Chile 1985 A/equine/Santiago/1/1985(H3N8) 
AY855341 USA 2002 A/equine/Kentucky/5/2002(H3N8) 
AY919314 Sweden 2001 A/equi 2/Gotland/01(H3N8) 
BD244629 n/a n/a Equine influenza virus H3N8 
BD244630 n/a n/a Equine influenza virus H3N8 
BD244631 n/a n/a Equine influenza virus H3N8 
BD244632 n/a n/a Equine influenza virus H3N8 
CS287777 n/a n/a Equine influenza virus H3N8 
CY018869 USA 1991 A/equine/Idaho/37875/1991(H3N8) 
CY028796 USA 1978 A/equine/Kentucky/1/1978(H3N8) 
CY028804 USA 1980 A/equine/Kentucky/4/1980(H3N8) 
CY028812 USA 1980 A/equine/California/1/1980(H3N8)
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Table 5.3 (continued)   
Genbank 
accession 
Country of 
isolation
Year of 
isolation virus name
CY028820 USA 1981 A/equine/Kentucky/2/1981(H3N8)
CY028828 USA 1981 A/equine/Kentucky/1/1981(H3N8)
CY028836 USA 1963 A/equine/Miami/1/1963(H3N8) 
CY028844 USA 1976
A/equine/Kentucky/pass_the_pepper1
/1976(H3N8)
CY028852 USA 1976
A/equine/Kentucky/bitter_boredom5/1
976(H3N8)
CY028860 USA 1981 A/equine/Georgia/1/1981(H3N8)
CY028868 USA 1981 A/equine/Georgia/3/1981(H3N8)
CY028876 USA 1981 A/equine/Georgia/9/1981(H3N8)
CY028884 USA 1981 A/equine/Georgia/10/1981(H3N8)
CY028892 USA 1981 A/equine/Georgia/13/1981(H3N8)
CY028900 USA 1981
A/equine/Kentucky/magnificent_geniu
s1/1981(H3N8)
CY028908 USA 1982 A/equine/California/103/1982(H3N8)
CY028916 USA 1983
A/equine/New York/VR-
297/1983(H3N8)
CY030077 USA 1981 A/equine/Kentucky/3/1981(H3N8)
CY030085 USA 1982 A/equine/California/83/1982(H3N8)
CY030093 USA 1986 A/equine/Kentucky/1/1986(H3N8)
CY030101 USA 1987 A/equine/Kentucky/1/1987(H3N8)
CY030109 USA 1988 A/equine/Kentucky/692/1988(H3N8)
CY030117 USA 1988 A/equine/Kentucky/694/1988(H3N8)
CY030125 USA 1988 A/equine/Kentucky/698/1988(H3N8)
CY030133 USA 1990 A/equine/Kentucky/1277/1990(H3N8)
CY030141 USA 1991 A/equine/Texas/39655/1991(H3N8)
CY030149 USA 1992 A/equine/Kentucky/1/1992(H3N8)
CY030157 USA 1991 A/equine/Alaska/29759/1991(H3N8)
CY030165 USA 1986 A/equine/Tennessee/5/1986(H3N8)
CY030173 USA 1991 A/equine/Kentucky/1/1991(H3N8)
CY030181 USA 1994 A/equine/Kentucky/8/1994(H3N8)
CY030189 USA 1983 A/equine/New York/1/1983(H3N8)
CY030743 USA 1981
A/equine/Kentucky/Rosie100/1981(H3
N8)
CY030751 USA 1997 A/equine/California/4537/1997(H3N8)
CY030759 USA 2002 A/equine/California/8560/2002(H3N8)
CY031538 USA 1987 A/equine/Kentucky/2/1987(H3N8)
CY032221 USA 1986 A/equine/Kentucky/2/1986(H3N8)
CY032229 USA 1986 A/equine/Kentucky/3/1986(H3N8)
CY032293 Brazil 1963 A/equine/Sao Paulo/6/1963(H3N8)
CY032301 Argentina 1985 A/equine/Cordoba/18/1985(H3N8)
CY032309 USA 1985 A/equine/Santa Fe/1/1985(H3N8)
CY032317 
United 
Kingdom 1989 A/equine/Sussex/1/1989(H3N8)
CY032325 
United 
Kingdom 1989 A/equine/Rook/93753/1989(H3N8)
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Table 5.3 (continued)   
Genbank 
accession 
Country of 
isolation
Year of 
isolation virus name
CY032333 Italy 1991 A/equine/Italy/824/1991(H3N8)
CY032341 Italy 1992 A/equine/Italy/1199/1992(H3N8)
CY032349 Austria 1992 A/equine/Austria/421/1992(H3N8)
CY032357 Switzerland 1993 A/equine/Switzerland/173/1993(H3N8)
CY032365 Italy 1991 A/equine/Rome/5/1991(H3N8)
CY032373 Italy 1991 A/equine/Italy/1062/1991(H3N8)
CY032381 Switzerland 1979
A/equine/Switzerland/1118/1979(H3N
8) 
CY032389 Romania 1980 A/equine/Romania/1/1980(H3N8)
CY032397 Brazil 1969 A/equine/Sao Paulo/1/1969(H3N8)
CY032405 France 1979 A/equine/Fontainbleu/1/1979(H3N8)
CY032413 Germany 1989 A/equine/Berlin/1/1989(H3N8)
CY032421 Uruguay 1963 A/equine/Uruguay/1/1963(H3N8)
CY032937 USA 1980 A/equine/Kentucky/2/1980(H3N8)
CY032945 Algeria 1972 A/equine/Algiers/1/1972(H3N8)
CY032953 South Africa 1986 A/equine/Johannesburg/1/1986(H3N8)
CY033481 n/a 1978 A/equine/Kascakew/1/1978(H3N8)
CY034934 Japan 1971 A/equine/Sachiyama/1/1971(H3N8)
D30677 
United 
Kingdom 1979 A/equine/NewMarket/D64/79(H3N8)
D30678 
United 
Kingdom 1989 A/equine/Sussex/93753/89(H3N8)
D30679 France 1989 A/equine/Yvelines/2136/1989(H3N8)
D30680 USA 1991 A/equine/Alaska/1/1991(H3N8)
D30681 USA 1991 A/equine/Arundel/12369/91(H3N8)
D30682 Hong Kong 1992 A/equine/Hong Kong/1/92(H3N8)
D30683 USA 1992 A/equine/Kentucky/1/1992(H3N8)
D30684 Italy 1991 A/equine/Rome/5/1991(H3N8)
D30685 
United 
Kingdom 1992 A/equine/Lambourn/22778/92(H3N8)
D30686 Spain 1993 A/equine/LaPlata/1/1993(H3N8)
DQ124189 USA 1999 A/equine/New York/1/1999(H3N8)
DQ124191 USA 2002 A/equine/Kentucky/5/2002(H3N8)
DQ124192 USA 2003 A/equine/Ohio/1/2003(H3N8)
DQ124193 USA 2003
A/equine/Massachussetts/213/2003(H
3N8) 
DQ124194 USA 2003 A/equine/New York/452/2003(H3N8)
DQ124195 USA 2003 A/equine/California/191/2003(H3N8)
DQ222913 USA 2003 A/equine/Wisconsin/1/03(H3N8)
EF117330 Italy 2005 A/equine/Bari/2005(H3N8)
EF536318 Italy 2003 A/equine/Rome/1/2003(H3N8)
EF536319 Italy 2003 A/equine/Rome/2/2003(H3N8)
EF536320 Italy 2004 A/equine/Rome/2004(H3N8)
EF536321 Italy 1999 A/equine/Brescia/1999(H3N8)
EF541428 Germany 2000 A/equine/Berlin/00(H3N8)
EF541429 Germany 2002 A/equine/Berlin/13/02(H3N8)
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Table 5.3 (continued)  
Genbank 
accession 
Country of 
isolation
Year of 
isolation virus name 
EF541430 Germany 2002 A/equine/Berlin/14/02(H3N8)
EF541431 
United 
Kingdom 2000 A/equine/Leicestershire/2/2000(H3N8)
EF541432 
United 
Kingdom 2004 A/equine/Aboyne/410355/04(H3N8)
EF541433 
United 
Kingdom 2004
A/equine/Stoke-on-
Trent/410956/04(H3N8)
EF541434 
United 
Kingdom 2004 A/equine/Arundel/410749/04(H3N8)
EF541435 
United 
Kingdom 2001 A/equine/Cheltenham/1/01(H3N8)
EF541436 
United 
Kingdom 2000 A/equine/Leicestershire/1/2000(H3N8)
EF541437 
United 
Kingdom 2005 A/equine/Lanark/1/2005(H3N8)
EF541438 
United 
Kingdom 2005 A/equine/Wales/1/2005(H3N8)
EF541439 
United 
Kingdom 2005 A/equine/Essex/1/2005(H3N8)
EF541440 
United 
Kingdom 2005 A/equine/Essex/2/2005(H3N8)
EF541441 
United 
Kingdom 2005 A/equine/Essex/3/2005(H3N8)
EF541442 
United 
Kingdom 2005 A/equine/Aboyne/1/2005(H3N8)
EF541443 Italy 1991 A/equine/Italy/788/91(H3N8)
EU503046 Argentina 2001 A/equine/Argentina/1/2001(H3N8)
EU855741 Canada 2003
A/equine/Guelph/G03-
55399/2003(H3N8) 
EU855742 Canada 2004
A/equine/Guelph/G04-
54701/2004(H3N8) 
EU855743 Canada 2003
A/equine/Guelph/G03-
0250/2003(H3N8) 
EU855744 Canada 2006
A/equine/Guelph/06-
28865/2006(H3N8) 
EU926631 Chile 2006 A/equine/Lonquen/1/2006(H3N8)
FJ209731 Egypt 2008
A/equine/Egypt/6066NAMRU3-
VSVRI/2008(H3N8) 
FJ605181 Greece 2007 A/equine/Athens/02/2007(H3N8)
FJ605182 Greece 2007 A/equine/Athens/04/2007(H3N8)
L27597 Hong Kong 1992 A/equine/Hong Kong/1/92(H3N8)
L39913 Argentina 1993 A/equine/Argentina/1/93(H3N8)
L39914 USA 1994 A/equine/Kentucky/1/1994(H3N8)
L39915 USA 1990 A/equine/Kentucky/1/1990(H3N8)
L39916 USA 1993 A/equine/Florida/1/93(H3N8)
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Table 5.3 (continued)   
Genbank 
accession 
Country of 
isolation
Year of 
isolation virus name 
L39917 USA 1992 A/equine/Kentucky/1/1992(H3N8)
L39918 USA 1991 A/equine/Kentucky/1/1991(H3N8)
M24718 Uruguay 1963 A/equine/Uruguay/1/1963(H3N8)
M24719 USA 1963 A/equine/Miami/1/1963(H3N8)
M24720 Japan 1971 A/equine/Tokyo/1971(H3N8) 
M24721 Algeria 1972 A/equine/Algiers/1972(H3N8) 
M24722 
United 
Kingdom 1976 A/equine/New Market/1976(H3N8) 
M24723 France 1976 A/equine/Fontainebleau/1976(H3N8) 
M24724 Romania 1980 A/equine/Romania/1980(H3N8) 
M24725 Chile 1985 A/equine/Santiago/1/1985(H3N8) 
M24726 USA 1985 A/equine/Tennessee/5/1985(H3N8) 
M24727 USA 1986 A/equine/Kentucky/2/1986(H3N8) 
M24728 USA 1987 A/equine/Kentucky/1/1987(H3N8) 
M29257 USA 1963 A/equine/Miami/1963(H3N8) 
M65018 China 1989 A/equine/Jilin/1/1989(H3N8) 
M73773 France 1976 A/equine/France/1/1976(H3N8) 
S64310 Sweden 1991 Equine influenza virus H3N8 
S77429 Sweden 1979 Equine influenza virus H3N8 
U58195 USA 1981 A/equine/Kentucky/1/1981(H3N8) 
X68437 
United 
Kingdom 1989 A/equine/Suffolk/89(H3N8) 
X85085 USA 1991 A/eq/Arundel/91/(H3N8) 
X85086 Netherlands 1989 A/eq/Ella/89/(H3N8) 
X85087 
United 
Kingdom 1992 A/eq/Lambourn/92/(H3N8) 
X85088 
United 
Kingdom 1993 A/eq/Newmarket/93/(H3N8) 
X85089 
United 
Kingdom 1993 A/eq/Newmarket/93/(H3N8) 
X85090 
United 
Kingdom 1989 A/eq/Sussex/89/(H3N8) 
X95637 Nigeria 1991 A/equine/Ibadan/6/91(H3N8) 
X95638 Nigeria 1991 A/equine/Ibadan/9/91(H3N8) 
Y14053 Sweden 1988 A/equi 2/Skara/88(H3N8) 
Y14054 Sweden 1988 A/equi 2/Solvalla/79(H3N8) 
Y14055 Sweden 1984 A/equi 2/Aby/84(H3N8) 
Y14056 Sweden 1990 A/equi 2/Visingso/90(H3N8) 
Y14057 Sweden 1993 A/equi 2/Avesta/93(H3N8) 
Y14058 Sweden 1994 A/equi 2/Soderala/94(H3N8) 
Y14059 Sweden 1996 A/equi 2/Alvdalen/96(H3N8) 
Y14060 Sweden 1996 A/equi 2/Bollnas/96(H3N8) 
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Genbank 
accession 
Country of 
isolation 
Year of 
isolation 
virus name 
DQ124157 USA 2003 A/canine/Florida/242/2003(H3N8) 
DQ124190 USA 2004 A/canine/Florida/43/2004(H3N8) 
DQ124196 USA 2004 A/canine/Texas/1/2004(H3N8) 
DQ146419 USA 2005 A/canine/Iowa/13628/2005(H3N8) 
EU402407 USA 2005 A/dog/Jacksonville/C3/2005(H3N8) 
EU402408 USA 2005 A/dog/Miami/E3/2005(H3N8) 
 
 Table 5.4: Overview of canine influenza sequences used to assess the population-
level evolution of canine H3N8 influenza virus.  
 
5.4.  Results 
Overall, we obtained >400,000 bases of sequence from naturally and experimentally 
CIV infected dogs as well as the challenge virus inoculum. Consecutive samples, 
collected on days 2, 3 and in one case 4 p.i., were analyzed and compared to each 
other and to the challenge virus. Due to low viral loads on day 1 and after day 3 or 4 
p.i. (15), we restricted our analysis to those days on which the viral populations were 
sufficiently large (Table 5.5). By day 8 p.i., all inoculated dogs had produced 
detectable antibody titers, which in nearly all animals further increased by day 15, 
indicating that the virus challenge had elicited an immune response (see Table 5.2). 
All dogs showed pyrexia and mild to moderate clinical signs on day 2 p.i., which in 
most cases lasted until day 4 p.i. (see Table 5.1). In both naïve animals temperatures 
transiently decreased on day 3 before rising again on day 4 p.i.  Similar dynamics were 
observed for the viral titers during that same time period, indicating that the viral 
population size in naïve animals potentially temporarily decreased on day 3 p.i (15).  
 
 
 
 
153
 5.4.1.  Analysis of intra-host dynamics after experimental challenge.  
Samples collected from naïve dogs on day 2 p.i. were similar in genetic diversity to 
the challenge virus, with the mean estimate for the challenge virus equaling 0.0014 
and that for dogs 1 and 2 equaling 0.0017 and 0.0012 respectively. Samples collected 
on later days showed lower levels of diversity, with the estimates for day 3 equaling 
0.0005 and 0.0008 for dogs 1 and 2, respectively (Table 5.5). Intriguingly, the mean 
pairwise genetic diversity appeared to follow similar dynamics as described above for 
viral titers. For dog 1 where data for all three days are available, the mean pairwise 
genetic diversity decreased on day 3 p.i. from 0.0014 to 0.0005 and then increased 
again to 0.0010 on day 4 (Table 5.5).  
 
Importantly, we detected far weaker purifying selection – such that dN/dS ratios 
were close to the random expectation of 1.0 – in both the challenge virus and the naïve 
dogs than in our sample of EIV GenBank sequences (Table 5.5); the mean dN/dS ratio 
was 0.277 for the EIV sample and 0.694 for the challenge virus.  Intriguingly, the 
dN/dS ratio increased on day 3, from 0.73 to 1.63 in dog 1 and from 1.13 to 1.41 in dog 
2, and decreased again to 0.77 for dog 1 on day 4.  
 
Neither insertions nor deletions were detected in any of the naïve dog samples 
or in the challenge virus, but stop codons were detected in both the challenge virus 
(amino acid (aa) 176 of the mature HA) and dog 1 on day 3 p.i. (aa 143 of the mature 
HA), suggesting that these particular strains were defective. 
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Intriguingly, while the challenge virus contained several sequences that shared 
the same mutations, these sequence clusters had nearly completely disappeared in both 
naïve animals by day 3 p.i. (Figures 5.1 and 5.2). In all samples, the majority of 
sequences were identical to the challenge virus consensus sequence, indicating that 
there was not a major bottleneck at transmission. Most mutant sequences were 
characterized by a single mutation, which was commonly only detected once (i.e. 
‘singeltons’; Table 5.6).  Mutations present at higher frequency were generally pre-
formed in the challenge virus (Table 5.7). In some cases, different mutations were 
detected at the same site in different samples (Table 5.8), but the location of mutations 
was generally not identical in different samples and mutations did not cluster in 
specific regions of HA1 (Figure 5.3).   Overall, only 34% of mutant sites were 
detected more than once, which included mutations pre-formed in the challenge virus 
and apparently retained for some time in the infected dogs.   
 
Of the 7 sites that were shared between different samples from infected naïve 
dogs, 6 (86%) were repeatedly sampled from the same animal, indicating that those 
mutations had probably at least temporarily remained at low level in the viral 
population. 8 out of 12 sites (66.7%) that were present at frequency >1 in at least one 
sample were also polymorphic in the EIV population, even though the amino acids 
present in the EIV population sometimes differed from those detected in the naïve 
dogs (Table 5.7). Several of these mutations were located in antigenic sites B, C,D or 
E, and the same was true for mutations detected in more than one sample (Table 5.8). 
Unfortunately, the very limited number of CIV sequences available in GenBank 
precluded a meaningful analysis of variable sites in the CIV population. 
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Figure 5.1. Phylogenetic relationship between CIV sequences isolated from the 
challenge virus or dog 1 on days 2, 3 or 4 post inoculation. Branch lengths are drawn 
to scale.  
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Figure 5.2. Phylogenetic relationship between CIV sequences isolated from dog 2, 
collected on days 2 and 3 post inoculation. Branch lengths are drawn to scale.  
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Table 5.6. Location of mutations detected in challenge virus and naturally infected 
animals. Mutations with frequency >1 are indicated in bold. 
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sample Location of mutations frequency 
Challenge virus signal peptide aa 6 1 
 signal peptide aa 7 1 
 30 2 
 31 2 
 32 1 
 44 1 
 77 1 
 104 1 
 123 1 
 126 1 
 155 1 
 156 2 
 165 1 
 176 1 
 185 1 
 218 6 
 220 10 
 225 1 
 248 5 
 290 1 
 291 3 
 301 1 
dog1, day 2 29 1 
 46 1 
 56 2 
 68 1 
 83 1 
 120 1 
 161 1 
 187 1 
 195 1 
 212 1 
 218 7 
 220 16 
 271 1 
 281 1 
 287 2 
288 1 
289 1 
 290 1 
 292 1 
 301 1 
dog1, day 3 80 1 
 83 1 
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Table  5.6 (continued)  
sample Location of mutations frequency 
dog1, day 3 143 1 
(continued) 156 1 
 186 1 
 219 1 
 220 4 
 242 1 
 253 1 
 285 1 
dog1, day 4 signal peptide aa 9 1 
 19 3 
 44 1 
 49 1 
 56 1 
 76 1 
 83 2 
 88 1 
 92 1 
 126 1 
 195 1 
 220 9 
 232 1 
 242 1 
 254 1 
 277 1 
 287 1 
dog2, day 2 signal peptide aa 1 1 
 32 1 
 38 1 
 49 1 
 50 1 
 83 1 
 116 1 
 118 4 
 160 1 
210 1 
 218 6 
 220 11 
 226 1 
 231 1 
 274 1 
 296 1 
 300 1 
dog2, day 3 41 1 
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Table  5.6 (continued)  
sample Location of mutations frequency 
dog2, day 3 83 4 
(continued) 156 1 
 220 1 
A1100 15 1 
 116            1 
 126 2 
 135 1 
 175 1 
 247 1 
 299 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 : Frequency with which mutations were detected at specific sites in HA1. 
Mutations are mapped onto the nascent form of the HA protein. 
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Table 5.7.  Characterization of mutations present at frequency 
> 1.  Mutations were mapped on the inferred structure of the 
mature HA1 protein. Antigenic properties were inferred based 
on the studies by Wilson et al. and Smith et al. (17, 20).  
“Cluster-difference” mutation refers to the study by Smith et 
al., identifying sites distinguishing antigenic clusters. Only 
position 136 was detected as positively selected among the 
EIV isolates using the SLAC algorithm (dN/dS = 6.27, 
p=0.028). 
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 Many of those mutations that appeared to be generated de novo in the infected 
animals and that were sampled at frequency > 1 in at least one sample were also 
maintained in these dogs. Mutations Y56H and S287G, for instance, were detected in 
2 sequences (3.2%) each in dog 1 on day 2, and in one sequence each on day 4 in the 
same dog (Table 5.6).  Mutation N83S is particularly noteworthy since this mutation 
was present in 2 (2.8%) of the sequences sampled from dog 1 on day 4 and in 4 
sequences (18.2%) sampled from dog 2 on day 3. Moreover, except for the challenge 
virus, mutation N83S was present at least at frequency one in all samples analyzed 
(Table 5.6), indicating that it was probably not pre-formed in the challenge virus but 
was maintained in the dogs. Of those 5 de novo generated mutations in that category 
(Y56H, S287G, A19T, S83N and V118M), 3 were also polymorphic in the EIV 
sample. Mutation V118M is particularly intriguing since that site does not vary in EIV 
and the mutation L118V appears to differentiate older from more recent CIV isolates, 
suggesting that it represents a host-specific adaptation (12).   
 
5.4.2.  Analysis of intra-host dynamics following natural infection.  
The sample collected from a naturally infected dog showed a generally similar 
population structure to the samples from experimentally infected dogs described 
above.  Again, the majority of sequences were identical to the consensus sequence 
while most mutant sequences differed by only one mutation (Figure 5.4). One cluster 
of sequences was present in the sample, characterized by a mutation at position 299 
(Table 5.7). The mean pairwise genetic diversity in the sample was with 0.0009 
comparable to that observed in some naïve dogs (Table 5.5). However, the mean dN/dS 
ratio in this sample was with 0.34 considerably lower than in any of the samples from 
naïve dogs and comparable to that observed in the EIV population level analysis, 
 
166
potentially indicating stronger purifying selection in this naturally infected dog. A 
single deletion, in frame, was present in one of the sequences from this naturally 
infected dog (at aa 47 of the mature HA), and a stop codon was detected in one of the 
other sequences (at aa 131 of the mature HA). 7 variable sites were detected in this 
sample, two of which (116 and 126) were also detected in the naïve dogs. One of two 
mutations present at frequency > 1 (T126A) is polymorphic in the EIV sample, and 
was also detected in the naïve dogs (Table 5.6).  Interestingly, this mutation is located 
in close proximity to antigenic site A (Table 5.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Phylogenetic relationship between CIV sequences isolated from a 
naturally infected animal. Branch lengths are drawn to scale.  
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 5.5.  Discussion 
The emergence of CIV through transfer of a complete EIV sequence from horses to 
dogs represents a valuable and rare opportunity to study the evolution of a newly 
emerged virus in a novel host population. Here, we define the intra-host dynamics of 
CIV over the course of infection, contrasting the dynamics in experimentally infected 
animals to those in naturally infected dogs.  
 
 
5.5.1. Sequence diversity and population structure in naïve animals.  
In general, the evolutionary dynamics observed in the naïve dogs, characterized by a 
high turnover of mutations, the predominance of singletons and a consensus sequence 
that remains unaltered over the course of infection, are characteristic for influenza 
infections of mammalian hosts. The viral populations detected in both naïve animals 
on day 2 p.i. were fairly comparable to those detected in the challenge virus, 
potentially indicating a relatively small transmission bottleneck. This is further 
supported by the observation that many mutations detected in the infected animals 
were already present in the challenge virus, and therefore were likely transmitted 
during the inoculation and remained in the population at very low levels, even though 
it cannot be formally disproven that these mutations arose de novo in the infected 
dogs. The size and nature of transmission bottlenecks during natural infections are 
unknown for most viruses, including influenza, but artificially induced population 
bottlenecks have been shown to exert an important effect on the pathogenicity and 
evolution of RNA viruses (see for example (2, 5, 6)). The route of inoculation used in 
our experiment and the relatively large amount of virus used for inoculation might 
have inflated the number of viruses that are able to pass among hosts. However, the 
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spatial distribution of CIV appears patchy, and CIV is predominantly being 
maintained and transmitted in populations with high population densities such as 
animal shelters or racetracks. This might suggest a low efficiency of transmission and 
a large number of viruses necessary to establish infections, but further field studies are 
needed to address this question.    
 
 An important observation from our study was that weaker purifying selection 
was observation within than among hosts, manifest as inflated dN/dS ratios.  A similar 
observation has been made in dengue virus (9) and suggests that the intra-host samples 
contain transient deleterious mutations that have yet to be removed by purifying 
selection.  However, the absence of viruses containing stop codons and/or indels 
indicates that lethal mutations are purged quickly.  It is also possible that the high 
dN/dS ratios contain some signal of positive selection.  In particular, since the 
challenge virus was amplified in eggs, the inoculum virus may have been adapted to 
the chicken such that back-adaptation occurs in dogs. Indeed, since most of the 
mutations that appear to have been generated de novo in the naïve dogs fall at known 
antigenic sites, some positive selection for antigenic escape is possible. All dogs 
analyzed mounted strong immune responses by day 8 post inoculation, again 
indicating a potential role for immune selection. However, given the comparably low 
frequency of most mutations that were not found in the challenge virus, and since even 
on day 4 p.i. most virus sequences were identical to the challenge virus consensus 
sequence, a predominant role of immune escape appears unlikely.  
 
The strong, temporary increase in dN/dS ratio and decrease in genetic diversity 
observed on day 3 p.i. is also compatible with the role of innate or early adaptive 
immune responses on that day. A temporary predominance of the immune responses 
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could explain the drop in viral titers and body temperature observed in the naïve 
infected animals on that day. These dynamics, though not well understood, appear to 
be common for several influenza infections in mammalian hosts and are likely an 
effect of the commencing immune response. The fact that two apparently de-novo 
generated mutations (at aa 19 and 83) appear on day 4 p.i. again lends to the idea of a 
second bottleneck event on day 3 p.i.  
 
The S83N mutation is particularly intriguing since it seems to arise de novo in 
both animals (on days 3 or 4 respectively), falls in antigenic site E, and has previously 
been characterized as defining differences in antigenic clusters (17). This site appears 
to be variable in EIV (with aa N, K and S present in the EIV population) but is 
conserved among all CIV GenBank sequences available to date, with the mutation of 
N83S representing one of 5 conserved mutations that distinguish the CIV from 
contemporary EIV isolates (12). Since this site reverted independently in some 
sequences from both animals, the N83S mutation might be deleterious or slightly 
deleterious in these animals. Epistatic interaction or hitchhiking with another mutation 
elsewhere in the genome frequently complicates the evolutionary dynamics of 
emergence (16) and might conceivably be involved in the emergence of CIV. 
Moreover, since the mutation at aa 83 emerged later during the infection and appears 
to affect a highly antigenic site, a role of immune escape appears possible.  
 
Mutation V118M is also noteworthy as this mutation seems to have been 
generated de novo in animal 7151 and reached considerably high frequency in this 
animal on day 2 but was not detected again on day 3 (although this might be due to the 
limited number of sequences available for this sample). Residue 118 is located in 
antigenic site D and a role in antigenic escape therefore appears likely. Moreover, a 
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L118V mutation appears to distinguish the early from more recent CIV consensus 
sequences (12) and the second mutation at this site therefore appears surprising.  
 
 
5.5.2.  Sequence diversity and population structure after natural infection.  
The population structure observed in the naturally infected dog appears comparable to 
that observed in naïve animals and to influenza infections of mammalian hosts in 
general, with most mutations present as singletons, and only one or a few mutations in 
any sequence that differ from the consensus sequence. However, the sample was 
characterized by a markedly lower dN/dS ratio than in the experimentally infected 
dogs, which was comparable to the inter-host estimate obtained based on the EIV 
sequences. Intriguingly, this sample stemmed from a client-owned and clinically sick 
dog, while the experimentally infected dogs showed only mild, transient clinical signs. 
Experimental inoculations of healthy, well-fed animals under laboratory conditions 
frequently fail to produce the severe clinical signs observed in the field, and for some 
pathogens it has been shown that stress or starvation can enhance the likelihood of 
clinical disease. The clinically ill dog analyzed in this study may have differed from 
the experimentally infected animals with respect to immune status, elicited immune 
response or viral load, and unfortunately no serological information and no detailed 
case history is available for this animal.  The fact that both Indels and stop codons 
were readily detected in this sample appears surprising as this would support the 
absence of strong purifying selection on the viruses in this animal, which appears to 
contradict the apparently strong purifying selection that seems to be shaping this viral 
population.  
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 In conclusion, our studies of CIV intra-host diversity show that viral 
populations appear to be dynamic and vary over time.  Mutations seem to arise readily 
in the infected animals, but never reach high frequency and appear to be frequently 
lost on subsequent days. Immune selection might be one driving force of CIV intra-
host dynamics, but the intra-host dynamics appear to be mainly dominated by genetic 
drift, with considerably weaker purifying selection acting within a host  than on the 
population-level.  
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CHAPTER 6 
PRESENCE AND ROLE OF CYTOSINE METHYLATION IN DNA VIRUSES 
From:  Hoelzer, K., Shackelton, L.A. and Parrish, C.R. 
Presence and role of cytosine methylation in DNA viruses. 
Nucl. Acids Res. 2008.  36:  2825-2837, with permission.  
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6. 1. Abstract 
Nucleotide composition varies greatly among DNA viruses, yet the evolutionary 
pressures and biological mechanisms driving these patterns are unclear.  One of the 
most striking discrepancies lies in the frequency of CpG (the dinucleotide CG, linked 
by a phosphate group), which is underrepresented in most small DNA viruses (those 
with genomes below 10kb) but not in larger DNA viruses. Cytosine methylation might 
be partially responsible, but research on this topic has focused on a few virus groups. 
For several viruses that integrate their genome into the host genome, the methylation 
status during this stage has been studied extensively, and the relationship between 
methylation and viral-induced tumor formation has been examined carefully. 
However, for actively replicating viruses—particularly small DNA viruses—the 
methylation status of CpG motifs is rarely known and the effects on the viral life cycle 
are obscure. In vertebrate host genomes, most cytosines at CpG sites are methylated, 
which in vertebrates acts to regulate gene expression and facilitates the recognition of 
unmethylated, potentially pathogen-associated  DNA. Here we briefly introduce 
cytosine methylation before reviewing what is currently known about CpG 
methylation in DNA viruses. 
 
6. 2. Introduction 
6.2. 1. CpG underrepresentation in vertebrate genomes. 
 The denotation ‘CpG’ is shorthand for the occurrence of a cytosine linked, through a 
phosphate bond, to a guanine. CpGs are underrepresented in most eukaryote genomes, 
but the frequency varies widely among species and is negatively correlated with the 
presence and extent of cytosine methylation in the genome (see, for example, (1,2)). In 
vertebrate genomes, CpGs are present at one-third to one-fourth of the expected 
frequency, yet the reasons are disputed (1-4). Cytosine and guanine tend to have 
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higher stacking energies than adenine and thymine, so structural constrains may be 
important in CpG avoidance (see, for example, (5)). In many species, the proportion of 
tRNAs containing CpG in their anticodons is lower than that of tRNAs with other 
dinucleotides; therefore, the transcription efficiency might be higher for codons not 
containing CpGs (e.g., reviewed in (6)). Another explanation may lie in the fact that 
unmethylated CpGs can stimulate innate immune responses, potentially resulting in 
autoimmune reactions (reviewed in (7-9)); therefore, large numbers of CpGs may be 
detrimental if not all are methylated. Finally, methylated cytosines have a tendency for 
spontaneous deamination, which may also account for the CpG depletion (see for 
example (10-12)). While the deamination of unmethylated cytosines leads to uracil 
and can be corrected by cellular DNA repair machinery, the transition of methylated 
cytosines to thymines is irreversible, leading to elevated mutation frequencies in 
highly methylated genomes.   
 In general, vertebrate genomic CpGs are highly methylated. Sixty to 90% of 
genomic CpGs are thought to be in a methylated state (reviewed in (13,14)), but both 
CpG frequency and methylation patterns can vary widely across a single vertebrate 
genome.  Notably, some regions are CpG-enriched yet  practically devoid of 
methylation.  These sequence stretches, termed ‘CpG islands’, are >500bp in length 
and comprise ~1% of total genomic DNA (e.g. the human genome contains more than 
29,000 such islands, with estimates reaching as high as 45,000 islands per haploid 
genome (15,16)). The islands are often associated with 5’ promoter regions of 
housekeeping genes (for reviews see, among others, (15,17,18)). 
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6.2.2. Vertebrate CpG methyltransferases. 
 Vertebrate genomes are methylated by DNA methyltransferases (DNMTs) which 
convert cytosine to 5-methylcytosine (5Me-cytosine). DNMTs are functionally 
divided into ‘de novo’ (DNMT3a and DNMT3b) and ‘maintenance’ (DNMT1) 
methyltransferases (Table 6.1). Their catalytic domains appear highly conserved 
across species and S-adenosyl methionine (SAM) appears to function as the only 
methyl donor (reviews of mammalian DNA methyltransferases can be found in (19-
22)).  
 
Table 6.1: Overview of vertebrate DNA methyltransferases and their functions. 
The enzymatic functions attributed to known DNMTs are summarized below, and 
some key references are provided. Some simplifications were made for the purpose of 
clarity, and the reader is referred to specific reviews of DNMTs, indicated in the text, 
for more detail. Cases where the functional role has been proposed, but not yet 
established conclusively, are indicated by question marks. 
 
DNMT Functional role reference 
De-novo DNMTs 
DNMT 3a Embryonic development, methylation of CpG sites, 
meiosis induction in sperm (?) 
(110-112) 
DNMT 3b Embryonic development, spermatogenesis (?) (110,113) 
DNMT 
3L 
Maternal genomic imprinting, silencing of 
retrotransposons in spermatogonial stem cells 
(114) 
Maintantance DNMTs 
DNMT 1 Cellular maintenance methylation, maintenance of 
imprinting, silencing of mobile elements during 
genomic demethylation, contribution to histone 
deacetylases 
(115-118) 
DNMT 2 Unclear. Methylation in Drosophila melanogaster (?) (119) 
 
DNMT expression levels in non-transformed tissues have rarely been studied 
explicitly. The available data indicate the translation of all three DNMTs in the 
majority of tissues, but translation levels seem to vary between tissues, cell 
differentiation levels, host developmental stages and potentially host species. 
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Robertson et. al (23) analyzed DNMT mRNA levels in various human tissues and 
found DNMT1, 3a and 3b expressed in nearly all analyzed fetal and adult tissues. In 
adult tissues, DNMT1 appeared to be generally more highly expressed than DNMT3a 
and 3b, and DNMT1 mRNA was detected in all analyzed tissues except the small 
intestine. DNMT3a and 3b mRNAs were detected in large quantities in heart, skeletal 
muscle, thymus, kidney, liver and peripheral blood mononuclear cells, but were 
present at low levels in all analyzed tissues. DNMT1 and 3a seemed to be expressed at 
high levels in all analyzed fetal tissues, while DNMT 3b was expressed at high levels 
only in fetal liver. The authors proposed fetal hepatic hematopoiesis as the reason for 
the observed high levels of DNMT3b in the fetal liver.  In bovine fetuses, Golding et 
al. (24) found DNMT3b highly expressed in rumen, kidney, testes and lung while the 
highest mRNA levels were again detected in the liver. MRNAs of all three DNMTs 
were again detected in all of the adult bovine tissues analyzed, but highest levels were 
detected in kidney, brain and testes.  Mizuno et al. (25) detected mRNAs for all three 
DNMTs in human neutrophils, monocytes, T-lymphocytes, bone marrow cells and 
CD34 positive immune cells, but mRNA levels varied between cell types. DNMT1 
appeared to be expressed at high levels in all cell types except neutrophiles, while 
DNMT3a mRNA levels in neutrophiles and T lymphocytes appeared high. DNMT3b 
mRNA levels were low in differentiated cells such as neutrophiles, but high in bone 
marrow and particularly CD34 positive cells.  
 Methylation patterns are generally stable, sustained by DNMT1 and are 
inherited by both daughter DNA molecules during mitosis. However, during meiosis 
both parental genomes are demethylated prior to fertilization, and cellular methylation 
patterns become established de-novo during embryogenesis. This process usually 
starts during implantation and is finished by the end of gastrulation (recently reviewed 
in (26)). The development of site-specific methylation patterns is crucial for normal 
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embryonic development (see, for example, (27-29)) and is responsible for genomic 
imprinting and for X chromosome silencing (30,31). 
 
6.2.3. Methylation-induced gene silencing.  
CpG methylation acts to suppress transcription in several ways (reviewed, for 
example, in (32)). It can directly prevent the binding of transcription factors to the 
promoter regions of genes, most likely due to steric hindrance. Alternatively, a number 
of proteins, known as methyl-CpG binding (MeCP) proteins, can selectively bind 
methylated CpG sites. One of these, Kaiso, recognizes methylated CpG sites through a 
zinc-finger motif, while another subgroup shares a conserved methyl-CpG-binding 
domain (MBD). The MBD proteins MBD 1, 2 and MeCP2, as well as Kaiso, all 
function as transcriptional repressors.  MBD 3, however, associates with the 
nucleosome remodeling and histone deacetylation (NuRD) complex, a co-repressor 
complex containing histone deacetylases. Deacetylation of histones increases their 
affinity for DNA, leading to the formation of inactive heterochromatin (reviewed in 
(30,33,34)).   
 
6.2.4. Methylation-induced silencing of foreign DNA. 
Methylation is involved in the inactivation of integrated foreign DNA, such as 
retrotransposons, proviral sequences, and other transposable elements (TEs) (33). 
These ‘parasitic’ DNAs constitute a quantitatively significant portion of mammalian 
genomes, comprising, for example, ~40% of the human genome. They are notably GC 
rich and, within mammalian genomes, are hypermethylated at CpG motifs. In several 
studies the inhibition of de-novo or maintenance methylation was associated with 
increased transcription levels of TEs, indicating that effective TE silencing requires 
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both de-novo and maintenance methylation, likely catalyzed by DNMT3L and 
DNMT1, respectively (reviewed by (35,36)). 
 
6.2.5. Methylation and innate immunity.  
CpG methylation also plays an important role in immune surveillance and the 
detection of pathogens, as unmethylated CpGs are a signature of bacterial and other 
pathogen-associated DNA.  CpG-containing oligodeoxynucleotides (ODNs), even as 
short as six nucleotides in length, can be potent stimulators of the vertebrate immune 
system, resulting in the activation of a wide variety of immune cells such as B cells, 
NK cells, monocytes/macrophages and dendritic cells (DCs). Stimulation with CpG 
ODNs directly activates plasmacytoid dendritic cells (PDCs) and B cells.  The PDCs 
secrete large amounts of IFN-α and IL-12 which subsequently stimulate monocytes, 
myeloid DCs, T cells and type-1 NK cells (37-39). One pathway through which 
unmethylated CpGs trigger innate immune responses is by binding a member of the 
Toll-like receptor (TLR) family, TLR9 (see, as one example, (40)). TLR9 is expressed 
at high levels on subsets of human and mouse DCs and gene homologues have been 
found in many other mammalian species.  The degree to which particular CpG 
sequences stimulate immune responses depends upon their flanking nucleotide 
sequences, and motifs which confer maximal stimulation are at least partially species-
specific (reviewed in (41)). For example, ODNs containing the motif GACGTT very 
efficiently stimulate murine and rabbit B cells, but only weakly stimulate human B 
cells, which are most effectively stimulated by GTCGTT (42). Some similarities in 
recognition sequences among related species appear likely.  For example, GTCGTT 
motifs are highly immune-stimulatory in a variety of vertebrates including humans, 
dogs, cats, cows, chicken and non-human primates (41).  ODNs that are thymine rich 
at the 3’ end and contain a TpC dinucleotide at their 5’ end appear to be generally 
 
181
 potent immune stimulators, while those that contain CpG motifs towards the 3’ end 
appear to be less immunogenic (41). Generalities, however, may be misleading in 
some cases, as resulting immune effects are thought to be highly cell-type and species 
specific (43-45).  
CpG dinucleotides in vertebrate genomes are most commonly preceded by a C 
and followed by a G (46), a signature which does not appear to be immune-
stimulatory.  Motifs such as TTCCGA, on the other hand, appear to be potent 
stimulators of the human immune system and may play a role in autoimmune diseases 
such as lupus erythematosus.  Other CpG motifs, for example those containing 
poly(G) sequences, are thought to inhibit NF-κB induced immune stimulation (47). 
The relatively low occurrence of stimulatory motifs in mammalian DNA might 
explain the lower immunogenicity of unmethylated vertebrate DNA compared to 
bacterial DNA.  
 
6.2.6. Stimulatory motifs in DNA virus genomes.  
The genomes of some, but not all, viruses are also lacking many such stimulatory 
sequences. For example, likely stimulatory sequences are highly underrepresented in 
the genomes of adenovirus serotypes 2 and 5, but not in serotype 12. Adenovirus type 
2 and 5 can cause persistent infections, their DNA is not immune-stimulatory and it 
might even suppress immune stimulation by DNA from other sources. Type 12, 
however, does not cause persistent infections, and its DNA appears highly immune-
stimulatory. Experimental evidence for a correlation between the stimulatory potential 
of the viral DNA and the number of supposedly stimulatory motifs has been presented 
(48). 
 Table 6.2 summarizes the frequencies of certain putatively stimulatory and 
non-stimulatory motifs in genomes from several members of different viral families.  
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Table 6.2. Frequency of TLR9 stimulatory and non-stimulatory/inhibitory 
sequences. GpC and CpG contents, as well as individual nucleotide and motif 
frequencies, were determined from the publicly available reference sequences 
(RefSeq) in Genbank. (MatLab script available from the authors upon request.) 
Sequence length, frequencies and percentages of individual nucleotides, GpC and 
CpG content, as well as the frequencies of potentially stimulating and non-
stimulating motifs, are provided below, along with RefSeq accession numbers. 
Expected values were calculated for each motif and are shown in brackets 
following the observed number of motifs in the sequence. The expected values 
were rounded to the next integer.  Potentially stimulating motifs (i.e. GACGTT, 
GTCGCT, GTCGTT) were selected from motifs that Rankin et al. ((120)) found to 
be stimulatory in some domestic animals. Motifs that are most likely non-
stimulatory (i.e. GTCGTT, CGCGCG, CCCGCG) and that might be inhibitory are 
those described in (41). Potentially stimulatory sequences are those described by 
Rankin et al.(120); values represent the total number of the respective motif present 
in the genome. The number in parentheses indicates the number of motifs expected 
in the sequence, given the individual nucleotide composition. This was calculated 
using the following formula: E(UVWXYZ)= 10^-12* sequence 
length*(%U*%V*%W*%X*%Y*%Z), where E(UVWXYZ)= expected value of 
the motif UVWXYZ;  U,V,W,X,Y,Z  = nucleotides of which the motif consists, 
and %U = % of viral sequence consisting of base U. Expected values were rounded 
to the nearest integer. 
Likely non-stimulatory and potentially inhibitory sequences are those described by 
Krieg; values again represent the total number of the respective motif present in the 
genome, and expected values were calculated as describe above.  
‘Total stimulatory’ or ‘total non-stimulatory’ values represents the sum of all 
putatively stimulatory or non-stimulatory motifs in the sequence. 
‘Ratio of stimulatory/non-stimulatory sequences’ represent the fraction of the total 
number of stimulatory divided by the total number of non-stimulatory sequences. 
‘CpG’ or ‘GpC’ represents the total number of the respective dinucleotide CpG or 
GpC in the viral DNA sequence.
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General conclusions are difficult to draw since the biological effects of individual 
motifs likely differ between virus families and host species. Moreover, the limited 
genome size and CpG underrepresentation complicates inference for small DNA 
viruses. However, certain patterns appear noticeable even without using formal 
statistical inference.  The ratio of total stimulatory to total non-stimulatory motifs is 
higher than expected based on the viral nucleotide composition for Frog adenovirus, 
Frog virus 3 and HSV1, while it is lower than expected for all other viruses for which 
this value can be calculated.  Putatively stimulatory motifs are rarely present more 
frequently than expected based on the viral nucleotide composition, with the exception 
of Herpes simplex virus 1 (HSV1) and Frog virus 3. Putatively non-stimulatory 
motifs, on the other hand, are present at higher frequency than expected in several 
cases, as seen for several adeno- and herpesviruses. The driving forces determining 
this nucleotide composition are difficult to disentangle.  HSV1 induces mainly 
subclinical, persistent infections but HSV1 DNA has been shown to efficiently 
stimulate TLR9 responses (49). The mammalian genomes examined contain a 
functional TLR9 ortholog, but chickens lack an orthologous TLR9 gene, and the same 
is likely true for most if not all avian species.  Unfortunately, data on other avian 
species is thus far limited (50) and it is not known, in most cases, whether amphibian 
species have a functional TLR9. Several other factors likely influence presence and 
distribution of CpG containing motifs, but many of these remains to be understood. 
 
6.3. DNA viruses and cytosine methylation 
To understand the impact of cytosine methylation on the viral life cycle and the 
evolution of base composition, the particularities of each virus will need to be 
considered. Differences will inevitably exist between actively replicating viral DNA 
and that which is integrated into the host genome. The type of viral persistence will 
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also be of importance.  The integration of adeno- or polyomavirus DNA into the host 
genome is usually a terminal process since the viruses cannot liberate their genomes 
and are therefore no longer infectious.  The evolutionary roles of methylation in these 
cases will likely differ from that in other viruses, such as Herpesviruses, which can 
liberate their genome after periods of latency.  But differences may also exist between 
large and small viruses- with many larger viruses encoding their own replication 
machinery and additional proteins which modify host cell processes and immune 
responses. The susceptibility of the viral genome to methylation and immune 
recognition will also be affected by other factors, such as the location of replication 
within the cell and the specific intracellular trafficking route (Figure 6.1).   
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Comparison of DNA virus infection pathways.  Major intracellular 
trafficking routes and characteristics of replication are shown for the DNA virus 
families discussed. The importance of methylation and immune recognition is 
indicated. Simplifications and generalizations were made for the purpose of clarity.  
 
Viruses that integrate into the host genome and the effects of methylation on 
their life cycles have long been of particular interest.  Many studies have focused on 
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adenoviruses, but comprehensive knowledge of the methylation status of other viruses, 
such as polyomaviruses and herpesviruses, has also been obtained (Table 6.3).  
Early studies of viral methylation focused on DNA from polyomavirus-
infected cells (51). The early methods (e.g. quantification of methyl-H3 incorporation 
into the genome) used to measure methylation were limited in their sensitivity and did 
not show the genomic distribution of methylated sites. Technical advances later made 
it possible to study cytosine methylation in a more detailed and site-specific manner. 
However, the various roles of methylation during persistent viral infections, in the 
silencing of viral genomes, and in immune evasion and tumor formation are still being 
uncovered. 
The impact of methylation during active viral replication is generally 
incompletely understood, and for many small DNA viruses it is currently not known 
whether the viral genome is methylated during active replication. 
 
6.3.1. Adenovirus DNA methylation – summarizing technical advances in viral 
methylation studies 
Early studies of adenovirus methylation relied on chromatographic and radioactive 
techniques to distinguish methylated from unmethylated bases. The techniques were 
complicated by limited sensitivity, the difficulty of isolating pure viral fractions, and 
the inability to discriminate between host and integrated viral DNA. The investigators 
nevertheless carefully compared actively replicating and integrated viral DNA and 
their conclusions have stood the test of time. Genomic DNA from adenovirus type 2 
and 12 infected cells was heavily methylated, more than cellular DNA from uninfected 
control cells (52). Whether the integration of viral DNA altered methylation patterns 
in the host genome or whether the observed differences were due exclusively to the 
integrated viral DNA was not determined.  
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 Table 6.3: Overview of GC content, CpG frequency and methylation 
status of small and large DNA viruses. The GC content, CpG content and, 
where known, methylation status is shown for viral families/subfamilies. 
Where applicable, a distinction is made between active replication and 
latency. If latent, the state of the genome (i.e. integrated or episomal) is 
specified. Preferred host species are indicated along with any known effect 
the virus has on host cell methylation. Where relevant, representative 
references are provided.
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However, actively replicating adenovirus type 2 and 12 DNA appeared to have few or 
no methylated bases (52).  
More sensitive analysis was allowed by pairs of methylation sensitive and 
insensitive restriction endonucleases.   In particular, the isoschizomers HpaII and MspI 
have been used frequently in studies of DNA methylation . Both enzymes recognize 
the motif CCGG, but the catalytic activity of HpaII is inhibited by CpG methylation 
while the activity of MspI is not affected. The new technique verified the previous 
results with actively replicating adenovirus type 2 and 12 DNA showing no detectable 
methylated CCGG sites and the restriction patterns were consistent among viral DNA 
from different cells (53). Inference from restriction enzyme analyses, however, 
remained limited to those sites recognizable by restriction enzyme pairs. Several 
subsequent studies focused on adenovirus DNA and the absence of methylated sites 
could later be conclusively established through bisulfate sequencing (51-53). Bisulfate 
converts unmethylated cytosines to thymines and thus allows the sensitive detection of 
specific methylated sites by sequencing the genome prior to and after treatment. The 
absence of methylated sites in the replicating adenovirus 2 genome has been shown 
using this technique (54-56).  
Many studies of adenovirus DNA have focused on integrated viral genomes or 
genomic segments, largely because of their oncogenic potential.  Integrated adenoviral 
DNA is known to be hypermethylated, but the regulatory events which determine the 
methylation status of replicating or integrated sequences are not well understood. A 
recombinant between adenovirus 12 and host cell DNA (referred to as SYREC) is 
unmethylated over the whole genome during active replication including the host-
derived sequence, which is methylated in the chromosome. This led to speculations 
about the existence of adenovirus-encoded de-methylation proteins, or a role for the 
virus-encoded replication machinery in methylation avoidance (reviewed recently in 
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(57)). However, no specific mechanism has been defined, and the speed of viral 
replication or compartmentalization of this process within the host cell have also been 
proposed as factors contributing to the lack of methylation. 
 
6.3.2. Methylation status of polyoma- and papillomaviruses 
Studies of papovavirus methylation also focused on integrated sequences, mostly of 
human papillomavirus strains and SV40 polyomavirus. Polyomavirus and 
papillomavirus genomes  are CpG-depleted (Table 6.3) and any CpG motifs present 
are clustered within certain regions of the viral genome (58), complicating the analysis 
of methylation patterns.  The early studies, however, concluded that there was little 
methylation in replicating polyomaviruses (51), with the possible exception of a CpG 
site near the early promoter (reviewed in (59)). Several other studies concurred and 
found several human papillomavirus strains to be hypomethylated during active 
replication, again with methylated sites clustering in specific regions of the viral 
genome. The integrated viral DNA, on the contrary, appeared heavily methylated. 
However, distinguishing between actively replicating and integrated DNA appears 
difficult in some cases (60-62).  
 
6.3.3. Methylation status of herpesvirus genomes 
Herpesviruses establish latent infections without integrating into the host genome, and 
reactivate to reestablish active replication. During latency, the circularized viral 
genome remains quiescent in an episomal state, and can be replicated by the host cell 
replication machinery. Active (e.g. lytic) viral replication differs in several respects.  
Production of viral progeny inevitably results in cell lysis, utilizes the viral-encoded 
replication machinery and involves a separate origin of replication. (e.g. in the case of 
Epstein-Barr Virus (EBV) oriLyt functions as the origin of replication in the lytic 
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cycle while oriP is responsible for replication of episomal EBV DNA (63)) The 
methylation status during lytic DNA replication is likely different from that during 
latency, but most studies have focused on latent infections and the differences have 
rarely been studied explicitly.  
Differences might also exist among herpesvirus subfamilies, as CpG motifs are 
highly underrepresented in gammaherpesvirus genomes, but not in alpha- or 
betaherpesvirus genomes (64). The reasons for these differences remain elusive. 
Gammaherpesviruses cause predominantly persistent, lymphoproliferative diseases. 
Studies of some gammaherpesviruses, such as EBV and Kaposi’s sarcoma-associated 
herpesvirus (KSHV), indicate that methylation serves an intricate regulatory role 
during the viral life cycle (see below). The EBV genome appears to be 
hypomethylated or unmethylated during lytic infection, but highly methylated during 
latency, and appears to become demethylated during reactivation (65). There is some 
evidence for methylation during active replication of another gammaherpesvirus, 
herpesvirus saimiri, since Kaschka-Dierich et al. (1981) found both the linear and 
circular viral DNA to be heavily methylated. (66). The alphaherpesvirus herpes 
simplex virus (HSV) appears unmethylated during active replication and latency (67-
69) while two frog herpesviruses (ranid herpesvirus 1 and 2) appear to be methylated 
during replication. The ranid herpesvirus genomes also contain putative DNA 
cytosine-5 methyltransferases sequences located in ORFs 86 and 120 (70).  
 Methylation plays a pivotal role in the life cycle of EBV (reviewed in (71,72)), 
where methylation of specific genes appears to be involved in the transition from lytic 
to latent infection. Most EBV nuclear antigens (EBNAs) are expressed only for short 
periods during the lytic infection, after which their transcription is silenced through 
hypermethylation of the viral promoters Cp and Wp.  Production of the indispensable 
EBNA1 is then achieved by expression from an alternative “TATA-less” promoter 
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Qp. Reinitiation of lytic infection can occur spontaneously or may be triggered by 
events such as immunoglobulin crosslinking of the host cell and cell proliferation. 
Reactivation is mediated through the expression of the immediate early genes Zta and 
Rta, which are regulated by the promoters Zp and Rp, the latter of which is 
hypermethylated during latency.  While Rp hypermethylation is a major regulator of 
latent infection, Zp hypermethylation is dispensable. EBV therefore seems to use 
methylation-induced gene silencing as an immune evasion strategy.  While a role for 
methylation in the EBV lifecycle is widely accepted, its importance for other 
herpesviruses is still disputed.  
 
6.3.4. Methylation status of iridiviruses and ascoviruses   
The genomes of iridoviruses appear to be heavily methylated during active replication 
and methylation might again have a regulatory role. Iridoviruses are large DNA 
viruses that infect fish, amphibians and reptiles. Initial stages of replication occur in 
the nucleus, after which the nascent viral genomes are transported into the cytoplasm 
where the second stage of replication occurs (reviewed by (73)). Willis and Granoff 
(74) analyzed the iridovirus frog virus 3 (FV3) by radioactive labeling/restriction 
enzyme digestion and found the viral DNA to be heavily methylated, with an 
estimated 20% of cytosines methylated. Time-course experiments later indicated 
changing methylation patterns over the course of infection. Willis et al. (75) analyzed 
nuclear and cytoplasmic extracts collected at various times post-infection (p.i.) and 
found methylated viral DNA after ~6-7h p.i. This DNA appeared to be located in the 
cytoplasm, while nuclear DNA, collected at earlier time points, appeared to be 
hypomethylated. The authors also provided evidence against demethylation of parental 
viral genomes upon host cell infection. Further, Schetter et al. (76) showed that 
nascent FV3 DNA in the nucleus is unmethylated or hypomethylated at early times p.i, 
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but later becomes hypermethylated (after ~6h p.i. in their assay).  Cytoplasmic viral 
DNA, on the other hand, appears to be methylated at all times. The authors reported 
DNA methyltransferase activity in nuclear extracts of FV3 infected cells, beginning at 
a time p.i. which coincided with the appearance of methylated viral genomes. This 
activity was absent from cytoplasmic extracts, indicating FV3 might regulate 
methylation of its genome.  It was later discovered that the FV3 genome encodes a 
putative DNA cytosine-5 methyltransferase sequence, which bears similarities to other 
known methyltransferases (77). The putative methyltransferase, however, is more 
homologous to prokaryotic enzymes than to eukaryotic methyltransferases. While 
transcription (from an early promoter) and translation of this FV3 protein have been 
verified, direct evidence for its methylation activity is still limited.   
Another iridovirus, fish lymphocystis disease virus (FLDV), was also found to 
have a highly methylated genome, even though its GC content is considerably lower 
than that of FV3 (78,79). FLDV also contains a putative 5-cytosine methyltransferase 
(53.3% identical to that of FV3) (80) but evidence for its function is, thus far, scarce. 
Besides the frog herpesviruses and iridoviruses, ascoviruses, which infect insects and 
are closely related to the iridoviruses, are also heavily methylated during replication 
(81).  
 
6.3.5. Methylation status of small DNA viruses 
In contrast to most large DNA viruses, CpG is underrepresented in the majority of 
small DNA viruses (64,82,83). It is possible that cytosine methylation is partly 
responsible for this underrepresentation. Small DNA viruses encode only a minimal 
number of proteins and use the host cell replication machinery for replication.  Low 
CpG frequencies may have been selected to avoid methylation by host 
methyltransferases, to maximize translation efficiencies, or as a means to reducing 
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CpG mediated immune responses. However, apart from the small polyomaviruses and 
papillomaviruses described above, there appears to have been few close examinations 
of the methylation status of small DNA viruses (particularly those that do not 
integrate), such as autonomous parvoviruses, circoviruses and anelloviruses. The roles 
and effects of methylation might be different from those seen in integrating and/or 
large DNA viruses, but further research is needed to understand the specific effects of 
methylation on small, non-integrating DNA viruses.  
Adeno-associated parvovirus (AAV) integrates into the host genome, and has 
been examined primarily in the context of guanine methylation. Productive infection 
with an AAV normally requires co-infection with a helper virus (usually an 
adenovirus or, less frequently, a herpesvirus). In the absence of a helper virus, AAVs 
may remain in the cell as persistent dsDNA, or they may be stably integrated into the 
host genome. Upon infection by a helpervirus, the integrated AAV DNA can be 
rescued and undergo active replication. The CpG contents of AAVs more closely 
resemble those of their helper viruses than those of the closely related autonomous 
parvoviruses, which show strong CpG suppression.  The mechanisms of integration 
have been extensively studied in AAV serotype 2 (AAV2), which predominantly 
integrates in a specific region of chromosome 19 (locus 19q13.3t). Integration is 
directed by AAV-encoded Rep proteins, which likely recognize guanine residues 
within GCTC repeating motifs (located in the AAV terminal hairpin). In vitro 
methylation of these guanine residues has been shown to effectively inhibit DNA-
protein interactions and likely interferes with integration in vivo (84). Similar results 
were obtained when examining the integration of AAV4 (which utilizes a slightly 
different recognition motif) into African green monkey cells (85).  Nevertheless, it is 
not known what role, if any, cytosine-5 methylation plays in the natural AAV life 
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cycle, if AAV methylation influences integration, or if guanines or cytosines are 
methylated during active replication.  
 
 
6.4. Methylation and integrated or latent viral DNA  
Methylation of integrated viral DNA has been studied extensively and the topic is 
extensively covered in the scientific literature. Areas of interest have included changes 
in methylation patterns during integration, the effects of viral methylation on host cells 
and the correlation between virally-induced methylation and tumor formation. 
Excellent reviews have been published on these topics and the reader is referred to 
these articles, indicated in the following discussion, for additional detail. Here we 
briefly summarize what is known about methylation during integration and latency 
and the regulatory elements involved, contrasting the level of understanding to what is 
known about methylation during active replication.  
As already mentioned above, most DNA viruses such as adenoviruses 
(57,59,86-88) and polyomaviruses (83) appear specifically methylated during latency 
or when in an integrated form. In contrast, the alphaherpesvirus HSV does not appear 
to be methylated during latency (89), but the reasons for this difference are unclear. 
The processes by which integrating viruses are de-novo methylated are only partly 
understood, but it is clear that the extent and pattern of de-novo methylation depend 
upon the time after integration and site in the host genome (90), the integrated 
sequences (90,91,92 ,93,94), and possibly the cell type (90); (reviewed in (57)). De-
novo methylation tends to be initiated within confined genomic regions and then 
spreads throughout the viral genome (90,93,95), (reviewed in (87)).  For example, in a 
study examining the methylation pattern of adenovirus 12 over the course of 
integration into hamster cells, methylation began in the center of the viral DNA 
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(between map units 30-75) and subsequently spread outward in both directions. Some 
regions of the viral genome remained unmethylated throughout the study, namely the 
right terminal repeat and regions near the left terminus (95). It is not known which 
factors initiate methylation of the genome, nor the determinants of the sequential 
methylation pattern.  
Methylation patterns appear to be site-specific. In many viruses there seems to 
be an inverse correlation between viral gene expression and degree of methylation, 
with late viral genes being generally more susceptible to methylation effects than early 
genes (see, for example, (53,91)).  Promoter regions of integrated viruses are 
frequently hypomethylated. For example, promoter regions in adenovirus 12 are 
hypomethylated at CCGG sites while the viral genome is otherwise heavily 
methylated (reviewed in (57,59,96)). Methylation of viral genes, particularly at 
promoter sequences, appears to be a reversible event (reviewed in (96)) but the 
mechanism by which viral genomes are demethylated remains to be determined. 
Demethylation has also been shown to occur after in vitro methylation of several viral 
DNAs.  For example, SV40 DNA recovered 20h after microinjection into cells 
retained the artificial methylation pattern under non-permissive culture conditions, 
while allowing early gene transcription. The DNA, however, became demethylated 
after viral replication (97).  Loss of methylation has also been observed in 
adenoviruses, in the case of the SYRECs mentioned above (86,98) which are 
methylated when covalently linked to the host genome, but unmethylated during 
active replication. They require the presence of fully functional adenovirus helper for 
efficient lytic replication, which led some to postulate a role for the viral transcription 
machinery in the loss of methylation.  Unfortunately experimental data in support of 
this hypothesis is so far scarce.  
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Infection with integrating (and even some non-integrating) viruses can induce 
alterations in the methylation patterns of host DNA, a potential factor in the 
development of malignant tumors. For example, herpesviruses KSHV and EBV, 
polyomaviruses BK and SV40, papillomavirus HPV, several adenoviruses and 
hepatitis B virus encode proteins that activate/upregulate DNMT1, 3a, or 3b.  This 
results in the hypermethylation and, therefore, the downregulation of a number of 
cellular genes.  One of the cellular genes frequently hypermethylated in these 
infections is the cell cycle regulating tumor suppressor gene p16INK4a, which is 
commonly hypermethylated in many types of cancer (reviewed in (99)). 
Differentiation of host cell tumors and the level of genome methylation of integrated 
viruses generally appear to be positively correlated, as seen for various 
papillomaviruses such as Shope papillomavirus (100) and  human papillomavirus 
(HPV) (101,102), the herpesvirus EBV (reviewed in (72,103)), and various 
adenoviruses (reviewed in (96)).   
 
6.5. Methylation and viral gene expression 
For iridoviruses, gene expression at functional levels can be maintained despite 
genome hypermethylation. Methylated sites, however, are not distributed randomly 
across the genome and methylation levels differ among CpG motifs. FLDV, for 
example, has a considerably higher level of methylation at CCGG than CGCG motifs 
(79). The physiological significance of this, however, is still disputed. In vitro studies 
of the related FV3 showed that specific methylation (using HpaII methyltransferase) 
of CCGG motifs in a late promoter, L1140, abolished its function. However, the 
methylation of all CpG sites by the indiscriminate SssI methyltransferase or the 
specific methylation of GCGC motifs by HhaI methyltransferase had no dramatic 
effect. This appears to be a rare example where, counterintuitively, complete 
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methylation of a late promoter does not abolish its function (methylation frequently 
abolishes the function of late viral promoters, while early promoters tend to be less 
susceptible to the repressive effect of cytosine methylation). The underlying 
mechanism has not been elucidated, but steric hindrance in asymmetrically methylated 
DNA might play a role (104). It seems possible that methylation of CCGG motifs 
results in complex secondary structures in the promoter region, whereas indiscriminant 
CpG methylation or methylation of GCGC motifs balances these secondary structures.  
A similar phenomenon was seen in adenovirus type 2, where methylation of CCGG 
sites within the (late) E2a promoter inhibited the transcription of viral DNA, while 
methylation of GCGC motifs had no repressive effect (105,106).  The transcription 
activity of the polyomavirus SV40 was found  not drastically decreased when in vitro 
methylated with indiscriminant DNMTs from rat liver (107,108). In contrast, upon 
specific methylation of HpaII sites (CCGG-specific), transcription activity was 
reduced markedly (reviewed in (59)). However, the interpretation of these latter results 
is complicated by the possibility of incomplete methylation by the rat liver extract, as  
rat liver DNA is a competitive inhibitor of adenovirus methylation (55) and low level 
contaminants might likewise have inhibited complete methylation of SV40.  
In vitro methylation studies involving human papillomavirus type 16 (HPV16) 
showed that indiscriminate SssI methylation significantly decreased the transcriptional 
activity of the long control region (LCR), which is devoid of ORFs but contains 
several cis-acting regulatory elements.  Enhancers located in the LCR are responsive 
to both cellular and viral factors, such as the viral E2 gene products. Transcriptional 
silencing was measured using a LCR-containing reporter plasmid and inhibition was 
again believed to be steric, specifically due to interference with the binding of 
transcription regulator E2. Notably, hypomethylation of HPV16 E2 binding sites has 
been observed in highly differentiated, but not in undifferentiated, tumor cells (101). 
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However, direct comparison of the HPV16 and SV40 studies is difficult. The effects 
of indiscriminate methylation on early and late viral gene products in the genomic 
context are hard to infer from this study. 
The time of transcription appears to impact the effects of methylation in 
several viruses. For example, the in vitro HpaII (CCGG-specific) methylation of SV40 
early genes (i.e. those coding for the large T-antigen) does not lead to transcriptional 
repression, and the in vitro methylated sites are subsequently lost during active 
replication (108). Late viral gene expression, however, can be efficiently inhibited by 
in vitro methylation of HpaII sites within the 5’ part of this region (109). Site-specific 
methylation might be involved in the transition to latency in some cases (as in the case 
of EBV). On the other hand, methylation does not seem to be involved in the switch 
from early to late gene expression in HSV (89). Likewise, the major late promoter of 
adenovirus 2, which induces the switch from early to late gene expression, is 
unmethylated in non-integrated viruses (56), suggesting methylation does not play a 
major role in the regulation of early versus late gene expression for this virus. 
 
 
6.6. Concluding Summary 
 
A number of studies show that CpG methylation can greatly affect the life cycles of 
DNA viruses, but its exact role in natural infections remains unclear.  Those effects 
likely differ between different viruses and are dependent upon many factors, such as 
the stage in the viral life cycle, the host species and infected tissue, the flanking 
nucleotide motifs, the genes in question and the genomic location.  Where it has been 
studied, major differences have been seen for some viruses between the actively 
replicating and the latent or integrated viral DNA; the former is often unmethylated or 
hypomethylated, while the later often shows specific and regulated methylation. 
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 Differences may also exist between large and small DNA viruses, potentially because 
of their rate and site of replication and differences in their ability to manipulate the 
host responses to unmethylated DNA. Thus, it is necessary to not only examine 
individual viruses, but to examine their dynamic methylation status and the effects of 
any viral methylation on both the virus and the host cell.  The various ways in which 
mutational bias, codon usage and host selections (e.g. through TLR9-dependent 
responses) influence CpG frequency and methylation status need to be defined.  It will 
be especially important to determine the unique roles and regulators of methylation, 
and their divergent effects on the genome evolution of small and large DNA viruses 
during active or latent infection, and in packaged, integrated or episomal DNA.  A 
deeper knowledge of the relationships among the virus, the host cell and methylation 
(and de-methylation) machinery will provide essential insights into determinants of 
methylation status, gene expression, replicative behavior, as well as activation of 
pattern recognition receptors and immune responses.
201
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CHAPTER 7 
SYNONYMOUS RECODING OF THE PARVOVIRUS CAPSID PROTEIN 
GENE REDUCES VIRAL FITNESS 
Dr. Laura A. Shackelton generated the recoded gene sequence 
studied here. 
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7.1. Abstract 
 
The evolution of viral genomes is subject to a variety of selective pressures, some of 
which act on gene products while others are directly linked to the DNA sequence 
composition.  For example, the frequency of cytosine-guanine (CpG) dinucleotides 
(which are generally underrepresented in many vertebrate and invertebrate species) 
varies greatly among DNA viruses. This dinucleotide is strongly suppressed in most 
viruses with genomes of <10,000 bases, but rarely suppressed in viruses with larger 
genomes.  CpG motifs represent mutation hot-spots, can trigger innate immune 
responses and are a key component of numerous regulatory responses.  The biological 
relevance of CpG bias in DNA viruses, however, remains elusive. Here we addressed 
the biological role of CpG avoidance for the case of a small autonomous parvovirus:  
canine parvovirus (CPV). We focused on the capsid protein gene because this genomic 
region exhibits the strongest underrepresentation of CpGs, and increased the CpG 
composition in this region by nearly 20-fold while keeping the coding sequence 
unaltered. Because this recoded virus failed to produce viable progeny we constructed 
two additional viruses with smaller portions of the capsid protein gene replaced.  All 
three recoded gene constructs successfully expressed proteins at approximately 
equivalent levels to the wild-type virus sequence when expressed from mammalian 
expression vectors. However, only the virus with the shortest recoded sequence 
produced viral progeny - and at a markedly lower level than wild-type virus. The 
genome of the wild type virus was unmethylated after replication in tissue culture, 
suggesting a minor role of CpG methylation. The synonymous recoding strongly 
decreased viral fitness in what appears to be a translation-independent manner, 
indicating that translational silencing was most likely not a major driver of CpG 
avoidance in this case. 
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 7.2. Background 
 
The genome composition and evolution of most organisms is affected by nucleotide-
composition biases, dinucleotide frequencies, and non-random synonymous codon 
usage. Codon usage is generally species specific (14), but some trends such as the 
scarcity of  codons containing the dinucleotides ‘CG’ or ‘TA’ appear to be nearly 
universal (22). In higher vertebrates, codon choice may also affect tissue-specific gene 
expression (see for example (35, 38)).  The strength of codon bias and the choice of 
synonymous codons varies between species and also between individual genes in a 
genome (reviewed for example in (17, 29)). Translational optimization appears to be 
the major determinant of codon bias in highly expressed genes of prokaryotes and 
lower eukaryotes, with well-studied examples including Escherichia coli and 
Saccaromyces cerevisiae (e.g. (1, 4, 12, 13, 41)). In contrast, mutational pressures and 
selection on GC content seem important in determining codon usage in mammalian 
genes (recently reviewed in (7)).  
 
Non-random synonymous codon usage and dinucleotide-composition bias in 
viruses is less well understood but some evidence points towards adaptation to host 
translation as an important evolutionary driver (e.g.  (20, 27, 49)). For example in 
influenza A, the asteroviridae and potentially the irioviridae, nucleotide composition 
and codon usage appear to correspond well with those of the host species and have 
been proposed as one mechanism of viral adaptation after cross-species transmission 
(15, 43, 44). Replacement of preferred with non-preferred codons in a poliovirus 
resulted in reduced virulence and replicative fitness (6, 30), also indicating some  
codon optimization.  However, in other virus families such as the adenoviridae, no 
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association of viral codon-usage biases with those of their host species can be detected 
(9). Some viruses (such as papillomaviridae (49) and maybe hepatnaviridae (34)) seem 
strategically to choose codons that are relatively rarely used by their hosts to express 
some of their viral genes, perhaps to restrict the level of protein production and reduce 
their immunogenicity (recently reviewed in (48)).  
 
Nucleotide composition and dinucleotide patterns within viral genomes vary 
considerably among virus families, and occasionally even between subgroups (21, 39). 
The CpG dinucleotide (i.e. a cytosine linked to a guanidine through a phosphate bond) 
represents one of the most striking examples;  in most small DNA viruses (genomes of 
<10,000 bases) this dinucleotide is reduced by > 75% compared to the frequencies 
predicted from their overall base compositions (39).  In contrast, the genomes of larger 
DNA viruses generally do not show a suppression of CpGs.  The small parvoviruses 
are particularly intriguing, because CpGs are highly underrepresented in most of their 
members;  the exception are the adeno-associated viruses (AAVs) which replicate in 
cells co-infected with large adeno- or herpesviruses (39).  The AAVs appear 
comparable in nucleotide composition to their helperviruses. 
 
Numerous reasons for the various nucleotide compositional discrepancies have 
been proposed:  the ability of the larger viruses to encode viral polymerases;  
differences in the tolerance of mutations; control or avoidance of immune reactions; 
and the avoidance of gene silencing (reviewed for example in (19)). CpG methylation 
(or the lack thereof) might be involved in any of these scenarios.  In eukaryotic cells, 
methylation patterns are used to discriminate between methylated host and largely 
unmethylated pathogen DNA, and non-methylated CpGs can trigger innate immune 
responses.  Cytosine methylation also regulates differential gene expression and can 
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control replication and error correction (reviewed recently for example in (10, 37, 
45)).  Methylation can inactivate transposable elements (reviewed in (40)) and 
(particularly in promoter regions) can lead to transcriptional silencing (37).  
Methylated CpGs are also prone to mutation due to spontaneous deamination which 
cannot be corrected by the cellular repair machinery (8, 11).  Thus, methylation can 
affect viral evolution in several ways. The DNA of many animal viruses appears to be 
unmethylated during active replication, but for several small DNA virus families 
including the parvoviridae, the nature and any role of the CpG methylation is not well 
understood (reviewed in (18)).   
 
Canine parvovirus (CPV) is a member of the autonomous parvoviruses which 
emerged in the mid-1970s from the endemic feline panleukopenia virus (FPV) or a 
closely related carnivore parvovirus.  This group of viruses has been endemic for a 
long time, and members infect various domestic and wild hosts including many felids, 
raccoons, foxes and mink (2). Transmission of FPV between those host species 
appears to occur readily while host-range barriers restricted transmission to dogs until 
CPV- a strain adapted to dogs - emerged (42). Infections of cats with more recent 
strains of CPV have been reported, but dogs and their wild relatives represent the 
major host species of CPV. 
Here we report the synonymous recoding of part of the capsid protein gene of 
CPV to favor CpG-containing codons. We analyzed the observable effects on viral 
fitness and gene expression, and examined the potential interplay between the recoded 
sequence and CpG methylation. Additionally, we showed for the first time that the 
CpGs of the parvovirus genome are not methylated during active replication. 
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7.3 Methods 
 
7.3.1. Computational analysis of nucleotide composition and codon usage.   
Viral nucleotide and dinucleotide compositions as well as sequence-specific codon 
usages were analyzed using LaserGene (DNASTAR, version 7). Analysis of the 
effective number of codons (ENC), frequency of optimal codons (Fop) and GC 
content of the third codon position (GC3) was performed using Codon W 
(http://mobyle.pasteur.fr/cgi-bin/MobylePortal/portal.py?form=codonw). Codon 
usages of vertebrate species were reported from the literature (Homo sapiens) or for 
domestic cat (Felis catus), domestic dog (Canis familiaris), grey wolf (Canis lupis) 
and American mink (Neovison vison) obtained from the codon usage database (31).   
 
7.3.2. Viruses and recoding.   
CPV wild-type (wt) virus (CPV-wt), of antigenic type CPV-2 (GenBank reference 
number: M38245.1), was produced from a previously described infectious plasmid 
clone of the viral genome (33). A partially recoded VP2 gene sequence (between nts. 
3008 and 4526 of sequence M38245.1) was constructed using the program Se-Al 
(http://tree.bio.ed.ac.uk/software/seal/) by converting CpN to CpG at all sites where 
this introduced synonymous changes. The recoded VP2 gene was synthesized and 
cloned into CPV_2wt using the BsrGI and PacI sites, generating the recoded virus 
(CPV-Rec). Two viruses with smaller portions of the recoded sequence were created 
(CPV-1/3Rec and CPV-2/3Rec) by swapping the 645bp PflMI-SpeI fragment between 
the CPV-wt and CPV-Rec.  Virus stocks were generated in Norden Laboratory Feline 
 
218
Kidney (NLFK) cells by lipofectamine transfection (Invitrogen, Carlsbad, CA) of 5µg 
plasmid DNA containing the full length genomes, and cells were subsequently 
subcultured for 2 to 5 days.  The cultures were frozen and thawed, then a 1:2 dilution 
was used to inoculate fresh NLFK cultures to measure the ability of any virus 
generated to infect cells.  
 
7.3.3. Expression vector generation.   
A mammalian expression plasmid containing the CPV-2 VP1/2 gene fragment in 
pcDNA neo (CPV-Exp-wt) has been described previously (47). The BsrGI- PacI 
fragment in this construct was replaced by the corresponding fragments of CPV-Rec, 
CPV-1/3Rec or CPV-2/3Rec, resulting in expression vectors CPV-Exp-Rec, CPV-
Exp-1/3Rec, and CPV-Exp-2/3Rec respectively. Plasmid DNAs (5 µg amounts) were 
transfected into NLFK cells using lipofectamine and cultured for 2 to 5 days.  
 
7.3.4. Immunofluorescence assays.  
Cells were either seeded on glass coverslips 2 days after transfection with infectious 
plasmids as described above, or inoculated with cell culture passages 24 h after cells 
were seeded onto the coverslips. After 2-5 days cells were fixed in 4% 
paraformaldehyde (PFA) for 10 min, then permeabilized in phosphate-buffered saline 
(PBS) with 0.5% bovine serum albumin (BSA), 0.2% Triton X100. Cells were then 
stained for infection with a Cy-2 labeled anti-NS1 antibody (CE-10.Cy2), or stained 
for assembled capsids using an Alexa594 labeled anti-capsid antibody 
(MAb8.Alexa594). Assembly of viral capsids from expression vectors was also 
determined by staining with MAb8.Alexa594. 
For the determination of transfection or infection efficiencies, cells were 
transfected with infectious plasmids or inoculated 24 h after seeding onto glass 
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coverslips and fixed 2 days post transfection or infection. Cells were then analyzed for 
the presence of viral capsids by staining cells with MAb8.Alexa594 and nuclear DNA 
was detected with 4'-6-Diamidino-2-phenylindole (DAPI). A total of 300 cells were 
counted per coverslip and the reported infection ratios represent averages of 3 or more 
coverslips. All statistical analyses were performed in Microsoft Office Excel 2007.   
 
7.3.5. Western blot analysis.  
NLFK cells transfected with the expression vectors were washed and lysed in SDS 
sample buffer (10% SDS, 50 mM Tris.HCl and 2-mercaptoethanol).  After boiling for 
5 min samples were run on 8% denaturing SDS polyacrylamide gels, transferred to a 
nylon membrane and detected with the polyclonal rabbit anti-CPV antibody.  Bound 
antibody was detected with a horseradish peroxidase conjugated goat-anti mouse 
antibody (Jackson ImmunoResearch Laboratories, West Grove, PA), and analyzed 
with the SuperSignal substrate (Pierce Chemical Company, Rockford, IL). 
 
 
7.3.6. Restriction fragment length polymorphism (RFLP) analysis.  
Viral RF DNA was isolated from infected or transfected NLFK cultures as described 
previously. As controls, approximately full-length viral genomic DNA was recovered 
from bacterial plasmid CPV-wt using endonucleases SphI and XmaI (NEB, Ispwich, 
MA), with the bacterial DNA serving as negative control. To obtain positive controls, 
this DNA was subsequently in-vitro methylated using MssI methylase (NEB, Ipswich, 
MA) according to the manufacturer’s recommendations. All methylation reactions 
were performed for at least 6 h to ascertain sufficient methylation.  Restriction 
analysis was performed by digestion with isoschizomer pairs HpaII and MspI or HhaI 
and CfoI for 3 h. Fragments were separated by agrose gel electrophoresis in a 1% TAE 
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gel, and DNA bands were visualized under UV light after staining with ethidium 
bromide. 
 
 
7.4. Results 
 
7.4.1. Analysis of CpG frequencies and recoding of part of the viral genome.  
We analyzed nucleotide composition, codon usage and CpG content in the ~5.1 kb 
ssDNA genome of CPV.  We found CpGs to be strongly suppressed - particularly in 
the capsid protein gene, with only 12 of the 75 CpG sites located within the ~ 1700 nt 
long capsid gene VP2 (Table 7.1). The parvovirus genomes are characterized by a 
considerably lower GC content (Table 7.1) and a lower effective number of codons 
(ENC) than their hosts (Table 7. 2). CPV and its ancestor FPV are very similar in 
codon usage, as would be expected from their close phylogenetic relationship (Table 
7.2). The codon preferences of their mammalian host species (i.e. cats, dogs, mink, 
and wolves) are also very similar, but clearly distinct from that of humans (Table 7.3). 
Intriguingly, the codon usage of CPV and FPV generally does not correspond to that 
of their hosts. 
We targeted a 1518 nt. long sequence in the capsid protein region for recoding, 
and introduced 198 additional CpGs through synonymous recoding (Table 7.1). We 
further constructed 2 intermediate viruses with portions of that capsid protein gene 
region replaced (Table 7.1; Figure 7.1), introducing 144 or 65 additional CpGs, 
respectively. By doing so we strongly increased the frequency of some CpG-
containing low frequency codons, while leaving the usage of other codons largely 
unaltered (Table 7.3). Overall, the effective number of codons (ENC) increased from 
36 to 46, with particularly the GC3 value increasing from 0.16 to 0.3 (Table 7.2), 
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indicating a tendency towards the use of lower frequency codons in the recoded 
viruses. In general, the codon usage and GC content of the recoded viruses shifted to 
that of the host species. 
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Figure 7.1.  Schematic outline of the CPV-2 wt and recoded genomes, indicating the 
number of CpGs present in the genomic regions and the relative location of the 
recoded sequences.   
 
 
 
7.4.2. Replication fitness of the recoded viruses.  
After transfection of the viruses containing recoded portions in full length plasmid 
clones we detected expression of the non-structural protein NS1 and the capsid genes 
in all cases (Figure 7.2). Expression from CPV-Rec and CPV-2/3Rec viruses was very 
weak and no infectious progeny were detected after the culture supernatants were used 
to inoculate new cultures (Figure 7.3). After transfection or infection with virus CPV-
1/3Rec we saw clear protein expression (Figures 7.2 and 7.3), but the infection rates 
were clearly lower than for virus CPV-2wt (Table 7.4.), indicating a strong decrease in 
transfection and infection efficiency associated with the recoded virus. 
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Table 7.3.  Codon usage in humans (from (28)), domestic cats (Felis catus), 
American mink (Neovison vison), grey wolves (Canis lupis), domestic dogs (Canis 
familiaris),  Feline Panleukopenia virus (FPV), CPV-2 wt and recoded genomes 
(complete coding region covering NS1 and VP2, introns and UTRs removed), with 
codons containing CpG or GpC motifs indicated by shading. 
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7.4.3. Expression of recoded genes from mammalian expression vectors.  
All recoded capsid-protein sequences allowed successful expression of the capsid 
proteins from a plasmid under the control of the CMV promoter. The expression levels 
were comparable to the wild-type sequence as determined by Western-blot analysis 
(Figure 7. 5) and by immunofluorescence staining of assembled capsids (Figure 7.4).  
All expression vectors expressed both capsid proteins VP1 and VP2 which assembled 
capsids, indicating that the recoding had not strongly affected the ability of the gene 
sequence to be translated. 
 
7.4.4. Methylation status analysis of the wild type virus genome.  
Restriction fragment-length polymorphism (RFLP) analysis of viral replicative form 
(RF) DNA with methylation-sensitive and - insensitive isoschizomeres showed the 
absence of methylation at HpaII (motif:CCGG) and Hha I (motif: GCGC)  sites from 
the CPV-2wt genome (Figures 7.6. and 7.7.).  As controls we analyzed non-
methylated (neg. control) and in-vitro methylated (pos. control) CPV-2wt ds DNA 
recovered from the bacterial plasmid. As predicted, the methylated DNA was resistant 
to HpaII or HhaI digestion, but not to MspI digestion, and restriction patterns of the 
latter were similar to those obtained from RF DNA. In vitro methylated DNA was 
partially resistant to CfoI digestion (Figure 7.7.), indicating that overhanging CpG 
methylation blocked digestion with this enzyme, while the RF DNA digested with this 
enzyme appeared completely digested. In conclusion, these results strongly indicate 
the absence of methylation from these sites in the CPV-2wt genome.  
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CPV-2wt CPV - Rec CPV2/3 - Rec CPV 1/3 - Rec 
Figure 7.2.  Characterization of recoded genomes - expression of viral proteins and capsid 
assembly after transfection. Green = NS1 expression; Red = capsid expression. 
 
 
 
 CPV-2wt CPV - Rec CPV2/3 - Rec CPV 1/3 - Rec  
 
 
 
Figure 7.3. Characterization of recoded genomes - presence of assembled capsids after 
inoculating cultures with tissue-culture supernatants.  
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 CPV-Exp-1/3Rec CPV-Exp-2/3Rec CPV-Exp-Rec CPV-Exp 
 
 Figure 7.4. Characterization of recoded genomes: expression and assembly of viral 
capsids from expression vectors. 
 
 
 
 
 
 
 
 
 
 
neg. control CPV-2wt CPV-Exp CPV-Exp-
Rec 
CPV-Exp-
2/3Rec 
CPV-Exp-
1/3Rec 
Figure 7.5. Characterization of recoded genomes: Western-blot analysis of expression of 
viral capsid proteins VP1 and VP2 from expression vectors. Top band = VP1, bottom 
band = VP2. 
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1 1 2a 2b 3a 3b 4a 4b 5a 
Figure  7. 6. Restriction enzyme polymorphism analysis of CPV-2wt RF DNA by 
digestion with HpaII (i.e. CpG methylation sensitive) & MspI (methylation 
insensitive) restriction enzymes. 1= uncut viral DNA liberated from CPV-2wt; 2= 
neg. control; 3 = viral RF DNA from  CPV-2wt transfected cultures; 4= viral RF 
DNA from CPV-2 wt inoculated cultures; 5 = positive control; a= digested using 
HpaII; b= digested using MspI.  
5b 
 
 
 
 
 
 
 5b 1 5a 4b 4a 3b 3a 2b 2a 1  
 
 
Figure 7. 7. Restriction enzyme polymorphism analysis of CPV-2wt RF DNA by 
digestion with HhaI (i.e. CpG methylation sensitive) & Cfo I (i.e. partially methylation 
sensitive) restriction enzymes. 1= uncut viral DNA liberated from CPV-2wt; 2= neg. 
control; 3 = viral RF DNA from  CPV-2wt transfected cultures; 4= viral RF DNA 
from CPV-2wt inoculated cultures; 5 = positive control; a= digested using HhaI; b= 
digested using CfoI. 
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7.5. Discussion 
 
The genomes of most parvoviruses show highly suppressed CpG composition, but the 
underlying reasons are not fully understood (21, 39).  Here we added many additional 
CpGs to the capsid protein gene of CPV to examine the functional roles of that 
suppression, and also analyzed the potential relation to cytosine methylation. We 
showed that synonymous recoding strongly reduced viral fitness but not viral gene 
expression, and further showed the absence of detectable cytosine methylation from 
CPV-2wt. A significant role of CpG methylation through genome inactivation or 
mutational pressures therefore appears unlikely. 
 
The engineering of a viable virus with altered codon usage in a ~400 base 
region of the capsid protein gene (CPV1/3-Rec) indicates the tolerance of the CPV 
genome towards at least moderate recoding. However, the lower transfection and 
infection efficiencies compared to wild type indicate a fitness cost associated even 
with this moderate amount of synonymous recoding. Because all recoded capsid 
proteins were expressed at reasonable levels from the expression plasmid, and initial 
viral replication and capsid assembly was seen after transfection of all full length 
plasmids, a block in viral packaging might be a plausible explanation for at least some 
of the observed fitness cost, particularly for the viruses containing the larger recoded 
region. Studies of genome replication and packaging in a closely related parvovirus 
(the minute virus of mice (MVM)), show that changes in the sequences near the right-
hand end of the viral genome which increase the frequency of Gs interfere with the 
packaging of the viral DNA, most likely through interference with the folded DNA 
structures on capsid insertion (5). 
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The RFLP-based analysis of methylation status limits our analysis to those 
sites recognized by the restriction enzymes used. Although this limits the certainty 
with which conclusions about the complete absence of cytosine methylation can be 
made, HpaII sites appear to be of particular importance for the methylation-induced 
inactivation of promoters (recently reviewed in (16)).  Moreover, HpaII and HhaI sites 
constitute a considerable amount of the CpG sites present in CPV-2wt (16) and appear 
very representative of all CpG sites present in the CPV genome. The absence of 
methylation at these sites therefore certainly indicates the scarcity, if not complete 
absence, of CpG sites in the CPV genome.  The absence of detectable methylation of 
the CPV-2wt genomes raises the potential of CpG suppression being selected to 
avoide immune stimulation.  It is unclear what role (if any) immune recognition has on 
the genome composition of CPV. Parvoviruses traffic through the endosomal pathway 
during cell entry and therefore would co-localize with TLR-9 in cells that express that 
receptor (16, 26, 32, 36, 46). Internalized herpesvirus DNA can be recognized through 
the TLR-9 pathway and a similar effect for DNA in CPV capsids (or perhaps free viral 
DNA released from lysed cells) appears likely (25). However, the stimulatory 
potential of CpGs is determined by the flanking nucleotides and the host species 
affected (3, 23, 24), and little is known about the functional roles of TLR-9 in dogs. 
This topic and in particular the innate immune responses to CPV DNA during 
infections of canine cells therefore merits further study.  
We detected efficient protein expression from the wild type and recoded 
sequences but subtle impacts on translational efficiencies might have been missed in 
the analysis. However, our observation of reduced replicative fitness but relatively 
unaltered protein expression after recoding corresponds well to previous studies of 
poliovirus, where codon deoptimization led to reduced replicative fitness and 
pathogenicity but relatively unaltered protein expression (6, 30). In the case of polio, 
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 codon deoptimization has been proposed as a potential means to improve vaccine 
safety because deoptimization greatly decreases viral pathogenicity. 
 
 Our study represents the first applied study of codon usage and cytosine 
methylation in autonomous parvoviruses. We have shown that CpG 
underrepresentation is related to viral fitness in a (most likely) translation-independent 
manner, and that cytosine methylation does not appear to be a major driver of CpG 
underrepresentation in these genomes. Although further studies are needed to elucidate 
the true importance and role of CpG underrepresentation in the autonomous 
parvovirus genome, our study proves the importance of CpG underrepresentation for 
viral fitness and raises the question of a potential role of immune evasion as major 
driver for CpG avoidance in the CPV genome. 
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 CHAPTER 8 
SUMMARY AND CONCLUSIONS 
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In conclusion, the scientific studies presented in the scope of this thesis explore some 
of the molecular and evolutionary determinants of viral host switching. Because the 
success of a cross-species transmission event is strongly affected by host- and 
pathogen-associated factors, we centered our studies in these areas. We however 
acknowledge that numerous other aspects such as those related to ecology, politics, the 
environment, socio-economic drivers or geology simultaneously influence disease 
emergences.  
 
As we have shown, emerging diseases can differ significantly in their core properties 
and no ‘one-size-fits-all’ approaches to understanding disease emergences appear 
promising. When we analyzed the intra-host dynamics in two recently emerged 
viruses of dogs - canine parvovirus (CPV) and canine influenza virus (CIV) - we 
detected striking differences in their evolutionary dynamics, underlining the dangers 
inherent in drawing general conclusions. However, in both cases the intra-host 
dynamics of the emerged virus appeared to be similar to those observed for the 
ancestral virus in the donor host, indicating that the host switch had not greatly 
affected the evolutionary dynamics within infected hosts. Moreover, when we 
artificially transferred CPV between hosts we did not detect marked differences in 
evolutionary dynamics; this further supports the hypothesis that many host changes do 
not strongly affect viral intra-host dynamics.  
 
Conversely, however, our study of CPV and its ancestor feline panleukopenia virus 
(FPV) on a population level showed marked differences in their evolutionary 
dynamics, which reinforced the discrepancy between evolutionary forces on a 
population versus an intra-host level. We further detected changes in evolution and 
spread from the initial emerged CPV strain (CPV-2) to more recent CPV isolates 
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 (CPV-2a etc.), signifying how starkly evolutionary dynamics can change in the time 
after a host-switching event.  
  
The interactions between viruses and their hosts are fine-tuned and likely determined 
on many different levels, several of which are still incompletely understood. We 
addressed some of these more subtle levels of host adaptation by addressing the 
impact of non-random synonymous codon usage in CPV. We clearly showed that 
synonymous recoding starkly decreased viral fitness in a translation-independent 
manner and provide evidence that cytosine-methylation is not a major driver of the 
observed codon bias. While further studies are needed to prove this hypothesis, in this 
case a role of codon bias in immune evasion appears likely. This highlights the 
potential for additional, more subtle barriers to successful host switching. 
 
In conclusion, this thesis presents one of the first integrative studies of the molecular 
and evolutionary determinants of viral host jumping. While many questions remain 
open and several aspects of cross-species transmission have been deliberately 
excluded from this analysis for simplification purposes, some common characteristics 
of successful host jumps have emerged and the thesis represents a first tentative step 
towards understanding disease emergence through host jumping.  
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